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Virtual colonoscopy (VC) is a minimally invasive means for identifying colorectal 
polyps and colorectal lesions by insufflating a patient’s bowel, applying contrast agent via 
rectal catheter, and performing multi-detector computed tomography (MDCT) scans.  The 
technique is recommended for colonic health screening by the American Cancer Society 
but not funded by the Centers for Medicare and Medicaid Services (CMS) partially because 
of potential risks from radiation exposure.  To date, no in‐vivo organ dose measurements 
have been performed for MDCT scans; thus, the accuracy of any current dose estimates is 
currently unknown.   
In this study, two TLDs were affixed to the inner lumen of standard rectal catheters 
used in VC, and in-vivo rectal dose measurements were obtained within 6 VC patients.  In 
order to calculate rectal dose, TLD-100 powder response was characterized at diagnostic 
doses such that appropriate correction factors could be determined for VC.  A third-order 
polynomial regression with a goodness of fit factor of R2=0.992 was constructed from this 
data. 
Rectal dose measurements were acquired with TLDs during simulated VC within a 
modified anthropomorphic phantom configured to represent three sizes of patients 
undergoing VC.  The measured rectal doses decreased in an exponential manner with 
increasing phantom effective diameter, with R2=0.993 for the exponential regression model 
and a maximum percent coefficient of variation (%CoV) of 4.33%.  In-vivo measurements 
yielded rectal doses ranged from that decreased exponentially with increasing patient 
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effective diameter, in a manner that was also favorably predicted by the size specific dose 
estimate (SSDE) model for all VC patients that were of similar age, body composition, and 
TLD placement.  The measured rectal dose within a younger patient was favorably 
predicted by the anthropomorphic phantom dose regression model due to similarities in the 
percentages of highly attenuating material at the respective measurement locations and in 
the placement of the TLDs. The in-vivo TLD response did not increase in %CoV with 
decreasing dose, and the largest %CoV was 10.0%. 
 
 
  
v 
 
TABLE OF CONTENTS 
 
LIST OF FIGURES          xi 
LIST OF TABLES          xiv 
1.0: INTRODUCTION          1 
 1.1 Virtual Colonoscopy (VC)        1 
  1.1.1 VC Background        1 
  1.1.2 VC Procedure at MD Anderson Cancer Center   2 
  1.1.3 VC Computed Tomography (CT) Radiation Dose   6 
 1.2 Thermoluminescent Dosimeters (TLDs)      8 
  1.2.1 TLD Overview        8 
  1.2.2 TLD Physics        12 
  1.2.3 TLD Readout Process       15 
  1.2.4 TLD Correction Factors       19 
   1.2.4.1 Fading Correction Factor     19 
   1.2.4.2 Linearity Correction Factor     19 
   1.2.4.3 Sensitivity Correction Factor     20 
   1.2.4.4 Energy Correction Factor     21 
   1.2.4.5 f-Factor Utilization      21 
  1.2.5 TLD Dose Calculation       22 
 1.3 CT Radiation Dose Measurements      23 
  1.3.1 Background of CT Dose Measurements    23 
  1.3.2 CT Dose Index (CTDI)       23 
  1.3.3 Monte Carlo Method       29 
  1.3.4 CT Point Dose Measurements      30 
  1.3.5 MD Anderson VC Rectal Dose Estimates    32 
vi 
 
 1.4 Hypothesis and Specific Aims       36 
  1.4.1 Hypothesis        36 
  1.4.2 Specific Aims        36 
   1.4.2.1 Specific Aim 1:  Establish TLD Linearity Correction 
    Factors for VC Scan Parameters on a MDCT  37 
   1.4.2.2 Specific Aim 2:  Obtain Rectal Dose Measurements 
    in an Anthropomorphic Phantom and In-Vivo in  
Patients Undergoing VC with TLDs    37 
   1.4.2.3 Specific Aim 3:  Compare In-Vivo Rectal Dose 
    Measurements to Anthropomorphic Phantom  
    Measurements, CTDI-Based Dose Estimates and Point 
    Dose Measurements from a Uniform Phantom  38 
2.0 Materials           39 
 2.1 Introduction         39 
 2.2 GE LightSpeed VCT Scanner       39 
 2.3 CTDI Body Phantom        41 
 2.4 CIRS ATOM Adult Anthropomorphic Phantom     43 
 2.5 PeopleSize Software        46 
 2.6 Thermoluminescent Dosimeter (TLD) Capsules     48 
 2.7 Custom-Made PMMA CTDI Insert Rod      51 
 2.8 Ionization Chambers        54 
  2.8.1 Farmer Ionization Chamber      57 
  2.8.2 CTDI Pencil Ionization Chamber     59 
  2.8.3 Electrometer        61 
 2.9 Double Contrast Enema Delivery System     63 
3.0 Methods           66 
vii 
 
 3.1 Introduction         66 
 3.2 Specific Aim 1:  Establish TLD Linearity Correction Factors for VC Scan  
      Parameters on a MDCT        66 
  3.2.1 MDCT Beam Characterization      67 
   3.2.1.1 HVL and QVL Measurement     68 
   3.2.1.2 (CTDI100)air, CTDIw, and CTDIvol Determination  74 
  3.2.2 Determination of TLD Dose Linearity Correction Coefficients for 
           Virtual Colonoscopy       78 
   3.2.2.1 TLD Irradiation at Exposures Received by Patients 
    Undergoing Virtual Colonoscopy    78 
   3.2.2.2 TLD Readout and Dose Linearity Correction Factor  
    Calculation       82 
 3.3 Specific Aim 2:  Obtain Rectal Dose Measurements in an Anthropomorphic 
      Phantom and In-Vivo in Patients Undergoing VC with TLDs   84 
  3.3.1 Rectal Dose Measurement Simulation in an Anthropomorphic  
           Phantom        85 
   3.3.1.1 Modifications to the Anthropomorphic Phantom  85 
   3.3.1.2 Modification to the Rectal Catheter    92 
   3.3.1.3 Anthropomorphic Phantom Assembly   94 
   3.3.1.4 Phantom Measurements and Determination of Population 
    Percentages Represented     95 
   3.3.1.5 Virtual Colonoscopy Simulation in an Anthropomorphic 
    Phantom       103 
   3.3.1.6 Simulated Virtual Colonoscopy Data Analysis  113 
  3.3.2 In-Vivo Rectal Dose Measurements during Virtual Colonoscopy 114 
   3.3.2.1 QC Step 1:  Testing TLD Capsules for Leakage  115 
viii 
 
   3.3.2.2 Attaching TLDs to the Rectal Catheter   116 
   3.3.2.3 QC Step 2:  Testing for Secure TLD Attachment to the 
    Rectal Catheter      123 
   3.3.2.4 QC Step 3:  Disinfection of Rectal Catheter Assembly 124 
   3.3.2.5 Irradiating TLDs during VC and QC Step 4:  Maintenance 
    of Control of TLDs at All Times    125 
   3.3.2.6 TLD Retrieval and QC Step 5:  Disinfection of Rectal  
Catheter Assembly and TLD Capsules   128 
   3.3.2.7 Patient Rectal Dose Determination    130 
 3.4 Specific Aim 3:  Compare In-Vivo Rectal Dose Measurements to  
      Anthropomorphic Phantom Measurements, CTDI-Based Dose Estimates  
      and Point Dose Measurements from a Uniform Phantom   131 
 3.4.1 Introduction        131 
 3.4.2 Size Specific Dose Estimate (SSDE)     133 
 3.4.3 Outlier Analysis        134 
 3.4.4 Statistical Analysis       136 
4.0 Results           138 
 4.1 Introduction         138 
4.2 Specific Aim 1:  Establish TLD Linearity Correction Factors for VC Scan  
      Parameters on a MDCT        138 
 4.2.1 MDCT Beam Characterization      139 
  4.2.1.1 HVL and QVL Measurement     139 
  4.2.1.2 (CTDI100)air, CTDIw, and CTDIvol Determination  141 
 4.2.2 Determination of TLD Dose Linearity Correction Coefficients for 
          Virtual Colonoscopy       146 
  
ix 
 
4.3 Specific Aim 2:  Obtain Rectal Dose Measurements in an Anthropomorphic 
      Phantom and In-Vivo in Patients Undergoing VC with TLDs   153 
 4.3.1 Rectal Dose Measurement Simulation in an Anthropomorphic  
          Phantom        153 
 4.3.2 In-Vivo Rectal Dose Measurements during Virtual Colonoscopy 156 
 4.4 Specific Aim 3:  Compare In-Vivo Rectal Dose Measurements to  
       Anthropomorphic Phantom Measurements, CTDI-Based Dose Estimates 
       and Point Dose Measurements from a Uniform Phantom   160 
  4.4.1 Introduction        161 
  4.4.2 Percent Coefficient of Variation (%CoV)    162 
  4.4.3 Outlier Analysis        163 
  4.4.4 Statistical Analysis       167 
5.0 Discussion          169 
 5.1 Introduction         169 
 5.2 Specific Aim 1:  Establish TLD Linearity Correction Factors for VC Scan 
       Parameters on a MDCT        169 
  5.2.1 MDCT Beam Characterization      170 
   5.2.1.1 HVL and QVL Measurement     171 
   5.2.1.2 (CTDI100)air, CTDIw, and CTDIvol Determination  172 
  5.2.2 Determination of TLD Dose Linearity Correction Coefficients for 
           Virtual Colonoscopy       174 
5.3 Specific Aim 2:  Obtain Rectal Dose Measurements in an Anthropomorphic 
      Phantom and In-Vivo in Patients Undergoing VC with TLDs   177 
 5.3.1 Rectal Dose Measurement Simulation in an Anthropomorphic 
          Phantom        177 
  5.3.1.1 Modifications to the Anthropomorphic Phantom  178 
x 
 
  5.3.1.2 Anthropomorphic Phantom Assembly   183 
  5.3.1.3 Phantom Measurements and Determination of Population 
   Percentiles Represented     184 
  5.3.1.4 Virtual Colonoscopy Simulation in an Anthropomorphic  
   Phantom       187 
  5.3.1.5 Simulated Virtual Colonoscopy Data Analysis  187 
 5.3.2 In-Vivo Rectal Dose Measurements during Virtual Colonoscopy 189 
  5.3.2.1 Maintenance of Control of TLDs during VC Procedure 190 
  5.3.2.2 Patient Rectal Dose Determination    190 
5.4 Specific Aim 3:  Compare In-Vivo Rectal Dose Measurements to  
      Anthropomorphic Phantom Measurements, CTDI-Based Dose Estimates 
      and Point Dose Measurements from a Uniform Phantom   198 
5.5 Potential Future Work        201 
5.6 Conclusions         205 
REFERENCES          208 
VITA            223 
 
  
xi 
 
LIST OF FIGURES 
 
Figure 1-1:  Trans-axial view of VC image       3 
Figure 1-2:  Rectal catheter and enema bag assembly     4 
Figure 1-3:  Processed sagittal 3D image generated during a VC exam   4 
Figure 1-4:  Administration of stool-tagging enema      5 
Figure 1-5:  Thermoluminescent dosimeter energy band diagram    12 
Figure 2-1:  GE LightSpeed VCT Scanner       40 
Figure 2-2:  32 cm CTDI body phantom with insert rods     42 
Figure 2-3:  CIRS model 701 ATOM adult male phantom     44 
Figure 2-4:  CIRS ATOM adult phantom simulated adipose tissue kit   45 
Figure 2-5:  ATOM phantom pelvis with simulated adipose tissue assembled  45 
Figure 2-6:  Double chamber TLD capsule obtained from the RPC    49 
Figure 2-7:  Custom-made CTDI insert rod in varying stages of assembly   53 
Figure 2-8:  Custom-made CTDI insert rod with TLD in seating    53 
Figure 2-9:  Radcal 0.6 cm3 9060/10x5-0.6 Farmer-style ionization chamber  58 
Figure 2-10:  Radcal 3 cm3 9060/10x5-3CT pencil-style ionization chamber  60 
Figure 2-11:  Radcal 9010 electrometer and converter unit and 90C5-6 extension cable 62 
Figure 2-12:  Close up view of E-Z-EM 8925 Miller™ Enema Air Tip rectal catheter 64 
Figure 2-13:  Interior view of rectal catheter tip      65 
Figure 3-1:  Pencil ionization chamber at CT isocenter for in-air measurements  71 
Figure 3-2:  X-ray tube located at 180 degree position of the CT scanner   72 
Figure 3-3:  Configuration used to measure unattenuated exposure (I0)   73 
Figure 3-4:  Configuration used to measure x1 and x2 attenuated exposures (I1 and I2) 74 
Figure 3-5:  Configuration used to measure CTDI body phantom center bore exposure 76 
Figure 3-6:  Configuration used to measure body phantom 12 o-clock bore exposure 77 
xii 
 
Figure 3-7:  Configuration measuring center bore exposure with Farmer chamber  79 
Figure 3-8:  Configuration measuring CTDI body phantom center bore TLD dose  81 
Figure 3-9:  Images of patients with TLDs located in ATOM sections 33, 34, 35  86 
Figure 3-10:  Maximum rectal diameter measurements at three TLD locations  87 
Figure 3-11:  Estimation of cross-sectional area of patients and insufflated rectums 88 
Figure 3-12:  Determination of the location of an insufflated rectum in the axial plane 89 
Figure 3-13:  ATOM phantom section 34 before insufflated rectum modification  91 
Figure 3-14:  ATOM phantom section 34 after insufflated rectum modification  92 
Figure 3-15:  Miller™ enema air tip rectal catheter after modification for phantom  93 
Figure 3-16:  Assembly of Styrofoam plug and rectal catheter to ATOM phantom  94 
Figure 3-17:  Circumference measurement locations on the ATOM phantom  97 
Figure 3-18:  ATOM phantom configuration in simulated VC of 15th percentile patient 104 
Figure 3-19:  ATOM phantom alignment via laser with marks on MDCT table   106 
Figure 3-20:  Assembly of 87th percentile phantom configuration in simulated VC  108 
Figure 3-21:  ATOM phantom configuration in simulated VC of 87th percentile patient 109 
Figure 3-22:  ATOM phantom configuration in simulated VC of 99th percentile patient 111 
Figure 3-23:  Disassembly of 99th percentile phantom configuration   113 
Figure 3-24:  QA test #1:  Placement of TLDs into water bath for 24 hours   116 
Figure 3-25:  Cross section diagram of TLD placement within the rectal catheter  117 
Figure 3-26:  Application of silicone glue to the interior of the rectal catheter  119 
Figure 3-27:  Correct application of silicone glue to the interior of the rectal catheter 119 
Figure 3-28:  Two suture strings tied in the first throws of surgeon’s knots   120 
Figure 3-29:  Proper placement of the first TLD to the interior of the rectal catheter tip 120 
Figure 3-30:  Proper insertion of the second TLD into the rectal catheter tip  121 
Figure 3-31:  Proper final placement of two TLDs within the rectal catheter  122 
Figure 3-32:  Illustration of measurement of relative bone density by HUs    135 
xiii 
 
Figure 3-33:  Patient VC image histogram and thresholded VC image   136 
Figure 4-1:  Plot of linear output of x-ray tube with increasing mAs    143 
Figure 4-2:  Measured Farmer dose in body phantom versus uncorrected TLD dose 147 
Figure 4-3:  Regression of KL,120 values versus uncorrected TLD dose   151 
Figure 4-4:  Phantom rectal dose predictions versus effective diameter    156 
Figure 4-5:  In-vivo and phantom rectal dose measurements versus effective diameter 160 
Figure 4-6:  Distribution of VC patients participating in the study    163 
Figure 4-7:  Patient relative bone density as a function of HU measurements  164 
Figure 4-8:  Percent of highly attenuating voxels at the mean TLD location   165 
Figure 4-9:  Visual comparison of low and high percents of highly attenuating material 165 
Figure 5-1:  Comparison between ATOM phantom with and without solid water plug 180 
Figure 5-2:  Comparison between fat distribution in patients and ATOM phantom  194 
 
  
xiv 
 
LIST OF TABLES 
 
Table 1-1:  MD Anderson CT protocol for VC      6 
Table 1-2:  Potentially negative aspects of TLD-100 and potential prophylactic actions 11 
Table 1-3:  k values converting DLP estimates to effective dose estimates   27 
Table 3-1:  ATOM phantom circumference measurements and percentiles represented 97 
Table 3-2:  Phantom and first adipose layer measurements and percentiles  98 
Table 3-3:  Amount of supplemental lard to add to phantom with first adipose layer  99 
Table 3-4:  Phantom and second adipose layer measurements and percentiles  101 
Table 3-5:  Amount of supplemental lard to add to phantom with second adipose layer  102 
Table 4-1:  Results of HVL and QVL measurements under VC simulation conditions 141 
Table 4-2:  Results of in-air exposure measurements and (CTDI100)air values  142 
Table 4-3:  Results of CTDI body phantom exposures, CTDIw, and CTDIvol values  145 
Table 4-4:  Results of Farmer and TLD dose measurements in KL,120 determination 149 
Table 4-5:  Summary of rectal dose estimates from the uniform CTDI body phantom 152 
Table 4-6:  Results of TLD rectal dose measurements in the anthropomorphic phantom 154 
Table 4-7:  Estimated patient rectal doses resulting from scout images   157 
Table 4-8:  Results of in-vivo TLD rectal dose measurements during VC   159 
Table 4-9:  In-vivo TLD dose measurements and percent differences from predictions 162 
Table 4-10:  Mean square error (MSE) assessment of the phantom dose predictions 168 
 
 
 
  
1 
 
CHAPTER 1.0:  INTRODUCTION 
 
1.1 Virtual Colonoscopy (VC) 
 
1.1.1 VC Background 
According to the Agency for Healthcare Research and Quality (AHRQ), more than 
80 million Americans at average risk for colorectal cancer (CRC) should be screened, but 
only half have done so by any means (1).  As a result, CRC remains the second‐leading 
cause of cancer deaths in the United States.  Although optical colonoscopy (OC) is 
considered to be the gold standard for screening, the number of qualified endoscopists is 
limited and unable to meet the demands of screening, diagnosis, treatment, and 
surveillance; thus, additional screening options are needed (2).     
Virtual colonoscopy (VC) (also known as CT colonography (CTC)) was first 
described in 1994 by Dr. David Vining as a minimally invasive means for identifying 
colorectal polyps and colorectal lesions (3).  The majority of patients undergoing OC could 
avoid the procedure’s inherent risks of bowel injury and sedation by undergoing VC instead.  
The procedure consists of #1) bowel cleansing with cathartic agents, #2) gas insufflation 
with carbon dioxide, #3) computed tomography (CT) scanning of the abdomen‐pelvis in 
supine and prone positions, and #4) image analysis for identification of lesions.   
VC is most appropriate for the following populations:  asymptomatic patients at 
average-risk who are 50 years of age or younger, patients with previously known polyps or 
neoplasms that have not yet been resected (in some clinical contexts), symptomatic 
patients requiring diagnosis (in some clinical contexts), patients having undergone 
incomplete endoscopy and requiring additional structural information, patients with 
colorectal lesions deemed indeterminate by OC, and patients at high risk for OC.  
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Contraindications for the use of VC typically include:  patients with chronic inflammatory 
bowel disease, patients at high risk for colorectal polyps or colorectal lesions, patients (in 
appropriate clinical context) with various colorectal pathologies (colitis, diverticulitis, recent 
surgery or perforation, or high-grade small bowel obstructions), patients requiring 
evaluation for disease of the anal canal, patients with a prior history of anaphylactic 
reactions to contrast agents, and patients who are pregnant (4). 
VC has been proven to be an effective first‐line screening test in the average‐risk 
population (5).  As a result, the American Cancer Society now includes VC in its screening 
guidelines (6).  However, the Centers for Medicare and Medicaid Services (CMS) 
concluded in 2009 that the evidence was insufficient with respect to VC’s performance in 
the Medicare population and its potential harms, namely radiation risks and management of 
extracolonic findings; therefore, CMS denied coverage for VC until these issues can be 
resolved (7). 
 
1.1.2 VC Procedure at MD Anderson Cancer Center 
Thorough bowel cleansing and optimal distention of the colon are critical for 
obtaining accurate VC results, although both are difficult to achieve reliably.  As a result, 
patients often undergo CT scanning in supine and prone positions to evaluate segments of 
the colon that may be collapsed during one of the scans, as well as to shift residual feces 
and water that may mask or simulate colonic lesions.  MD Anderson VC protocols dictate 
that all patients receive both prone and supine CT scans.   
Stool tagging involves administering an iodine contrast agent to the colon to change 
the x‐ray attenuation of residual feces and water to aid in identification of underlying polyps 
(Figure 1-1).  The contrast enemas are prepared by mixing 120 cc of MD‐Gastroview® 
(Mallinckrodt Imaging Solutions, Hazelwood, MO) with 1000 cc of warm tap water in a 
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standard double‐contrast enema bag.  Patients are excluded from VC procedures if they 
report a prior history of a contrast reaction to iodinated‐contrast agents. 
The following outlines the steps of the VC procedure at MD Anderson Cancer 
Center (after initial screening qualifies a patient for this procedure):   
1.  The patient undergoes bowel cleansing prior to presenting at the clinic in a 
standard fashion with the oral administration of a polyethylene glycol solution.   
2. The patient is placed in a supine position on a 64 channel CT scanner table 
(typically the “CT9” scanner). 
3.  The rectal catheter assembly (Figure 1-2) is lubricated with water-soluble jelly 
and inserted into the patient’s rectum.  After insertion, a retention balloon on the end of the 
rectal catheter is inflated to maintain a seal against the anus and prevent rectal catheter 
and contrast expulsion (Figure 1-3). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1-1.  Trans-axial view of VC image.  Stool tagging aids detection of polyps under water. 
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Figure 1-2.  Rectal catheter and enema bag assembly. 
 
 
 
 
 
 
 
 
 
 
 
Figure 1-3.  Processed sagittal 3D image generated during a VC exam.  The rectal catheter is 
shown within the patient’s rectum (with the retention balloon inflated). 
 
 
Retention Balloon 
Rectal Catheter Tip 
Rectal Wall 
Colon 
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Figure 1-4.  Administration of stool‐tagging enema 
 
4.  The patient is placed in a left‐lateral decubitus position, and the enema solution 
is administered under gravity pressure (Figure 1-4).  The patient is then rolled to the right to 
allow the enema to flow into the ascending colon, and the patient is returned to a 
supine position.  This maneuver only takes a few minutes to perform. 
5.  The rectal enema bag is lowered to a level below the patient to drain excess fluid 
from the rectum.   
6.  The enema tubing is clamped.      
7.  Gas insufflation is performed using a CO2 insufflator connected to the air 
insufflation port of the double‐contrast rectal catheter.  At least 1.5 liters of CO2 gas 
delivered at a pressure of 25 mm Hg is administered prior to the start of the supine CT 
scan.  If patients experience excessive discomfort at the 25 mm Hg pressure setting, the 
pressure is often reduced to 20 mm Hg.   
8.  The patient is then placed in a supine position, and lateral and anterior-posterior 
(AP) survey (or “scout”) images are acquired by the CT technologist.  After the technologist 
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verifies patient positioning and specifies the scan length from these scout images, the 
patient undergoes a supine CT scan according to the standard MD Anderson Cancer 
Center CT technique described in Table 1-1.  Following the supine scan, the patient is 
rolled to the prone position, the retention balloon is deflated, and the process is repeated by 
acquiring two CT scouts and a prone CT scan (using the same imaging technique).   
 
Table 1-1. MD Anderson CT protocol for VC. 
Series Description Scan Type
Rotation 
Time (s)
Area
Image 
Thickness 
(mm)
Table Speed 
(mm/cycle)
Pitch
Image 
Interval 
(mm)
kVp mA Delay Reconstruction
1
SCOUT 
Supine
AP and 
Lateral
Mid‐Sternum 
to Trochanter
120 10
2 Supine Full Helical 0.5
Diaphram to 
Symphysis
1.25 39.37 0.984 0.8 120 100 0 Standard
3
SCOUT 
Prone
AP and 
Lateral
Mid‐Sternum 
to Trochanter
120 10
4 Prone Full Helical 0.5
Diaphram to 
Symphysis
1.25 39.37 0.984 0.8 120 100 0 Standard
 
9.  Upon completion of both CT scans, the rectal catheter is removed.   
10.  Each VC examination is processed and interpreted by a board certified 
radiologist using computer software that is routinely used at MD Anderson Cancer Center.  
Figures 1-1 and 1-3 demonstrate examples of colonic images that result from VC.  
 
1.1.3 VC Computed Tomography (CT) Radiation Dose 
One of the perceived harms of VC is the risk of radiation‐induced cancer.  The 
radiation dose received by patients while undergoing CT scans of any anatomy (not just 
VC) has been the subject of recent high-profile media activity (8-12).  A standard CT scan 
of the abdomen and pelvis delivers weighted sum of organ doses (called an effective dose) 
of 10‐15 milliSievert (mSv) (13). This patient risk metric is based on the linear no threshold 
risk model developed from research findings from atomic bomb survivors receiving total 
body mixed radiation (14).  Radiation dose contributions from CT scout images are typically 
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considered to be negligible compared with the dose administered by the actual CT scans 
(15).   
As a comparison to the dose a patient receives in CT, the average American 
receives about 3 mSv of annual ubiquitous background radiation (16).  Phantom 
measurement estimates suggest that the average patient undergoing a VC scan with the 
protocols used by MD Anderson receives an effective dose of 7 mSv and has an absolute 
increased risk of developing colon cancer by 1 in 2000 (17).  In an effort to mitigate 
radiation risks, several recent VC studies have used low‐dose CT techniques yielding 
effective doses as low as 0.8‐2.4 mSv (18, 19).   However, each of these estimates of 
effective dose are based on CT dose index (CTDI) values that are determined from 
homogeneous acrylic phantom dose measurements and mathematical geometric models of 
a standard reference person that do not represent the heterogeneous tissues or sizes of 
patients that undergo VC.     
Effective dose is a generic indicator relating to the risk of health detriment to a 
reference patient.  It is more appropriate to base risk estimates on the absorbed doses to 
the organs receiving the bulk of the radiation when only a limited number of organs are 
irradiated (20), as is the case in VC where only the abdomen and pelvis are irradiated.  In 
these circumstances, effective dose is diluted by the inclusion of many organs that receive 
little or no radiation dose.  A small effective dose, therefore, does not necessarily indicate a 
low risk from examinations such as VC.  A better alternative for quantification of risk 
assessment to an individual is provided by organ dose estimates or measurements specific 
to that individual (20), and such is the method preferred by epidemiologists focused on long 
term risk assessment.   
To date, no in‐vivo organ dose measurements have been performed for VC scans; 
thus, the accuracy of any current dose estimates is currently unknown.  Although MD 
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Anderson VC scanning protocol suggests a 7 mSv average patient effective dose using 
current methods, many uncertainties exist regarding the risk experienced by MD Anderson 
patients as a result of undergoing VC exams.  Therefore, the need exists to utilize available 
radiation dose measurement tools to better assess the risk to a patient undergoing VC.  In 
spite of these quoted risk estimates, however, Brenner recently suggested that the potential 
benefits of VC outweigh its potential radiation risks (17). 
 
1.2 Thermoluminescent Dosimeters (TLDs) 
 
1.2.1 TLD Overview 
Solid state dosimeters are those solid materials that provide at least one 
measurable response to radiation exposure and energy deposition within its active material 
(21).  The use of solid state dosimeters was first published in 1895 (22), and these 
materials are believed to be the first detectors ever used to evaluate the presence of 
ionizing radiation (21).  Today, the most common solid state dosimeters are 
thermoluminescent dosimeters (TLDs)—which are classified as solid state dosimeters that 
emit a light signal when appropriately heated that is proportional to the absorbed radiation 
dose within the material.  Optically stimulated luminescent dosimeters (OSLDs), which emit 
a light signal proportional to absorbed dose when exposed to a light of specific wavelength, 
are quickly rising in popularity (23).   
Over the years of development that have taken place since the introduction of 
CaSO4:Mn as a thermoluminescent phosphor in 1895 (22), many TLD materials have been 
introduced into the marketplace and are used today in medical applications.  Lithium 
fluoride (LiF), first introduced as a TLD material in 1950 by Daniels (24), was revitalized in 
1961 by Cameron, et al (25) and has grown in popularity to be the most widely used TLD 
material (26) because of its advantages over other TLD materials; including:  high-
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temperature thermoluminescence, inert qualities, insolubility, tissue equivalence, little 
change in response across a wide range of doses and energies, considerable detection 
capability across broad energy and dose ranges, low fading, and versatility for several 
types of radiation (21, 25-29).  The Harshaw Chemical Company (Cleveland, Ohio) worked 
with Cameron to develop “TLD-100” (21, 27), which is the most commercially used variety 
of LiF (LiF:Mg,Ti) that uses the naturally occurring isotope of Li (7.5% Li-6, 92.5% Li-7) and 
includes doping with Magnesium and Titanium (26) to act as activators of the material’s 
thermoluminesence (27).  Common variations of this material are “TLD-600” (which uses an 
enriched form of Li-6 (95.6%) to increase sensitivity to neutrons) and “TLD-700” (which 
uses less than 0.1% of Li-6 such that the material becomes insensitive to neutrons) (26).  
As available commercially today, TLD-100 dosimeters provide many advantages to 
users; most of which are for application in personal and radiotherapeutic dosimetry.  They 
can be manufactured as very small chips or ground into powder to conform to the geometry 
of its container.  They have a very wide useful range for photon dose ranging from 50 µGy-
1000 Gy (26).  They demonstrate little fading (5-10% per year) (21, 26, 27).  They are dose 
rate independent (28), can provide very good precision (as low as 0.22%(30)) and have 
good accuracy (below 3% with a precision of <1% (26)) with sufficient effort and cost.  
Finally, the photon effective atomic number (ZTLD-100=8.2) is very close to that of tissue 
(ZTissue=7.4); which makes this material substantially tissue equivalent for most applications 
(31). 
In spite of these advantages, proper TLD-100 utilization to obtain optimal results 
requires consideration of some inherent difficulties and disadvantages that can often be 
reduced with careful execution.   The shortcoming requiring the most consideration is the 
lack of response uniformity between TLD-100 batches, and even within thermoluminescent 
material samples taken from the same batch (26).  These non-uniformities can be 
accounted for by determining sensitivity corrections (in units of absorbed dose per charge-
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in-air per mass) for each specific batch by using sensitivity correction standards with each 
reading, by monitoring for drifts in TLD response throughout a reading session via controls, 
by using well-mixed and characterized TLD-100 powder as opposed to chips, and/or by 
using more than one dosimeter chip per measurement point.  Other difficulties intrinsic to 
quality TLD measurements, along with appropriate measures to minimize the 
accompanying negative impacts, are listed in Table 1-2 (26). 
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Table 1-2:  Potentially negative aspects of TLD-100 and potential prophylactic actions 
 Negative aspects of TLD-100 Corrective Actions 
1 Little uniformity between and within TLD-
100 batches 
Determine sensitivity corrections for each 
specific batch at each reading, use 
controls to monitor for drifts in TLD reader 
response, use well-mixed and 
characterized TLD-100 powder (versus 
chips), use >1 chip per measurement point 
2 Over-response of TLD at low energies  
(<100 keV) (21, 26, 28) 
Determine the energy correction 
coefficient in these low energy ranges, use 
a more tissue-equivalent TLD such as 
lithium borate (Li2B4O7) 
3 Over-response of TLD at high doses  
(>1000 Gy)  
Understand and adhere to the dose range 
limitations of the TLD material, use a TLD 
material that can appropriately respond 
such as Li2B4O7:Mn 
4 Spurious thermoluminescence and/or 
tribothermoluminescence caused by 
surface trapping states creating 
background light signals that impact TLD 
readout (21, 26, 28) 
Using nitrogen gas (versus ambient air) in 
the reader and use a uniform TLD powder 
size 
5 Significantly decreased TLD precision if 
adequate controls are not taken (often at 
10% or more (32)) 
Use carefully controlled conditions, a high-
quality TLD reader, an experienced 
technician, determine sensitivity 
corrections with each reading session 
using standard TLDs, use additional 
control TLDs when shipping, and monitor 
TLD response in a reading session with 
control TLDs 
6 Direction of radiation field affecting TLD 
response  
Use symmetrically sized chips or powders 
7 TLD response may change with exposure 
to visible or ultraviolet light 
Keep all TLDs in a light- and temperature-
safe environment when not in use 
8 Heating rate or overall reader instability 
during read-out affecting TLD response 
Use carefully controlled conditions, a high-
quality TLD reader, an experienced 
technician, and monitor TLD response in a 
reading session with control TLDs 
9 Size of TL detector may influence 
readings 
Use consistently sized dosimeters for 
every reading 
10 Thermal history affecting energy 
response of TLD 
Anneal the TLD material, do not store the 
TLDs longer than 1 week after annealing, 
maintain a consistent temperature cycle 
for an entire batch, minimize or eliminate 
the re-use of TLD material 
11 TLD-100 toxicity if ingested Appropriately train all personnel regarding 
the risks and proper handling of TLD-100 
material 
12 Time and cost associated with TLD-100 
readout 
Budget time and resources appropriately 
when using TLD-100 for measurements 
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1.2.2 TLD Physics 
 
 
 
 
 
 
 
 
Figure 1-5.  Energy band diagram modified from (31) demonstrating measureable light 
production as a result of exposure to radiation.  In an unexcited state, electron-hole pairs 
exist within the valence band of the crystal matrix.  When excited by ionizing radiation, 
electrons are launched into the conduction band (step 1).  In the conduction energy band, 
electrons may migrate in the crystal lattice (step 2) and positively-charged holes migrate 
along the valance band (step 2’).  Imperfections within the matrix create electron and hole 
trap levels (steps 3 and 3’, respectfully).  The excited TL material remains in a metastable 
state until sufficient heat energy is applied to the system to release these entities back into 
the conduction and valence bands, respectfully (steps 4 and 4’).  These electrons and holes 
recombine at luminescence centers within the crystal lattice (steps 5 and 5’) emitting light. 
 
The theory and physics of thermoluminescence is a very complex subject with 
intricacies that extend far beyond the scope of this work.  On a basic level, however, the 
theory of thermoluminescence can be explained with the assistance of Figure 1-5, which is 
an energy band diagram that demonstrates the production of measureable light (visible or 
ultraviolet) as a result of exposure to radiation.  In a normal state unexcited by ionizing 
radiation or temperature, electron-hole pairs exist within the valence band of the 
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thermoluminescent crystal matrix.  In the presence of ionizing radiation, electrons are freed 
and move to the conduction band as demonstrated in step 1 of Figure 1-5.  In the 
conduction energy band, electrons may migrate through the crystal lattice as demonstrated 
in step 2.  Accordingly, positively-charged holes may also migrate along the valance band 
as demonstrated in step 2’.  Thermoluminescent materials rely on imperfections within the 
matrix to create energy trap levels that may encumber both free electrons and holes, as 
demonstrated in steps 3 and 3’ (31).  Thus, after excitation the TL material remains in a 
metastable state with both the holes and electrons unable to move and recombine in a de-
excitation process.  The doping of LiF with Mg (300 ppm) in TLD-100 accomplishes the 
creation of such electron traps (26).   These electron and hole traps are thermally sensitive, 
and electrons and holes remain trapped until sufficient energy is applied to the system (in 
the form of heat) to release these entities back into the conduction and valence bands, 
respectively.  The specific amount of heat required depends on the depth of the traps and 
the temperature of the TLD material (31).  Once released, as demonstrated in steps 4 and 
4’, these electrons and holes may recombine at luminescence centers within the crystal 
lattice as shown in steps 5 and 5’ and emit measurable light proportional to the excitation 
received by ionizing radiation.  The doping of LiF with Ti (15 ppm) in TLD-100 accomplishes 
the generation of such luminescence centers (26). 
The radiation dose limits of detection are a function of the TLD-100 material, the 
material set-up and history, irradiation conditions, and TLD readout capabilities.  Many of 
these factors were discussed above and TLD readout specifics will be discussed below.  
However, with regard to limitations of the TLD-100 material specifically, the upper radiation 
dose limit is determined by saturation of available traps by electrons, irradiation history, and 
annealing (21, 26, 31).  This phenomenon is observed when TLD readings overestimate the 
radiation dose due to increased sensitivity, and is known as supralinearity (because the 
apparent dose response from the TLD material is no longer linear with the actual dose).  
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The actual dose where this permanent damage to the material is observed is batch 
dependent (for example, with slightly varying concentrations of Ti), but it is published to be 
commonly pronounced at 1000 Gy (26) for TLD-100 material.  The sensitivity, or linear dose 
response region, of a batch of TLD-100 material can be increased (sensitized up to a factor 
of five) or decreased with certain annealing techniques (26, 31, 33).   
The lower-limit of the radiation dose detection capabilities of TLD-100 material vary 
by batch (again, primarily based on batch composition), but is published to be 50 µGy (26).   
Besides composition, the lower radiation dose limits of a batch of TLD-100 material is 
(similarly to the upper radiation dose limits) observed as supralinearity (over-response).  In 
contrast to the upper radiation dose limit, though, this observed supralinearity is a function 
of low temperature traps within the lattice (26), spurious signals caused by ambient air 
being absorbed by the TLD-100 material during with the readout process (21), powder grain 
size (26), and tribothermoluminescence (21) (defined below).   
As a standard feature of a good TLD readout process, the composition variability is 
overcome by thoroughly mixing the ground TLD powder of a batch and by characterizing 
and quantifying the material to specific correction factors for every batch and every reading 
session.  Additionally, TLD materials are often preheated to 160°C for 10-20s (34) to 
eliminate low temperature electron traps; and spurious signals are overcome by minimizing 
TLD material exposure to air and by using nitrogen gas during TLD readout.  Decreasing 
powder grain size will decrease the relative dose response of TLD-100 material to radiation 
(26) (which may lead to reduced supralinearity in the low dose region), therefore the grain 
size of a batch of TLD powder should be as uniform as possible—which emphasizes the 
need for careful quality control in the manufacturing of TLD-100 materials and distribution of 
these powders into capsules.   
Tribothermoluminescence is defined as unwanted spurious background light signals 
that are related to the total surface area of the material in the form of friction (21, 26).  
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These surface trapping state effects (along with ambient air gas absorption) can be partially 
corrected by sufficient encapsulation of the dosimeter powder (21).  Further, the influence 
of tribothermoluminescence can be characterized by accomplishing TLD-100 radiation 
dosimetry measurements with TLD-100 powder grains of various sizes (26).  These 
measures are rarely undertaken, however, as the majority of applications for TLD-100 
dosimetry measurements are at cancer therapy energies and doses at which this effect is 
not observed.  These effects may, however, impact dose measurements obtained in low 
energies and dose environments such as those encountered in diagnostic imaging and VC.  
Additional measures may be required in TLD-100 dosimeter handling and in the 
quantification of dose linearity and energy correction factors if using TLD-100 dosimetry in 
such diagnostic applications (which can overrespond by as much as 40%) as opposed to 
lithium borate (Li2B4O7:Mn), which has better tissue-equivalence properties under these 
conditions (31).    
 
1.2.3 TLD Readout Process 
Although TLD-100 dosimeters can provide very precise and accurate radiation dose 
measurements for a wide range of doses and energies, a proper TLD readout process 
requires considerable attention to detail and substantial documentation.  The mission of the 
National Cancer Institute (NCI)-funded Radiologic Physics Center (RPC) at MD Anderson 
Cancer (Houston, TX) is “to assure National Cancer Institute and the Cooperative Groups 
that institutions participating in clinical trials deliver prescribed radiation doses that are 
clinically comparable and consistent.”  The RPC fulfills this mission through accurate and 
consistent radiation measurement capabilities and by conducting quality assurance audits 
of institutions.  More specifically, the RPC’s TLD equipment, policies, and professionals 
monitor the radiation dose delivered to patients in cancer therapy at sites participating in 
NCI clinical trials worldwide.  Thus, their TLD program is among the very best available and 
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is designed to minimize and/or eliminate the potential opportunities for the TLD 
uncertainties and reading errors mentioned above and to optimize measurement precision 
and accuracy.  They publish an overall uncertainty of 2.5% in their TLD measurement 
process at radiation therapy dose and energy levels (including phantom set-up and beam 
calibration) (35). 
The TLD-100 material used by the RPC is grown as LiF crystals by Thermo 
Scientific (Waltham, MA) and prepared for the RPC by Quantaflux, LLC (Dayton, OH).  
Upon purchasing the material from Thermo Scientific, Quantaflux grinds and sifts the 
crystals into a powder. Such grinding and thorough mixing is necessary to overcome both 
the small inherent non-uniformities within a single LiF crystal and the non-uniformities 
between the several LiF crystals contained in a TLD-100 batch sufficiently large to 
accommodate the quantity of TLDs used by the RPC.  Thus, appropriately prepared TLD-
100 powder will not have capsule-to-capsule variation in radiation response, as is the case 
with TLD chips (31).   
After mixing, Quantaflux loads specially-designed plastic TLD capsules (designed to 
maintain a snug fit into the RPC’s large inventory of acrylic blocks and anthropomorphic 
phantom inserts) to the RPC specifications (approximately 22 mg of powdered LiF per 
aliquot).  Upon receipt from Quantaflux, the RPC quantifies the fading, energy, and linearity 
correction factors for the batch of TLD-100 material (more specific explanations of these 
and other correction factors are provided below).  Once the material’s radiation response 
characteristics have been sufficiently quantified, they are sent (along with phantoms and 
instructions) to those institutions enlisted by the NCI to conduct clinical trials. 
After an institution has irradiated a TLD filled phantom as carefully instructed by the 
RPC, that institution returns the block and paperwork to the RPC for analysis.  When 
received, analysis begins at the RPC by reading 3 “standards” TLDs (a 4 mm diameter by 
15 mm length plastic capsule with a wall thickness of 1 mm containing a single aliquot of 
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TLD-100 material) that have been irradiated on the Cobalt V2 machine at MD Anderson 
Cancer Center.  This irradiation is conducted at least 14 days prior to the reading of the 
TLDs received by the institution being assessed (which are also read at least 14 days after 
irradiation to stabilize the dose response within the TLD-100 material—thus reducing 
potential time related variability (drift) in the dose measurements).    
Irradiation of the standards TLDs is a carefully controlled process conducted by the 
RPC that includes:  inserting 3 TLDs into an acrylic block phantom similar to that sent to the 
institutions for evaluation, positioning the TLD block on a jig attached at 80 cm source-to-
surface distance (SSD) from the cobalt-60 source, and irradiating the block to 3 clicks 
(4.45181 Gy as calibrated on 10/15/2005) in a 10 x 10 cm field.  These standards (which 
are from the same batch of TLD-100 material as those irradiated by the institution being 
assessed) are used to establish the sensitivity correction factors used for the calculation of 
dose to the irradiated TLDs.   
Next, 3 “control” TLDs are read, which are also carefully irradiated in a controlled 
process by the RPC by a different cobalt-60 source than that used to irradiate the standards 
(MD Anderson’s “Cobalt C” machine).  The two irradiation processes are similar, with the 
primary differences being the fact that the control TLDs are irradiated on a moving carousel 
attached to a jig and that the control TLDs are irradiated to 5 clicks (4.2924 Gy as calibrated 
on 10/15/2005).  Once the 3 standards and controls are read, the technician begins the 
reading process on the measurement TLDs irradiated by an institution. 
Every TLD is measured in a consistent manner to avoid uncertainties in the 
readings.  After the Harshaw TLD reader (ThermoFisher Scientific Corporation, Santa Fe, 
NM) has warmed-up for approximately 20 minutes, an independently-certified mass of 
approximately 20 mg is placed on the scale for calibration purposes.  Next, a plastic block 
fashioned to hold 3 TLD capsules is placed on the scale, the end of a TLD capsule that 
does not contain the plug is cut and discarded, the TLD is placed in this acrylic block and 
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on the scale for measurement, and the scale is again zeroed.  The TLD-100 material is then 
placed on the TLD reader planchette, the planchette is inserted back into the reader, and 
the emptied capsule is returned to the block on the scale and the mass deficit of the 
removed TLD material is recorded.   
At the next full minute, the reading process is begun by pressing the “start” button 
and typing the mass deficit measurement from the scale into the computer (thus 
documenting the mass of the LiF powder being read).  Once activated, the reader will 
steadily heat the LiF to 318°C and will measure the integrated charge generated by the 
stimulation of photomultiplier tubes as light is emitted from the TLD-100 material 
(specifically in glow peaks IV and V (26)).  This charge and mass are recorded on the 
technician’s worksheet, and when the reader temperature has cooled to 110°C the 
planchette is reopened and the read TLD-100 material is removed by vacuum.  The 
process of reading one TLD capsule should take a total of 2 minutes, and the TLD reading 
process continues with the next TLD in a series.  A typical TLD reading session begins with 
3 standards being read, then 3 controls, then 6-8 sets of 3 measurement TLDs, then 2 
controls, then 6-8 sets of 3 measurements, then 2 controls, then 6-8 sets of 3 
measurements.  The reading session ends with 3 controls and 3 standards being read; and 
a typical reading session lasts approximately 3 hours and includes 6 standard TLDs, 10 
control TLDs, and 54-72 measurement TLDs. 
Once the charge and mass readings have been obtained for each of the TLDs, the 
following correction factors are determined based on the properties of the TLD-100 batch 
and the irradiation parameters:  sensitivity (KS), fading (KF), linearity (KL), energy 
dependence (KE), and f-factor (or absorbed dose to the medium as opposed to the 
absorbed dose to the TLD material).  Finally, the TLD dose is calculated by multiplying the 
measured average charge per mass by all of the correction factors.  As the effective atomic 
mass of TLD-100 is similar to that of tissue, the estimated dose to tissue is easily calculated 
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by applying an f-factor (if necessary).   As standard protocol, the RPC provides their 
radiation dose measurements to their customers as absorbed dose to muscle (with the f-
factor already factored into the sensitivity correction factor). 
 
1.2.4 TLD Correction Factors  
 
1.2.4.1 Fading Correction Factor 
The TLD fading correction factor accounts for the fact that some electrons will gain 
sufficient energy at room temperature to escape from their traps, thus resulting in loss of 
signal and potential uncertainties in dose measurements.  For TLD-100 material, this value 
is relatively small (5-10% per year) (21, 26, 27) and is most unpredictable within the first 14 
days.  Therefore, the RPC recommends performing TLD readout 14 or more days after 
irradiation to reduce uncertainty.  Per RPC protocols, TLD fading (KF) is calculated by (36): 
 
( ) ( )( )F b X d X
NK
a e c e− ⋅ − ⋅
=
⋅ + ⋅
   (1-1) 
 
where N, a, b, c, d are values established when a TLD-100 batch is commissioned and X is 
the number of days since the TLD material being read was irradiated.   
 
1.2.4.2 Linearity Correction Factor 
The TLD linearity correction factor corrects for TLD material response to dose, since 
dose response is measured by the increase (or decrease) in the light per mass emitted 
during readout as dose to the material increases (or decreases).  For TLD-100 material, this 
value is typically linear (with variations existing between batches) from approximately 200 
mGy to 6 Gy (for the RPC’s B09 TLD-100 batch).  Radiation dosimetry measurements 
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performed for doses outside this range will require additional characterization to assess the 
supralinearity characteristics of this batch and determine appropriate batch linearity 
correction factors (KL) for the dose range being investigated.  Per RPC protocols, KL is 
calculated for doses within a commissioned dose range by (36): 
 
L rawK m d b= ⋅ +      (1-2) 
 
where m and b are values established when a TLD-100 batch is commissioned and draw is 
calculated from (36):   
 
   raw S F
Qd K Kmg= ⋅ ⋅      (1-3) 
 
with Q being the integrated charge read by the TLD reader (in µC), mg being the mass of 
the irradiated TLD-100 material (in mg), KS being the system sensitivity correction factor, 
and KF being the fading correction factor. 
 
1.2.4.3 Sensitivity Correction Factor 
The TLD sensitivity correction factor (KS) is calculated by dividing the decay-
corrected expected dose delivered to the standards by the cobalt machine by the product of 
the average of the standard measurements, the fading correction factor for the standards 
(which may be different from that of the TLDs being read), and the linearity correction for 
the standards (using the decay-corrected expected dose as the raw dose value) as shown 
by (36): 
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where dexp is the decay-corrected expected dose delivered to the standards TLDs by the 
cobalt machine, dcal is the dose delivered by the cobalt source when it was calibrated, T1/2 is 
the half-life of cobalt-60, t is the time elapsed between the calibration of the cobalt source 
and the irradiation of the standard TLDs, (KF)Std is the fading correction factor for the 
standard TLDs, (KL)Std is the linearity correction factor for the standard TLDs, and 
((Q/mg)Std)Avg is the average of the six standard TLD measurements. 
 
1.2.4.4 Energy Correction Factor 
The TLD energy correction factor corrects for TL material over-response (compared 
to tissue response) to the energy to which the TLD was irradiated, which can be as high as 
40% in low energy (diagnostic ) applications (31) and as high as 6.5% at cancer therapy 
energies (36).  For TLD-100 material, this value is typically unity (with variations existing 
between batches) from approximately 1 MV to 4 MV (for the RPC’s B09 TLD-100 batch as 
determined at batch commissioning).  Radiation dosimetry measurements performed for 
energies outside this range require additional characterization to assess the energy 
response characteristics of a specific TLD-100 batch for the energy range being 
investigated.   
 
1.2.4.5 f-Factor Utilization 
22 
 
As standard protocol, the RPC provides their radiation dose measurements to their 
customers as absorbed dose to muscle (with the appropriate f-factor already included in the 
sensitivity correction factor).  There are applications where it is necessary to determine an 
additional factor to correct from dose to muscle to another medium reflecting the 
environment in which a TLD was placed when irradiated (for example, in air or in an acrylic 
phantom).   In such situations, an additional f-factor (f) should be included in dose 
calculations considering TLD irradiation environment by (26, 37): 
 
( )
( )
/
/
en Environment
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f
µ ρ
µ ρ
 
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  
    (1-7) 
 
where (µen/ρ)Environment is the mass absorption coefficient of the environment in which the 
TLD was located (in cm2/mg), and (µen/ρ)Dosimeter is the mass absorption coefficient to which 
the TLD dosimeter was calibrated (in cm2/mg).  These mass absorption attenuation 
coefficient values can often be obtained from data published by the National Institute of 
Standards and Technology (NIST) (38). 
 
1.2.5 TLD Dose Calculation 
Finally, considering all of the correction factors presented above, the dose to a 
medium can be calculated from TLD light output and mass measurements by (26, 31):   
                                         
Medium S L E F
QD K K K K f
mg
= ⋅ ⋅ ⋅ ⋅ ⋅    (1-8) 
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where MediumD  is the dose to a medium (in mGy), Q is the integrated charge measured from 
the TLD light output of a TLD-100 sample during the reading process (in µC), mg is the 
mass of the irradiated TLD-100 material (in mg), KS is the sensitivity correction factor (in 
mGy*mg/µC), KL is the linearity correction factor (unitless), KE is the energy correction 
factor (unitless), KF is the fading correction factor (unitless), and f is the f-factor correcting 
for the medium in which the TLD was irradiated (unitless).   
 
1.3 CT Radiation Dose Measurements 
 
1.3.1 Background of CT Dose Measurements 
Although the radiation dose received by patients while undergoing CT scans has 
been the subject of recent high-profile media activity (8-12), the need to measure this entity 
was realized in the very early days of computed tomography.  Perry and Bridges were the 
first to publish CT radiation exposure and dose measurements in 1973 using an ionization 
chamber pressed in wax between a polymethyl methacrylate (PMMA) cylinder and a water-
filled soccer ball bladder taking point exposure measurements for single slice CT (39).  
TLD-100 was first used to measure single slice CT exposure in 1974 (40).  Among the first 
to present a system for characterizing multi-slice CT dose was a group from the US Food 
and Drug Administration (FDA) lead by Shope in 1981 when he introduced the concept of 
CT Dose Index (CTDI) and the corresponding phantoms (41), which has evolved with 
technological advances and continues to be the clinical standard for characterizing CT 
scanner x-ray beam output. 
 
1.3.2 CT Dose Index (CTDI) 
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CTDI provides a convenient technique used to estimate the average absorbed dose 
delivered from multiple contiguous CT irradiations (including scatter tail dose pile-up) by 
subjecting the standard PMMA CTDI phantom to one axial scan; or (42): 
 
1 ( )CTDI D z dz
N T
∞
−∞
=
⋅ ∫     (1-9) 
 
where N is the number of data channels, T is the detector width sampled by each channel 
(and the product N*T is therefore the total nominal x-ray beam width during the scan (37)), 
and D(z) is the radiation dose profile along the z-axis (the axis parallel to the CT table).  
Practically, this expression is simplified to an entity that can be realistically measured with a 
commercially available 100 mm pencil ionization chamber (42): 
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=
⋅ ∫     (1-10) 
 
Since the pencil ionization chamber effectively measures the integrated exposure along its 
active length, this expression can be simplified to (37): 
 
   ( )100
f C E LCTDI N T
⋅ ⋅ ⋅= ⋅     (1-11) 
 
where f is the f-factor that converts in-air exposures to dose in air (0.87 rad/R or 8.7 
mGy/R), C is the electrometer calibration factor, E is the reading provided by the 
electrometer after one axial scan in the center of the CTDI phantom (in R or mR), L is the 
25 
 
active length of the pencil ionization chamber (100 mm), and the product N*T is the total 
nominal x-ray beam width during the scan. 
However, since the dose distribution within an object (the CTDI phantom in this 
case) is not uniform throughout (with increased dose being deposited superficially), the 
CTDI-weighted index (CTDIw) was also created.  This is obtained by taking CTDI100 
measurements at the center of the CTDI phantom (CTDI100)center and by averaging CTDI100 
measurements taken 1 cm below the surface at the 12, 3, 6, and 9 o’clock positions 
(CTDI100)periphery , or (37): 
 
   ( ) ( )100 100
1 2
3 3w center periphery
CTDI CTDI CTDI= +  (1-12) 
 
It has been estimated that (CTDI100)center and (CTDI100)periphery tend to underestimate the 
equilibrium dose (i.e. the true “saturation” dose at z=0, including the dose scatter tails as 
the measured medium length approaches infinity (43)) by a factor of 0.6 and 0.8, 
respectfully (42).   
In order to account for the changes in dose deposition related to variable x-ray 
beam distribution (such as with gaps or overlaps in beam coverage), the CTDI-volume 
index (CTDIvol) is calculated from this CTDIw value as (37): 
 
   ( )vol w
N TCTDI CTDI I
⋅= ⋅     (1-13) 
 
where I is the table movement per rotation of the x-ray tube.  For helical scans, this 
expression becomes (37): 
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   wvol
CTDICTDI pitch=     (1-14) 
 
where pitch is the table distance traveled in one complete revolution of the x-ray tube 
divided by the nominal beam width, or (37): 
 
   ( )
Ipitch N T= ⋅      (1-15) 
 
CTDIvol provides a useful estimate of the average radiation dose (in mGy) within a 
scanned volume of PMMA for a specific scan protocol (42).  These estimates are only 
intended to be applied for CTDI phantoms of similar attenuation and size undergoing an 
identical CT scan technique; and can only be reliably used in such circumstances.  This 
does not typically include human imaging since patient anatomy is heterogeneous and 
exhibits varying attenuation and size properties. 
A noticeable shortcoming of the CTDIvol measurement is that it does not account for 
the length an object is scanned (lengthscan) (in cm).  In other words, regardless of whether 
an object is scanned for 20, 50, or 100 cm, the CTDIvol dose estimate remains the same 
(42).  Therefore, the dose length product (DLP) is calculated (in units of mGy-cm) by the 
following equation (37): 
 
   vol scanDLP CTDI length= ⋅     (1-16) 
 
It has been estimated that DLP underestimates the total energy imparted by 30% for all 
scan lengths (42).  Further, the units for this entity are not intuitive and therefore not very 
helpful in a clinical setting to determine the dose (or perhaps more appropriately, the risk) a 
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patient receives as a result of a CT scan.  Fortunately, DLP can be used to estimate the 
biological effect or detriment to an individual undergoing a CT scan based on the body 
region irradiated to yield an effective dose (E) (in mSv).  This is calculated by (42): 
 
   E k DLP≈ ⋅       (1-17) 
 
where k is a coefficient (in mSv/(mGy*cm)) published in AAPM Report 96 (shown in Table 
1-3) that is specific to a patient’s age and the region of body scanned.   
 
Table 1-3:  k values published in AAPM Report 96 (42) to convert 16 cm or 32 cm diameter 
head CTDI phantom-based DLP estimates to effective dose estimates.  Adult head, neck, head 
and neck, and pediatric patient k values were based on the 16 cm diameter phantom; while 
the remaining k values were based on the 32 cm diameter phantom. 
Region of Body k (mSv/(mGy*cm) 
  0 Years 
Old 
1 Year 
Old 
5 Years 
Old 
10 Years 
Old 
Adult 
Head and Neck 0.013 0.0085 0.0057 0.0042 0.0031 
Head  0.011 0.0067 0.004 0.0032 0.0021 
Neck 0.017 0.012 0.011 0.0079 0.0059 
Chest 0.039 0.026 0.018 0.013 0.014 
Abdomen and/or 
Pelvis 
0.049 0.03 0.02 0.015 0.015 
Trunk 0.044 0.028 0.019 0.014 0.015 
 
 
The k coefficients provided in Table 1-3 were determined by Monte Carlo 
simulations on the Medical Internal Radiation Dose (MIRD) Committee’s MIRD V 
anthropomorphic mathematical phantom (42, 44, 45); which has also been incorporated 
into the CT dose research performed by the United Kingdom’s formerly named National 
Radiological Protection Board (NRPB) (now known as Radiation Protection Division of the 
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Health Protection Agency), the Imaging and Performance Assessment of CT (ImPACT) 
group’s CT dose models (46-48), the Monte Carlo simulation program created by McNitt-
Gray’s group at the University of California at Los Angeles (UCLA), and many others.  
Although this phantom is based on reference data published in ICRP Publication 23 (49) 
and is considered among the best such models in existence (as evidenced by the fact that it 
is among the most common of the mathematical phantoms used for estimating patient 
dose), this phantom is based on the radiological response to only three generalized tissues 
(bone, lung, and soft tissue) in 27 radiosensitive organs modeled after geometric shapes; 
and therefore is limited in its ability to predict patient dose for the wide variety of patient 
sizes and shapes that undergo VC. 
Further, while CTDI is a good measure of CT scanner output, it is not intended to 
represent the dose for patients—who present in widely varying sizes, shapes, and 
attenuation (50).  Since a standard CTDI phantom is only 15 cm long in the axial direction, 
and a pencil ionization chamber is only 10 cm long, CTDI techniques will naturally 
underestimate scatter doses experienced in typical adult anatomy by not considering the 
“tails” of the z-axis dose profile (51).  Additionally, CTDI is technically expressed in terms of 
dose-to-air (not dose to tissue) based on its f-factor of 0.87 rad/R (or 8.7 mGy/R); so such 
estimates are technically a step away from tissue dosimetry (50).  The appropriate f-factor 
correlating dose in a material to dose in air for a CTDI phantom has been demonstrated by 
Monte Carlo modeling to vary by location within the phantom, the presence or absence of a 
bowtie filter, the kVp setting, the length of the pencil ionization chamber, and by the 
diameter of the CTDI phantom (51).   
CTDI is so ubiquitous in CT imaging that modern CT scanners provide CTDIvol and 
DLP value estimates to users, and DICOM structure reports at MD Anderson Cancer 
Center additionally provide a dose report for clinicians for those scans performed since 
January 2010.  The term “dose report”, however, as labeled in ClinicStation is something of 
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a misnomer and reported CTDIvol and DLP values are misleading because of these 
limitations.  Although effective dose can be calculated from these CTDIvol values and is 
commonly used to quantify risk, with anthropomorphic phantom experiments showing good 
agreement between cumulative organ dose measurements and these CTDI-based effective 
dose values (52), during a VC scan only the abdomen and pelvis are irradiated.  
Additionally, VC protocols at MD Anderson Cancer Center utilize a static CT technique 
regardless of the size of the patient, which will result in more centrally located organs (like 
the rectum) receiving lower doses on larger patients than on thinner patients.  Since the 
number of organs irradiated is low and the potential inter-patient organ dose variance may 
be high, using CTDI-based effective dose estimates may under- or overestimate true 
patient risk.  Therefore specific organ doses are more appropriate to quantify patient risk in 
such instances (20). 
 
1.3.3 Monte Carlo Method 
Monte Carlo modeling, when validated by independent phantom or in-vivo 
measurements, is considered the gold standard for calculating dose to an organ from 
irradiation.  Monte Carlo modeling is a computationally intensive technique developed 
through the 1930’s and 1940’s that has been used to study complex systems (including 
those in the physical sciences, engineering, applied statistics, business, 
telecommunications, and gaming fields) that have many coupled degrees of freedom, 
significant uncertainty of input parameters, and complicated boundary conditions (53).  As 
the term “Monte Carlo” was coined in honor of the famed casino of the same name in 
Monaco (54), this method relies on repeated sampling of random events (via random or 
pseudo-random numbers) and probability statistics to investigate problems; thus allowing 
for the examination of more complex systems than can be investigated by more 
deterministic means (55).  For example, calculating the interaction of a single x-ray photon 
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with one or two atoms of a single tissue type within the body can be solved fairly simply; 
however, solving the system of interactions for the many tissues within the body for the 
relatively large number of photons emitted during a VC exam is impractical by any other 
means besides Monte Carlo modeling.    
For CT, this simulation procedure requires development of the CT scanner model 
(as the source of the x-rays), the patient model (using the acquired images), and the x-ray 
beam path (in this case, a helical geometry).  ImPACT’s CTdosimetry software is probably 
the most used research tool for estimating organ doses and is based on CTDI and Monte 
Carlo data in a single-size patient geometry MIRD V mathematical phantom (56), but 
makes several assumptions in its methodology that may result in uncertainties in dose 
estimates (44).  The Monte Carlo process created by McNitt-Gray’s group at the University 
of California at Los Angeles (UCLA) is a well-documented and validated methodology (44, 
57-62) created specifically for MDCT; but this methodology is also limited in that since it 
uses patient images as the basis for its calculations, the results yielded by such simulations 
are very patient specific and therefore limited in terms of patient size and organ distribution.  
This Monte Carlo process is valuable, though, in that it can provide organ dose estimates 
for true patient geometries.  True (i.e. direct) CT point dose measurements would be ideal 
to validate or benchmark such a Monte Carlo modeling procedure. 
 
1.3.4 CT Point Dose Measurements 
Direct CT dosimetry measurements using TLDs, Farmer (aka thimble) ionization 
chambers, metal-oxide semiconductor field-effect transistors (MOSFET), film, diodes, 
plastic scintillators, or optically stimulated luminescent dosimeters (OSLDs) (23) are often 
performed in research to validate other indirect means of determining radiation dose (e.g. 
CTDI, surface exposure, mathematical models, or Monte Carlo simulations).  Ideally, direct 
methods are preferred for radiation dose measurement (63) because they provide true 
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measurements of radiation interactions in a medium.  Unfortunately, these measurements 
are rarely realized because they are typically considered invasive and often unsafe for use 
in a patient.  Therefore, various phantoms have been developed to mimic a true patient 
using standard reference organ sizes and locations and by using materials that are 
approximately tissue equivalent in the CT energy and dose range. 
When validating an indirect dosimetry assessment tool like a mathematical (64) or 
Monte Carlo (58, 63, 65, 66) model (for example) , or when estimating the dose to an organ 
during a procedure (40, 64, 67-71), TLDs are typically placed on the surface of and/or 
inserted into the organs of anthropomorphic phantoms and in-air exposure or organ dose 
measurements are made using the CT protocol modeled.  Since indirect methods/models 
are typically based on approximations from (often similar) reference patient and organ 
sizes, comparison results between indirect dosimetry methods (for example, between 
Monte Carlo simulations and anthropomorphic phantom measurements) are often reported 
to be favorably consistent with one another (65, 66) (with anthropomorphic testing being 
used to benchmark and/or validate Monte Carlo modeling results).  While agreement 
between model and phantom measurement results is a testament to the ability of such a 
model to represent the physics scenario within a given situation, such models may not in 
reality provide an accurate understanding of the absorbed doses received by a patient; as 
has been observed in a study comparing anthropomorphic phantom dose to cadaver dose 
from identical CT protocols (72).   
Non-agreement between cadaver and phantom measurements or Monte Carlo 
models may be due to the fact that both simulations and phantoms are fundamentally 
based on approximations to patient size, shape, and radiation response; and additionally to 
the possibility that radiation dose response within a cadaver may differ from that in living 
tissue or in a phantom.   Therefore, although phantom measurements are valuable from 
practical and risk-reward perspectives, they may not provide accurate patient organ 
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absorbed dose measurements as they are based on approximations to true patient size and 
in-vivo radiation dose response; and the accuracy of a Monte Carlo model that is 
benchmarked against a phantom (which is inherently based on approximations) can be 
questioned.  Thus, in-vivo organ absorbed dose measurements are necessary to 
benchmark and validate existing indirect measurement models such as phantoms or Monte 
Carlo simulations. 
 
1.3.5 MD Anderson VC Rectal Dose Estimates 
VC offers an opportunity to obtain in-vivo organ dose measurements without 
additional duress to a patient because a rectal catheter (to which TLDs can be affixed) is 
inserted into a patient as a routine aspect of the procedure.  Additionally, the centrality of 
the rectum within a patient’s body decreases the likelihood that surface dose variations that 
are characteristic of CT scans (61) will result in TLD point dose measurement 
inconsistencies and/or errors.  To date, direct in‐vivo organ dose measurements have never 
been performed for internal organs during VC scans or even during MDCT scans in 
general; thus, the accuracy of any indirect dose estimates is currently unknown (17-19, 73).  
Further, although the average VC patient effective dose is estimated to be 7 mSv at MD 
Anderson, such effective dose estimates are based on calculations from reference patients 
and uniform phantoms; therefore uncertainty exists with such risk estimates (20).   
Previous in-vivo CT measurements have been conducted for cone beam CT 
(CBCT) by Walter, et al and Jeng, et al.  Walter used a 7 mm diameter ionization chamber 
inserted into patients’ rectums (74) (that was connected to an electrometer requiring input 
potentials of up to ±400 V).  Jeng used TLDs attached to a rectal catheter that was inserted 
into the rectum (75).  Using rectal dose measurements from these studies to estimate VC 
rectal dose provides questionably correlated results because CBCT, not MDCT, was used 
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to acquire these in-vivo dose measurements; but these studies do lend credence to this 
general approach of obtaining in-vivo measurements within the rectum.   
CBCT is an imaging modality typically used in dental applications and in on-board 
imaging of modern linear accelerators (linacs) for image guided radiation therapy (IGRT) 
(which was the application for both Walter’s and Jeng’s research).  Although imaging on 
CBCT devices is faster than MDCT, the image quality provided by CBCT devices is 
generally inferior to that of MDCT devices.  The differences between the MDCT and CBCT 
modalities (and therefore opportunities for errors in dose estimation) are many, including:  
VC protocols at MD Anderson requires the use of a beam width of 40 mm and many 
rotations of the x-ray tube on the MDCT to obtain image data where CBCT imaging is 
accomplished in one rotation of the x-ray tube and with a beam width of 450 mm.  In fact, 
Kim, et al. compared the modalities and concluded that under as similar technique 
constraints as possible, the CTDI measurements for CBCT were 49% lower than those of 
MDCT (76)—which underscores the fact that the beam dose distribution characteristics of 
the two modalities are considerably different.   
Since the only previous direct in-vivo rectal CT dose measurements that have been 
obtained do not apply to VC or even MDCT, any VC dose predictions based on these 
CBCT data are prone to error.  In spite of these limitations in accuracy, by assuming CBCT 
and MDCT both demonstrate a linear relationship between mAs and absorbed dose, and by 
assuming the linear relationship of the two modalities are correlated, the rectal dose 
received by a patient undergoing VC can be approximated from the in-vivo data published 
by Walter (74) and Jeng (75) for the population of patient sizes represented in each study.  
Doing so, the CT technique used in VC at MD Anderson Cancer Center yield approximate 
mean rectal doses of 5.2 mGy and 4.4 mGy for each respective population of patient 
habitus (patient anthropomorphic measurements were not provided by Walter (74); and 
ranged in Jeng’s study (75) from 33.80 cm to 39.22 cm in patient width and from 18.70 cm 
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to 23.92 cm in patient thickness).  Again, these dose estimates were based on several 
assumptions and therefore are prone to error. 
DeMarco, et al performed Monte Carlo modeling using the UCLA code described 
above on six simulated patients of varying size to determine colonic dose based on whole 
body MDCT scans; obtaining colonic dose estimates ranging from 11 to 18 mGy (with an 
average of 13.8 mGy) across the varying sizes at the mAs used in the MD Anderson 
Cancer Center VC protocol (59).  However, this estimate also has limited applicability to the 
rectal dose received by patients undergoing VC at MD Anderson because the CT scanner 
x-ray source model used in these calculations was based on a different scanner 
manufacturer, with a different beam width, for a whole body scan (which will provide more 
scatter dose to the rectum than VC), and pertained to the dose received by the entire colon 
(versus just the rectum). For these reasons, the rectal dose received by patients at MD 
Anderson will likely be less than this value.   
Confirmation of this suspected lower rectal VC dose was obtained by simulating the 
MD Anderson VC protocol using the ImPACT CT dose calculation program. Using this 
protocol, an equivalent dose of 6.3 mSv is yielded for the lower large intestine of the MIRD 
V mathematical phantom on which this software is based (with equivalent dose being 
defined as the organ absorbed dose multiplied by the radiation quality factor, which is 1 for 
photons (14), thus implying a predicted absorbed dose of 6.3 mGy).  A previous study 
showed that the UCLA Monte Carlo code demonstrated good agreement with ImPACT 
dose estimates when applied to the same MIRD V mathematical phantom (44), therefore 
the rectal dose received by patients at MD Anderson is predicted to be less than the 11 to 
18 mGy range published by DeMarco (59). 
Using Farmer ionization chamber measurements within the center bore of a 
homogeneous CTDI body phantom exposed using the MD Anderson Cancer Center CT 
technique for VC, a preliminary rectal dose estimate of 6.1 mGy was achieved.  By 
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mathematically subtracting 6 cm from the CTDI body phantom and applying that thickness 
to the Lambert-Beer equation (Equation 3-2), an upper limit of a rectal dose estimate of 
11.2 mGy was attained (for a theoretical approximate smallest diameter VC patient).  An 
estimated lower rectal dose limit of 0.5 mGy for a very large patient was assumed for a 
patient undergoing VC at MD Anderson Cancer Center.   
This 0.5-11.2 mGy dose estimate is limited, however, since a patient’s irradiated 
volume during VC consists of heterogeneous tissues and since patients of different habitus 
will have different proportions of self-shielding (via adipose layers, soft and hard tissues, 
etc), this estimate is also subject to error.  Conducting similar measurements in an 
anthropomorphic phantom would likely eliminate some (but not all) of these phantom 
homogeneity errors because such measurements would reflect dose to a reference patient, 
but would not be able to account for random variations in organ size and position that exist 
between people.  Also, the largest source of variation in actual organ dose measurements 
is likely that introduced by the varying sizes and shapes of patients that undergo VC.  Jeng 
and DeMarco published organ dose variances (resulting from differences in subject body 
composition) from the mean organ dose of each study population of up to 16.2% (75) and 
22.9% (59), respectfully. 
In spite of all of the limitations of each of these methods for estimating the patient 
rectal dose received at MD Anderson as a result of VC, all of these rectal dose estimates 
are within a consistent range (0.7-14 mGy).  Therefore the rectal dose received by patients 
undergoing VC can reasonably be predicted to also fall within this range; but only actual 
direct measurements can verify any understanding of the radiation dose administered in 
such circumstances.  This described difficulty in estimating the rectal dose range to be 
encountered by patients while undergoing VC at MD Anderson underscores the need for in-
vivo organ dose measurements.   
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1.4 Hypothesis and Specific Aims 
 
1.4.1 Hypothesis  
Rectal dose measurements obtained in-vivo during virtual colonoscopy will have a 
rectal dose coefficient of variation that will be greater than 50%; and the anthropomorphic 
phantom dose measurements, CTDIvol-based dose estimates, and Farmer chamber 
measurements in a CTDI body phantom will estimate rectal doses outside a 95% 
confidence interval of the in-vivo patient dose measurements. 
 
1.4.2 Specific Aims  
Various options currently exist that can provide estimates of patient organ dose 
received during virtual colonoscopy (VC).  However, all of these techniques incorporate 
indirect methods that are based on estimates from reference anatomical geometry and may 
not reflect the actual organ dose received by any individual patient.  Such is the case not 
only for VC, but for all organ absorbed dose measurements for multi-detector computed 
tomography (MDCT) examinations, where in-vivo measurements have never been feasible 
to validate indirect dose measurements and estimates.  Currently, most MDCT dose 
estimates are based on measurements in a uniform phantom (which does not accurately 
represent patient anatomy) either in the form of CTDIvol (which is based on integral dose 
measurements) or point (Farmer ionization chamber) measurements.  Therefore the 
purpose of this research is to develop a method for obtaining in-vivo rectum dose 
measurements during VC and to compare these measurements to dose estimates obtained 
using the same CT scan protocols in an anthropomorphic phantom and a homogeneous 
acrylic phantom that is ubiquitously used to assess CT scanner radiation output. 
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1.4.2.1 Specific Aim 1:  Establish TLD Linearity Correction Factors for VC Scan Parameters 
on a MDCT  
Using thermoluminescent dosimeters (TLDs) obtained from the National Cancer 
Institute-funded Radiologic Physics Center (RPC) at MD Anderson Cancer Center, dose 
linearity correction factors will be obtained at 120 kVp specific to the polyenergetic 
spectrum produced by a MDCT in VC.  These values will be determined by inserting one 
TLD per scan in an acrylic insert rod (with a custom-made tight TLD seat) and placing the 
insert rod into the center of an acrylic CTDI phantom.   This phantom set-up will be used to 
irradiate several TLDs using helical scans irradiating the entire length of the CTDI phantom 
at varying mAs settings.  This acquired absorbed dose data (in mGy) will be compiled, 
compared to point dose data (in mGy) obtained via Farmer ionization chamber, and used to 
calculate the TLD linearity correction factors for the conditions encountered by variously 
sized patients undergoing VC at MD Anderson Cancer Center. 
 
1.4.2.2 Specific Aim 2:  Obtain Rectal Dose Measurements in an Anthropomorphic 
Phantom and In-Vivo in Patients Undergoing VC with TLDs 
An anthropomorphic phantom will be modified to approximate conditions during VC 
in three sizes of patients; and two double chambered TLDs will be inserted into the 
phantom in three iterations to assess VC rectal dose for those patients represented by each 
respective phantom configuration.  Additionally, in-vivo rectal dose measurements will be 
acquired by affixing two TLDs to the inner lumen of 6 rectal catheters for use in 6 patient 
VC studies.  During a VC procedure, when a catheter is inserted into a patient’s rectum, 
these affixed TLDs will acquire four measurements of the absorbed radiation dose delivered 
to that patient’s rectum using the standard MD Anderson VC MDCT scan technique.  12 
rectal dose measurements (in mGy) will be obtained for each of the three phantom 
iterations and four rectal dose measurements will be obtained within each of the 6 patients 
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using the dose linearity correction factors established for 120 kVp in Specific Aim 1; along 
with the charge per mass readings, fading correction factor, and sensitivity correction factor 
provided by the RPC. 
 
1.4.2.3 Specific Aim 3:  Compare In-Vivo Rectal Dose Measurements to Anthropomorphic 
Phantom Measurements, CTDI-Based Dose Estimates and Point Dose Measurements from 
a Uniform Phantom 
The rectal dose measurements of the three phantom configurations and in-vivo 
rectal dose measurements from 6 patients will be tabulated along with patient geometry 
measurements.  These dose measurements will be compared to CTDIvol-based dose 
estimates and point dose measurements (all in mGy) obtained from a 32 cm diameter CTDI 
body phantom while irradiated with the same technique.  Coefficients of variation and 95% 
confidence intervals will be constructed for phantom, patient rectal dose measurements.  
This data will be used to test whether the between-patient rectal dose coefficients of 
variation are greater than 50% and if the anthropomorphic phantom dose measurements, 
CTDIvol-based dose estimates, and the Farmer chamber dose measurement in a CTDI body 
phantom are outside the 95% confidence interval of the patient dose measurements.  
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CHAPTER 2.0:  MATERIALS 
 
2.1 Introduction 
In order to accomplish the specific aims of this project, several items were required; 
including:  a GE LightSpeed VCT scanner, a CIRS ATOM adult anthropomorphic phantom, 
a uniform polymethyl methacrylate (PMMA) 32 cm diameter CTDI body phantom (with 
accompanying insert rods), 79 double chambered thermoluminescent dosimeter (TLD) 
capsules, a custom-made PMMA CTDI insert rod with a tight TLD capsule seat, two 
ionization chambers (a Radcal model 9060/10x5-0.6 Farmer chamber and a Radcal model 
9060/10X5-3CT CT pencil chamber), a Radcal model 9010 electrometer, and 10 E-Z-EM 
Super XL double contrast enema delivery systems. 
  
2.2 GE LightSpeed VCT Scanner 
 Standard virtual colonoscopy (VC) at MD Anderson Cancer Center requires the use 
of a GE LightSpeed VCT scanner (GE Healthcare, Waukesha, WI) (see Figure 2-1) 
operating under the scanning protocol described in Table 1-1.  This MDCT scanner model 
was first introduced by GE in 2004, with VCT standing for “volume computed tomography”.  
At the time of its introduction, this model was a significant upgrade from other MDCTs 
available in imaging speed capabilities (advertising the capability of imaging a stationary 
organ in as little as one second and a moving organ like the heart in as little as five seconds 
(77)).  These imaging speeds are accomplished by incorporating more data channels than 
what was previously available (the GE LightSpeed VCT scanner utilized 64 data channels; 
while its primary competition at the time used a maximum of either 16, 32, or 40 data 
channels) and by using a very powerful x-ray tube that provided a beam width capable of 
irradiating detector lengths of 40 mm (versus the more standard 20 mm detector lengths) at 
fast rotation speeds (<400 ms) (78).  Additionally, regardless of specified scanner 
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parameter setting, this scanner always collects data at the level of the smallest detector 
size (0.625 mm), which allows for the retrospective creation of CT images at varying 
thicknesses.  With these developments, the GE Lightspeed VCT scanner was able to 
provide 73% more coverage per second (when at maximum pitch) than its CT predecessors 
(78).  Although several MDCT scanners have been developed between the launch of this 
scanner and this writing, this scanner remains a very capable resource for accomplishing 
VC. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2-1.  GE LightSpeed VCT Scanner (MD Anderson Cancer Center “CT9”). 
 
 The GE LightSpeed VCT scanner has the capability to receive image data acquired 
from its 0.625 mm detectors from 64 channels, and has a 70 cm bore diameter.  It has six 
axial nominal beam widths available (1.25 mm, 2.5 mm, 5.0 mm, 10 mm, 20 mm, and 40 
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mm).  Three pitch values are available for the 40 mm effective beam width used in VC 
(0.516, 0.984, and 1.375).  The table can move through the gantry at speeds up to 137.5 
mm/sec during imaging.  Additionally, the GE LightSpeed VCT scanner has dual focal spot 
capabilities, where the scanner chooses the focal spot size based on the selected tube 
current and voltage to balance spatial resolution (which is better with the smaller focal spot 
size of 0.9 mm x 0.7 mm) and x-ray tube target heat capability (which is better with the 
larger focal spot size of 1.2 mm x 1.2 mm) (79).  With the capabilities provided by the GE 
LightSpeed VCT scanner, a single VC prone or supine scan can be accomplished in 2.5-10 
seconds (depending on the size of the patient) using standard MD Anderson VC protocols. 
 At the time of this writing, the Radiologic Physics section of the Department of 
Imaging Physics at MD Anderson Cancer Center supported four GE LightSpeed VCT 
scanners; most VC procedures at MD Anderson Cancer Center were performed on MDCT 
scanner “CT9”, but were also performed on “CT5” and “CT12” as necessary for procedure 
scheduling purposes.   All TLD measurements used to accomplish Specific Aim 1 were 
performed on “CT9” scanner and VC rectal dose measurements were performed in this 
study on all three of these VCT scanners.  It is not believed that the use of multiple MDCT 
scanners negatively affected the accuracy of the rectal dose measurements as all four 
MDCT scanners supported by the Radiologic Physics section demonstrating reasonable 
consistency in computed tomography dose index (CTDI) measurements in a 32 cm CTDI 
body phantom in their most recent annual surveys (with percent coefficients of variation of 
2.3% for (CTDI100)center, 2.2% for (CTDI100)periphery, and 2.1% for CTDIw). 
 
2.3 CTDI Body Phantom 
The Computed Tomography Dose Index (CTDI) body phantom used for this protocol 
was manufactured by the MD Anderson Cancer Center Machine Shop (Houston, TX) 
according to standardized dimensions.  The original design for this phantom was first 
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published by Shope, et al in 1981 (41) as being a “cylindrical Plexiglas phantom 32 cm in 
diameter with arrays of LiF thermoluminescent dosimeters inside the phantom”.  Since the 
CTDI technique pioneered by Shope has become the clinical standard for CT dose 
characterization, the basic design of this phantom has changed little since it was first 
introduced.  The modern design for this phantom contains a bore in the center of the 
phantom that is sufficiently large (1.3 cm in diameter) to insert a pencil or Farmer ionization 
chamber; and at least four additional peripheral 1.3 cm diameter bores located at 90 
degrees from one another at a depth of 1.0 cm from center of each bore to the phantom 
surface. 
 
 
 
 
 
 
 
 
 
 
 
Figure 2-2.   32 cm CTDI body phantom with insert rods. 
 
The CTDI body phantom (see Figure 2-2) contains the five aforementioned bores, 
along with four additional bores of the same diameter located equidistantly between each of 
the peripheral bores and the center bore.  These additional bores were included into the 
phantom design to provide dose measurement capabilities that approximate for organ or 
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fetal locations.  The phantom utilizes 8 acrylic insert rods that slide into each bore that is not 
being used to take measurements (i.e. the remaining bores that do not contain a 
measurement device) with minimal air gap.  Additionally, the CTDI body phantom is 
uniformly composed of polymethyl methacrylate (PMMA), is fashioned as a 32 cm diameter 
cylinder that is 15 cm thick, and weighs approximately 13.2 kg (29 lbs).  Commercial 
manufacturers provide CTDI body phantoms with additional features, such as an all-in-one 
32 cm CTDI body, 16 cm CTDI adult head, and 10 cm CTDI pediatric head phantom.  
However, such features were not necessary for this project. 
 
2.4 CIRS ATOM Adult Anthropomorphic Phantom 
 In addition to the CTDI body phantom, an ATOM adult male model 701 
anthropomorphic dosimetry phantom (Computerized Imaging Reference Systems, Inc 
(CIRS), Norfolk, VA) (see Figure 2-3) was used to estimate the rectal dose received by 
patients undergoing VC at MD Anderson Cancer Center.  The ATOM phantom line was 
originally developed and manufactured by ATOM Ltd (Riga, Latvia) beginning in 1985, and 
CIRS assumed exclusive manufacturing privileges of this phantom in 1999 (80).  The 
standard ATOM model 701 adult male phantom consists of an anthropomorphic head, 
torso, pelvis, and upper femurs modeled in the representation of the “standard” man as 
published in ICRP 23 (49) from epoxy resins with tissue equivalent properties of adult bone 
(a composition of average age-based mineral densities and known trabecular and cortical 
ratios), soft tissue, lung (during held inspiration), spinal cord, cartilage (spinal discs), and 
brain (81, 82).  The epoxy resins representing the bone and soft tissue in this phantom 
have linear attenuation coefficients that are within 1% of actual bone and water, 
respectively, from 50 keV to 25 MeV; and the material representing lung tissue during 
inspiration has a linear attenuation coefficient within 3% of actual lung tissue in this same 
energy range (81).   
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Figure 2-3.   CIRS model 701 ATOM adult male phantom. 
 
In addition to these tissue equivalent materials, adipose tissue equivalent fat layers 
can be purchased from CIRS for application onto the ATOM model 701 adult male phantom 
in order to accomplish dosimetry studies for larger, more realistic patients (see Figures 2-4 
and 2-5).  This set of fat layers consists of 10 slabs (4 cm thick by 20 cm in length) of 
proprietary soft gel material (providing adipose tissue equivalence within 1% for therapy 
and diagnostic energy photon beams) that has been reinforced with nylon/Lycra mesh and 
hook-and-latch pads for assembly (83).  The 10 fat slabs are of varying lengths and are 
applied to the outer surface of the phantom abdomen in either one or two layers of four 
slabs (with two additional larger slabs available to accommodate adding fat to phantom 
dimensions larger than the abdomen, such as the thorax or pelvis). 
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Figure 2-4.   CIRS model 701 ATOM adult male phantom simulated adipose tissue kit. 
 
 
 
 
 
 
 
 
 
 
Figure 2-5.   A) ATOM phantom pelvis with first layer of simulated adipose tissue assembled; 
B) ATOM pelvis with second layer of simulated adipose tissue assembled. 
 
The adult male ATOM phantom is divided into 39 cross-sectional blocks, with each 
section measuring 25 mm in thickness.  The entire ATOM phantom line can be purchased 
 
A) 
 
B) 
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with five millimeter diameter bores (revealed after removing custom fitted plugs) 
strategically placed within 21 radiosensitive internal organs that are capable of housing TLD 
capsules.  Additional customized plugs are available for purchase to house other dosimetry 
measurement devices such as TLD rods, chips, optically stimulated luminescent dosimeters 
(OSLD), or metal oxide semiconductor field effect transistors (MOSFET).  Film can also be 
utilized for dosimetry by inserting appropriately sized film between phantom sections and by 
taping the adjoining sections together with dark tape to prevent light penetration (81). 
Overall, the adult male ATOM phantom (including the legs) measures 173 cm in 
stature (5 ft, 8 in), weighs 73 kg (161 lbs), and has a thorax measuring approximately 32 cm 
by 23 cm (80-82, 84-86).  The standardized anthropometry, access to internal organs, and 
photon beam tissue equivalence provided by the ATOM phantom have made this phantom 
a popular choice for experimentation regarding image quality and radiation dose 
assessment (82).  Thus, the ATOM adult male phantom was a useful tool to approximate 
the rectal doses received by patients undergoing VC at MD Anderson Cancer Center. 
 
2.5 PeopleSize Software 
 Although the ATOM phantom provided a valuable dosimetric tool with substantial 
tissue equivalence and the standardized anthropometry established in ICRP 23 (49), it was 
limited in that with the additional fat slabs this phantom could only represent those patients 
with one of three available pelvic circumferences.  Since the VC technique utilized by MD 
Anderson Cancer Center is a uniform technique that is not adjusted for patients of varying 
sizes, the amount of absorbed dose received by the rectum is therefore directly related to 
that patient’s habitus and body composition.  Since any phantom experiment can only 
provide data representative of a limited number of patient sizes, it was important to 
determine which percentiles of the patient population (generalized in this study to be adults, 
aged 18-64, residing in the United States) were represented by the phantom data in each 
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configuration.  Additionally, the fat slabs only extended 20 cm along the phantom pelvis; 
where the appropriate VC scan and scatter length of a patient represented by the phantom 
(and the average VC patient at MD Anderson Cancer Center) extends much further.  
Therefore, additional target population anthropomorphic data was needed; specifically 
regarding circumference measurements in the pelvis, abdomen and chest of a typical 
patient represented by the phantom with the fat slabs attached, such that additional 
attenuating material could be attached to the phantom surface in a proportionally 
appropriate manner.  These anthropomorphic data were acquired from PeopleSize 2008 
Professional software, version 1.1, developed by Open Ergonomics Ltd (Leicestershire, 
UK).   
 PeopleSize 2008 Pro software utilizes a simple user interface to provide customers 
with data regarding anthropomorphic dimension measurements and percentiles for a 
desired target population.  PeopleSize 2008 provides percentiles and measurements for up 
to 289 individual anatomical locations for nine nationalities (US, UK, German, Australian, 
Belgian, French, Japanese, Chinese, Swedish) in up to nine adult age groups (18-64, 18-
25, 18-39, 25-50, 40-64, 65+, 65-74, 75+, 85+) as well as pediatric data for every year from 
2-17 years and infant data for subjects under 2 years of age (87).  Due to limited data 
availability, complete data sets are not provided for some of these demographics in 
PeopleSize 2008.  At the time of this writing, this software had been incorporated into 
research conducted by many industries that require ergonomic information; including 
healthcare, clothing, motor vehicle, and consumer products.   
 The anthropomorphic data provided by PeopleSize 2008 is based on existing older 
anthropomorphic survey data (acquired in dates ranging from the 1950’s to the 1990’s) that 
have been scaled by size and weight to estimate modern dimensions (with bony 
dimensions changing over time by a small magnitude and fatty dimensions changing over 
time by a larger magnitude).  The modern dimensions calculated by this software have 
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been verified by comparing the predicted measurements to government-conducted surveys 
(including the US Government’s most recent National Health and Nutrition Examination 
Survey (NHANES), conducted from 2003-2006).  Such comparisons have found that at the 
most difficult dimensions to estimate (dimensions where fat is more likely to accumulate), 
the software demonstrated an overall average error of 0.0% in the 5th percentile and -0.1% 
in the 95th percentile; with individual landmark dimensions falling within approximately a 
±3% margin (87).  Thus, the PeopleSize 2008 software provided a dependable means to 
determine the necessary anthropomorphic dimensions for the target patient population 
represented by the respective ATOM phantom configurations used to measure simulated 
VC rectal dose with thermoluminescent dosimeters (TLDs) at MD Anderson Cancer Center. 
 
2.6 Thermoluminescent Dosimeter (TLD) Capsules 
As described in Chapter 1.4.2.1, TLDs were used to acquire all in-vivo VC rectal 
dose measurements.  TLDs provide many benefits to users, including the capability of 
being ground into powder and conformed to the geometry of its container (which provides 
the added benefit of eliminating directional dependence from dose measurements).  
Advantages of the TLD-100 (LiF:Mg,Ti) powder used in our measurements also include (26, 
31):  a wide useful linear dose range (from 50 µGy-1000 Gy), performance independent of 
dose rate, small size, excellent uniformity within a batch (if appropriately prepared), quick 
and convenient readout, very good precision (as low as 0.22%), low uncertainty (usually 
around 2-5%, with the uncertainty published by the RPC being 2.5% for their standard set-
up at therapeutic doses (35)), commercial availability, and substantial tissue equivalence for 
most applications.   
TLD-100 material has several inherent disadvantages as well, but most of these 
disadvantages can be overcome with sufficient effort.  Examples of such disadvantages 
include (26, 31):  careful calibrations at low doses and energies (diagnostic range) due to 
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supralinearity of TLD-100 response compared to tissue, the need for specific calibrations 
for each batch because of batch-to-batch inconsistencies, loss of TLDs due to small size, 
inconvenience associated with delayed dosimeter reading (a minimum of 14 days is 
typically desirable), inconvenience and cost associated with readings performed by an 
outside entity, spurious luminescence effects (which are mostly eliminated with N2 gas and 
by using uniform TLD-100 powder grain size), sensitivity that is altered after large doses or 
repeated doses (which is mostly eliminated with proper annealing techniques or by not 
reusing material), and reader instability (which can be improved with well-trained 
technicians and by control TLDs to track changes in charge measurements at uniform 
doses).  Ultimately, the advantages of TLD-100 were determined to outweigh these stated 
disadvantages, and TLD capsules were determined to be the best method available for 
measuring patient rectal dose from VC. 
 
 
 
 
 
 
 
 
 
 
 
Figure 2-6.  Double chamber TLD capsule obtained from the RPC. 
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The TLDs used in this experiment were obtained from and read by the NCI-funded 
Radiologic Physics Center (RPC) at MD Anderson Cancer Center (Houston, TX).  The 
TLDs consisted of plastic capsules containing two approximately 22 mg aliquots of ground 
TLD-100 powder in a double chamber plastic capsule with a wax plug.  As mentioned in 
Chapter 1, the TLD-100 material was grown by Thermo Scientific (Waltham, MA); and was 
ground, mixed, and packaged into plastic cylindrical capsules (4.0-4.2 mm in tapered 
diameter by 15.6 mm in length) (see Figure 2-6) by Quantaflux, LLC (Dayton, OH).  
When the RPC receives their order of TLDs from Quantaflux, the RPC quantifies the 
fading, energy, and linearity correction factors for the batch of TLD-100 material (as 
described above in Chapter 1.2.4).  Once the material’s radiation response characteristics 
have been sufficiently quantified, they then provide these TLDs to customers for therapy 
beam quality assurance purposes.  When the TLDs are returned to the RPC from their 
customers, they wait at least 14 days after irradiation to reduce the uncertainty effects of 
drift on the TLD charge measurement results.  During readout, the mass of an aliquot of 
TLD-100 powder is determined from a Mettler AT261 DeltaRange analytical balance 
(Mettler-Toledo International Inc, Griefensee, Switzerland).  This mass of TLD-100 material 
is then placed on the planchette of a Harshaw QS 3500 TLD reader (ThermoFisher 
Scientific Corporation, Santa Fe, NM) where it is heated at a constant rate to 318 degrees 
Celsius.  The light emitted from the TLD-100 material stimulates the reader’s photomultiplier 
tubes, which is converted to a charge measurement and reported to the RPC’s TLD 
technologist.  
The RPC calculates a sensitivity correction factor (KS) from measurements of 
Cobalt-60 irradiated standard and control TLDs.  This KS value (in cGy/µC/mg) allows one 
to determine the radiation dose to muscle tissue from the obtained charge and mass 
readings.  The RPC also calculates factors that correct for:  fading (KF) using Equation 1-1:  
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(with coefficient values determined at commissioning of this batch of TLD-100 material to 
be a=1.2815, b=0.00010885, c=0.067810, d=0.071908, N=1.3493, and X representing the 
number of days between irradiation and readout); linearity (KL) (defined for doses between 
200 mGy and 6000 mGy by Equation 1-2, with m=-0.00028943, b=1.08683, and draw being 
defined by Equation 1-3):  
 
L rawK m d b= ⋅ +      (1-2) 
raw S F
Qd K Kmg= ⋅ ⋅      (1-3) 
 
and energy (KE) (defined from energies ranging from Cobalt-60 (KE=1.000) to ≥17 MV 
(KE=1.065)).  However, as both the rectal doses and energies encountered by patients 
undergoing VC are less than the ranges for which the respective correction factors provided 
by the RPC are valid, Specific Aim 1 was necessary to quantify TLD performance by 
defining KL at 120 kVp (KL,120) for the range of doses encountered in VC. 
 
2.7 Custom-Made PMMA CTDI Insert Rod 
 In order to accomplish Specific Aim 1 and define KL,120 for the range of doses 
encountered in VC, it was necessary to provide appropriately varying doses to TLDs under 
controlled conditions.  Since the rectal dose and energy spectrum experienced by a patient 
undergoing VC at MD Anderson Cancer Center is a function of the size of the patient and 
the spectrum of the output of the MDCT scanner x-ray tube, it was determined that the 
easiest way to approximate such conditions would be in a common CTDI body phantom 
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(which roughly approximates the size and attenuation of a large reference patient).  This 
phantom was determined to be a reasonable and reproducible approximation of the beam 
hardening and attenuation produced by a patient.   
In order to create TLD irradiation conditions as reproducible as possible, such that 
TLD placement at each irradiation condition was as consistent as possible and the MDCT 
beam attenuation uniformly approximated the scatter observed in the rectum of a patient 
undergoing VC, a PMMA insert rod of approximately identical external geometry as that of 
the insert rods that fill the bores of the CTDI phantoms during standard CTDI phantom use 
(1.27 cm diameter x 17 cm long cylinder) was designed and created by the MD Anderson 
Cancer Center Machine Shop (Houston, TX) (see Figure 2-7A).  This custom-made insert 
rod differed from the standard CTDI insert rod in that it could be disassembled (via a tight 
fitting 0.95 cm diameter x 0.32 cm deep male/female mating).  Once disassembled (see 
Figure 2-7B), a single TLD capsule could be inserted into a tapered 0.45 – 0.46 cm 
diameter by a 0.80 cm cylindrical seat (see Figure 2-7C).  Tape was attached to one side of 
the insert rod (as seen in Figure 2-7) to ensure the TLD-loaded insert rod was consistently 
inserted into the CTDI body phantom with the TLD located in the geometric center of the 
phantom.  An additional view of a TLD seated within the female side of the custom-made 
insert rod is provided in Figure 2-8. 
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Figure 2-7.  A) Assembled custom-made PMMA CTDI insert rod with TLD seat; B) 
Disassembled custom-made insert rod; C) Disassembled custom-made insert rod with TLD in 
seating. 
 
 
 
 
 
 
 
 
 
Figure 2-8.  Female side of disassembled custom-made insert rod with TLD capsule placed in 
seating. 
A)  
B)  
C)  
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2.8 Ionization Chambers 
 To accomplish Specific Aim 1 and define KL,120 for the range of doses encountered 
in VC, independent dose measurements were additionally required to which TLD dose 
measurements could be compared.  Further, in order to identify any potential measurement 
discrepancies in the event of a change in the x-ray tube within a MDCT scanner between 
the time the KL,120 correction coefficients were determined and when actual 
anthropomorphic phantom and in-vivo patient VC measurements were acquired, several x-
ray beam quality factors were evaluated.  These beam quality factors included the beam 
half-value layer (HVL), quarter-value layer (QVL), CTDI in-air ((CTDI100)air) (88), and 
weighted CTDI (CTDIw).  Volume CTDI (CTDIvol) was calculated from this CTDIw value, and 
these measurements were compared to the CTDIvol value displayed on the scanner 
console.  Each of these measurements was obtained using an electrometer and one of two 
varieties of ionization chambers. 
 Ionization chambers operate by exploiting and measuring the effects that result 
when an ionized particle moves through a gas.  In their most basic form, ionization 
chambers are composed of a direct current (DC) voltage source connected to positive and 
negative electrodes separated by a gas (usually atmospheric air).  Significant insulation 
(often with measures such as a guard ring) is additionally required to protect the integrity of 
the voltage bias established between the electrodes (89).  When ionizing radiation (for 
example a photon) enters the active volume of the ionization chamber, it interacts with the 
gas within the active volume and produces an ion pair (a positive ion and a free electron) by 
either the photoelectric effect, Compton scattering, or pair (or triplet) production; depending 
on stochastic events and the energy of the incident photon.  Secondary photons, electrons, 
positrons or delta rays created by these interactions result in other ionizations occurring 
within the chamber as well; and the interactions occurring within the chamber should mirror 
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those occurring outside the chamber (as long as the chamber walls are sufficiently thick to 
achieve electronic equilibrium) (89). 
 The average energy deposited by an incident photon into an active volume is 
primarily a function of the binding energies of the gas within which it is interacting (90).  The 
number of ion pairs created by interactions initiated by an incident photon can therefore be 
estimated by dividing the energy of the incident photon by the experimentally-determined 
average values of energy dissipation per ion pair (also known as W-values) for a type of 
incident radiation and for a species of gas.  When an incident photon creates fast electrons 
within the active volume of an ionization chamber filled with air (or air equivalent material), 
the W-value is 33.8 eV/ion pair (89).  Therefore, if a 1 MeV incident photon becomes fully 
stopped within the active volume of an ionization chamber, approximately 33,000 ion pairs 
will be created. 
 Under normal conditions in a volume of gas, these newly generated ion pairs will 
quickly recombine and no net charge will result.  Ionization chambers, when connected to 
an electrometer, utilize a large voltage bias (±200 V to ±500 V) surrounding the active 
volume to minimize or prevent such ion pair recombination.  As the recombination of the ion 
pairs is prevented, the respective ions migrate to the attracting electrode; and the result is a 
decrease in the bias voltage.  An electrometer measures and amplifies this change in the 
DC voltage bias (ΔV) across a series resistor (RS) (typically between 109-1012 ohms), and 
determines the saturated ion current (IS) by Equation 2-1. 
 
S
S R
VI ∆=       (2-1) 
    
The exposure (R) in charge per unit mass (C/kg) is calculated from the saturated ion 
current provided in Equation 2-1 and time of exposure as shown in Equation 2-2:     
56 
 
 
t
M
IR S ⋅=       (2-2) 
T
T
P
PV
m
kgM 0
0
3293.1 ⋅⋅⋅=     (2-3) 
 
where M is the mass of air in the active volume calculated from Equation 2-3, V is the 
volume of the ionization chamber active volume (in m3), P is the air pressure in the 
chamber (in mmHg), P0 is the standard air pressure (760 mmHg), T is the air temperature 
in the chamber (in Kelvin (K)), T0 is the standard temperature (273.15 K), and t is the time 
of exposure (in sec).  Although C/kg is the SI unit for exposure, the more commonly used 
value for exposure is the Roentgen (R); which is additionally calculated by the conversion:  
1 R = 2.58 x 10-4 C/kg. 
As an example to provide insight to the order of magnitude of the measurements 
required to utilize this technology, if an ionization chamber with an active volume of 1000 
cm3 is exposed at a rate of 1x10-3 R/hr at standard temperature and pressure, a saturated 
ionization current of 9.27x10-14 amperes (A) would result.  Such low currents underscore 
the need for the above mentioned significant insulation and guard rings (to prevent leakage 
of current from the respective electrodes), and for quality electrometer instrumentation.  
Several models of quality ionization chambers and electrometers are commercially 
available that have been designed for specific measurement purposes; including the 
thimble (or Farmer) style ionization chamber, the pencil ionization chamber, and the 
electrometer described below.  These entities were used in Specific Aim 1 to measure 
beam quality and to establish TLD response correction factors to the MDCT x-ray spectrum 
experienced by patients undergoing VC at MD Anderson Cancer Center.   
 
57 
 
2.8.1 Farmer Ionization Chamber 
 The first fast-responding thimble ionization chamber (cylindrical ionization chambers 
incorporating two electrodes separated by insulation and a chamber of gas surrounded by 
air-equivalent material and connected by wire to a feed-back amplifying electrometer) was 
first introduced by Frank Farmer in 1946 (91).  Before his work, ionization chambers were 
both much slower and much more bulky.  In honor of his work developing this detection 
technology, such thimble chambers are commonly referred to Farmer chambers.  Over the 
years, Farmer ionization chambers have proven to be very valuable tools to medical 
physicists operating in both therapy and diagnostic disciplines; and they were used in our 
accomplishment of Specific Aim 1 by providing standard point exposure measurements 
used to determine the KL,120 values for the TLD-100 material for the energy and to estimate 
the rectal dose range received by patients undergoing VC during survey and CT imaging. 
The Farmer ionization chamber used to acquire the baseline values for our TLD 
exposure measurements was the Radcal model 9060/10x5-0.6 (S/N 16563) (Radcal 
Corporation, Monrovia, CA).  This chamber (shown in Figure 2-9A) has an active volume of 
0.6 cm3, utilizes C552 air-equivalent conductive plastic walls and electrode, has an active 
volume of air that is unsealed from the environment, has a 12 m low-noise triax cable, 
weighs 0.28 kg, and comes with a polyacetal build-up cap (see Figure 2-9B) (92).  In order 
to reduce air gap within a CTDI phantom when this chamber is in place and to provide as 
uniform a phantom environment as possible, the MD Anderson Cancer Center Machine 
Shop (Houston, TX) created an acrylic insert rod with a cut along the length of the cylinder 
to house the triax cord (see Figure 2-9C). 
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Figure 2-9.  A) Radcal 0.6 cm3 9060/10x5-0.6 Farmer-style ionization chamber; B) Radcal 
Farmer ionization chamber with build-up cap attached; C) Radcal Farmer ionization chamber 
with build-up cap and custom-made triax cord insert rod attached. 
 
The active volume of the chamber is 9 mm in diameter and 21 mm in length.  The 
total length of the chamber is 54 mm, and the total diameter is 12 mm.  The triax cord is 3 
mm in diameter.  This chamber can be operated in one of six modes:  dose rate (recording 
air kerma rates ranging from 1 mGy/min to 74 Gy/min), dose (recording total accumulated 
air kerma ranging from 0.1 mGy to 6 kGy), maximum dose rate (providing the peak air 
kerma in an exposure from 1 mGy/min to 74 Gy/min), auto dose (for repeated hands-off 
A)  
B)  
C)  
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measurements where respective measurement parameters (exceeding a 0.6 R/min 
threshold) don’t change between measurements, last dose (for determining total 
accumulated air kerma at any time during a continuous exposure from 0.1 mGy to 6 kGy), 
and cine mode (used for machines, like fluoroscopy, that produce exposures in pulses 
greater than 0.01 mGy/pulse).  The resolution provided by this ionization chamber is 1 
mGy/min or 0.1 mGy.  The energy dependence falls within ±5% for beams of energy 
between 40 keV and 1.33 MeV when a build-up cap is incorporated; and the exposure rate 
dependence operates within ±2% between the 6 mGy/min and 6 kGy/min (92).  The 
calibration accuracy provided by this chamber is ±4% after temperature and pressure 
condition correction when using Co-60 as the calibration source.  MD Anderson Cancer 
Center sends all Farmer ionization chambers for calibration on a biennial basis and cross-
calibration checks between similar chambers on an annual basis. 
 
2.8.2 CTDI Pencil Ionization Chamber 
 In 1978, Suzuki and Suzuki from Capintec, Inc (Montvale, NJ) introduced an 
expanded, pencil-shaped version of the Farmer-style ionization chamber that was capable 
of measuring an integrated exposure over a distance (compared to Farmer’s chamber that 
measured exposure at a point) (93).  This pencil ionization chamber was created for the 
expressed purpose of measuring exposures from CT scans, and this tool has found 
considerable usefulness with the development of computed tomography dose index (CTDI) 
as a ubiquitous method for measuring CT exposure characteristics.  A pencil ionization 
chamber was used to quantify several CT beam characteristics in the accomplishment of 
Specific Aim 1 (including half-value layer (HVL), quarter-value layer (QVL), CTDI in-air 
((CTDI100)air) (88), weighted CTDI (CTDIw), and volume CTDI (CTDIvol). 
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Figure 2-10.  Radcal model 9060/10X5-3CT 3 cm3 pencil chamber. 
 
 The pencil ionization chamber used to quantify the MDCT beam quality was a 
Radcal model 9060/10X5-3CT (S/N 8696) (Radcal Corporation, Monrovia, CA).  This 
chamber (shown in Figure 2-10) has an active volume of 3 cm3, utilizes C552 air-equivalent 
conductive plastic to compose the walls and electrode, has an active volume of air that is 
unsealed from the environment, has a 2 m low-noise triax cable, weighs 0.11 kg, and 
comes with a polyacetal build-up cap to create a fit with the CTDI phantom with minimal air 
gap (92).   
The active volume of the chamber is 3 cm3, measuring 9 mm in diameter and 100 
mm in length.  With the build-up cap, the diameter of the chamber becomes 12 mm and the 
length is 127 mm.  The total length of the chamber with the cap in place is 165 mm, and the 
total diameter remains 12 mm.  The triax cord is 3 mm in diameter.  This chamber can be 
operated in the same six modes as the Farmer chamber within the following air kerma 
limits:  dose rate (1 mGy/min to 15Gy/min), dose (0.01 mGy to 1.2 kGy), maximum dose 
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rate (1 mGy/min to 15Gy/min), auto dose (1200 mR/min threshold), last dose (0.01 mGy to 
1.2 kGy), and cine mode (greater than 1 nGy/pulse).  The resolution provided by this 
ionization chamber is 0.1 mGy/min or 0.01 mGy.  The energy dependence operates within 
±5% with beams of mean hardness ranging from 3 to 20 mm Al HVL; and the exposure rate 
dependence operates within ±2% between dose rates of 0.2 mGy/s and 300 mGy/min (92).  
The calibration accuracy provided by this chamber is ±4% after temperature and pressure 
conditions when moderately filtered x-rays at 150 kVp and 10.2 mm Al HVL hardness are 
used as the calibration source.  As with the Farmer ionization chamber, calibration of all 
pencil ionization chambers are performed on a biennial basis and cross-calibration checks 
are performed on an annual basis. 
 
2.8.3 Electrometer 
 As mentioned in the descriptions above, neither the Farmer nor the pencil ionization 
chamber operates unless attached to an electrometer to provide a bias voltage to the 
chamber, to receive voltage change information, to amplify and process the data, and to 
provide exposure measurements to the user.  A Radcal model 9010 Radiation Monitor 
Controller electrometer (S/N 90-2261) (Radcal Corporation, Monrovia, CA) was used in 
Specific Aim 1 to determine the exposures in each irradiation condition as detected by the 
respective ionization chambers.  In order to interchange ionization chambers, this 
electrometer was connected in series to a Radcal 9060 converter unit (S/N 90-2292), a 
Radcal 90C5-6 extension cable, and finally the ionization chamber as shown in Figure 2-11.  
This converter unit allows the Radcal 9010 electrometer to be used with any Radcal 10-
series interchangeable ionization chamber (92). 
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Figure 2-11.  Radcal 9010 Radiation Monitor Controller electrometer, Radcal 90C5-6 extension 
cable, Radcal 9060 converter unit, and Radcal model 10X5-3CT pencil chamber attached in 
series. 
 
 The Radcal 9010 electrometer shown in Figure 2-11 provides measurement 
displays and menu selections on a two-line liquid-crystal display with 16 characters per line.  
Menu selections are browsed by turning the “Select” dial and by pressing the “Enter” button 
when a desired setting is displayed.  This electrometer operates in the modes described 
above for the specific ionization chambers (dose rate, dose, maximum dose rate, auto 
dose, last dose, and cine mode).  The energy response and resolution for each of these 
modes depend on the ionization chamber utilized. 
 This electrometer is powered by three 9V batteries, which provide approximately 40 
hours of normal use.  A “Replace Battery” message is displayed when appropriate.  This 
 
Converter Unit 
Pencil Ionization Chamber 
Extension Cord 
Electrometer 
“Enter” 
“Select” 
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electrometer applies a ±260 V bias to the connected ionization chamber, which requires up 
to 60 seconds to stabilize when the electrometer is first turned on.  As per normal start-up 
procedures, this electrometer additionally performs room temperature and pressure checks; 
and displays the necessary ionization chamber correction factor that has been 
automatically applied to the measurement values displayed.  The Radcal 9010 electrometer 
boasts a measurement repeatability of ±1%, and a measurement accuracy of ±4% (92).  As 
with the ionization chambers described above, calibration of all electrometers are 
performed on a biennial basis and cross-calibration checks are performed on an annual 
basis. 
 
2.9 Double Contrast Enema Delivery System 
 As mentioned in Chapter 1, standard procedure for VC at MD Anderson Cancer 
Center requires the insertion of a rectal catheter into a patient for gas insufflation of the 
colon and for iodinated contrast agent administration and retention.  The rectal catheter and 
enema system routinely used by MD Anderson Cancer Center during VC procedures is the 
E-Z-EM Model 8925 Super XL Double Contrast Enema Delivery System (Bracco 
Diagnostics Incorporated, Princeton, NJ).  All contents of this enema delivery system are 
shown in Figure 1-2 and include:  a 2500 cm3 contrast agent bag, 152 cm of 12.7 mm 
lumen plastic tubing, two plastic tubing clamps, a blue insufflation tube, a blue insufflation 
bulb (which is not used during VC at MD Anderson Cancer Center), a retention cuff 
(balloon) inflation bag (containing approximately 100 cm3 of air), 51 cm of 1.6 mm diameter 
lumen plastic inflation bag tubing, and a flexible Miller™ Enema Air Tip with silicone 
elastomer inflatable retention cuff (balloon) (94).   All contents of this enema delivery 
system are latex-free, and are used clinically as described in Chapter 1. 
The Miller™ Enema Air Tip (see Figure 2-12) is the portion of the enema that is 
inserted into a patient’s rectum while undergoing VC (i.e. the rectal catheter) at MD 
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Anderson Cancer Center.  This is also the portion of the enema delivery system to which 
TLDs were attached in order to accomplish Specific Aim 2 and obtain in-vivo rectal dose 
measurements in patients undergoing VC.  As can be seen in Figure 2-12, the blue 
insufflation tube, the large clear contrast agent tube, and the small clear balloon inflation 
tube converge into the rectal catheter.   
 
 
 
 
 
 
 
 
Figure 2-12.  Close up view of Miller™ Enema Air Tip rectal catheter contained in the E-Z-EM 
Model 8925 Super XL Double Contrast Enema Delivery System. 
 
The entire rectal catheter wall thickness is approximately 1.8 mm.  Within the interior 
of the catheter (seen in Figure 2-13), the majority of the shaft volume (approximately 50%) 
accommodates contrast agent flow into the patient, with the rest of the shaft volume 
containing extrusions where tubes have been molded into the interior wall of the catheter to 
accommodate insufflation gas flow and balloon inflation (approximately 25% for each of the 
two tubes).  The balloon inflation tube terminates within the shaft of the rectal catheter into 
the balloon portion of the shaft just superior to the inferior balloon tie-down.  The gas 
insufflation tube terminates just inferior to the exterior holes on the head of the rectal 
catheter (perpendicular to the central axis) and contains a port into the central contrast 
agent volume to expel insufflation gas into a patient’s colon.   
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Figure 2-13.  Interior view of Miller™ Enema Air Tip rectal catheter. 
 
Superior to the shaft (which measures 9.5 mm across the largest lumen diameter (i.e. 
where the contrast agent flows)), the diameter opens to a maximum diameter of 13.5 mm in 
the head of the rectal catheter and narrows to 6.2 mm at the superior opening.  Besides the 
superior opening, the rectal catheter has eight exterior elliptically-shaped holes aligned 
perpendicularly to the central axis; each providing a port for insufflation gas and contrast 
agent administration into the rectum and colon that is 3.0 mm in the narrow diameter and 
3.9 mm in the large diameter.  Each of these internal features of the rectal catheter (the 
superior hole, the exterior holes, the enlarged diameter head, the shaft with the two 
extrusions, and the internal insufflation gas port) must be navigated when inserting and 
affixing TLDs into the head of the rectal catheter as described in Chapter 3 (and illustrated 
in Figure 3-25). 
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CHAPTER 3.0:  METHODS 
  
3.1 Introduction 
The methods used to estimate patient rectal dose during virtual colonoscopy (VC) 
are described in this chapter in order of the specific aims outlined earlier.  First, in 
accordance with Specific Aim 1, thermoluminescent dosimeter (TLD) linearity correction 
factors were established for a range of doses at 120 kVp for a multi-detector computed 
tomography (MDCT) scanner using VC scan parameters in a 32 cm CT dose index (CTDI) 
body phantom.  Next, in accordance with Specific Aim 2, rectal dose measurements using 
TLDs were obtained in VC simulations within an anthropomorphic phantom and in-vivo 
within patients undergoing VC.  Finally, in accordance with Specific Aim 3, in-vivo rectal 
dose measurements were compared to anthropomorphic phantom dose measurements, 
CTDIvol-based dose estimates, and point dose measurements taken in a CTDI body 
phantom.  These specific aims were accomplished in order to test our hypotheses:  in-vivo 
rectal dose measurements obtained during virtual colonoscopy will have a rectal dose 
coefficient of variation that will be greater than 50%; and anthropomorphic phantom rectal 
dose measurements, CTDIvol-based dose estimates, and Farmer chamber measurements 
in a CTDI body phantom will estimate rectal doses outside the 95% confidence interval of 
the mean patient dose measurements. 
 
3.2 Specific Aim 1:  Establish TLD Linearity Correction Factors for VC Scan 
Parameters on a MDCT 
Although the Radiologic Physics Center (RPC) (Houston, TX) typically provides 
energy and dose linearity correction coefficients to customers as a standard service, their 
established correction factors pertain to those doses and energies encountered in photon or 
electron cancer therapy by linear accelerator and are specifically defined for higher 
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energies (a minimum of 1 MV) and doses (a minimum of 200 mGy) than those obtained by 
MDCT dose to a patient’s rectum.  Therefore Specific Aim 1 was deemed necessary for this 
project, which provided correction factors relevant for MDCT at the energy and in the dose 
range encountered in VC.  Guidance, TLDs, and TLD readout for the establishment of 
these coefficients were provided by staff at the RPC (under the direction of Dr. David 
Followill).   
 
3.2.1 MDCT Beam Characterization 
 In order to identify any discrepancies in TLD readings and actual dose 
measurements in the event of a change in the MDCT x-ray tube between TLD irradiation 
and anthropomorphic phantom or in-vivo patient VC measurements, several x-ray beam 
quality factors were measured.  These measurements were conducted in the same CT 
sessions as when the TLDs were irradiated to establish the dose linearity correction factors 
for VC conditions, and upon completion of all in-vivo dose measurements.  Doing so 
provided the additional advantage of producing data that may reduce the variability or 
uncertainty between the TLD patient dose readings and future Monte Carlo rectal dose 
calculations because the equivalent source model of some Monte Carlo codes relies on this 
beam data to develop the virtual CT scanner that delivers the dose to the patient in the 
simulation (60).  These measured beam factors included the half-value layer (HVL), 
quarter-value layer (QVL), CTDI in-air measured with a 100 mm pencil chamber 
((CTDI100)air) (88), weighted CTDI (CTDIw), and volume CTDI (CTDIvol) for the MD Anderson 
Cancer Center VC technique on the institution’s “CT9” GE LightSpeed VCT scanner; as 
well as HVL and QVL measurements on the “CT5” and “CT12” GE LightSpeed VCT 
scanners to demonstrate consistency in x-ray tube output between the three MDCT 
scanners utilized for VC.   
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3.2.1.1 HVL and QVL Measurement 
The HVL and QVL measurements were made using the method described by 
Mathieu, et al (95) incorporating the Lambert W function (the multivalued inverse of 
Equation 3-1) as a more generalized form of the Lambert-Beer equation (Equation 3-2) 
such that it becomes appropriate for the polyenergetic spectrums encountered in CT:    
 
  ( ) ( )zWezWz ⋅=      (3-1) 
  xeII ⋅−⋅= µ0       (3-2) 
 
where z is a complex number (96), I is the intensity of the filtered photon beam (measured 
as exposure in mR), I0 is the intensity of the unfiltered photon beam (mR), µ is the linear 
attenuation of the filtering material (in mm-1), and x is the thickness of the attenuating 
material (in mm) .  Mathieu used these equations, along with an empirical model for a mean 
linear attenuation coefficient (µ ) for the polyenergetic photon spectrum in narrow-beam 
geometry (Equation 3-3) as the basis to derive Equation 3-4 and Equation 3-5 to interpolate 
the HVL and QVL, respectively:   
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where µ  represents the mean attenuation coefficient of the polyenergetic photon beam, 
and λ and µ0 are unknown coefficients whose values are simplified to Equation 3-6 and 
Equation 3-7, respectively, by Lambert W interpolation.   
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Equations 3-6 and 3-7 are based on attenuated exposure measurements 
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each represent the respective ratios of the exposure measurements made using x1 and 
x2 thickness of Al 1100 alloy filtration to the exposure measurements made with no filtration.   
The value of the technique proposed by Mathieu is its demonstrated ability to 
accurately interpolate x-ray beam hardness values (such a HVL or QVL, which describe the 
thickness in millimeters of aluminum 1100 alloy (mm Al) necessary to reduce the intensity 
of an attenuated beam to one half or one quarter of its unattenuated value, respectively) 
using only one unfiltered and two filtered beam intensity measurements (each of which are 
acquired with different thicknesses of aluminum alloy filtration).  This technique is 
contrasted with the more traditional technique, where HVL and QVL have been measured 
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taking several measurements with increasing aluminum thicknesses until the radiation 
intensity measurements were less than half of the unattenuated intensity; and the HVL was 
interpolated (using either linear or semi-logarithmic interpolation methods) between the two 
thicknesses that yielded slightly less and slightly more than half exposure value filtration.  
Thus, to measure both HVL and QVL required a minimum of five (and typically many more) 
exposure measurements traditionally and only three with Lambert W interpolation.  Mathieu 
showed that by attempting to obtain both HVL and QVL with only three total exposure 
measurements with a pencil ionization chamber on a CT scanner at 120 kVp, the 
interpolated HVL and QVL values will only be within 5% of the nearest measurable HVL 
thickness 22% and 23% of the time, respectively, when using linear interpolation; and 76% 
and 84% of the time, respectively, when using semi-logarithmic interpolation.  Under the 
same conditions, the Lambert W interpolation method yielded HVL and QVL values within 
5% of the nearest measureable thickness in 100% of the measurements (95). 
To obtain the HVL and QVL measurements, two thicknesses of aluminum 1100 
alloy were measured with electronic calipers, and the average of eight measurements at 
different points on each of the aluminum plates was determined to be the average thickness 
of each Al 1100 plate.  Next, the Radcal pencil ionization chamber described in Chapter 2 
was secured inside the center bore of a CTDI head phantom using paper towels to prevent 
chamber movement within the phantom resulting from CT scanner table movement during 
chamber alignment to the scanner isocenter, and the CTDI phantom was set onto the head-
holder attachment and was affixed to theGE LightSpeed VCT scanner table.  The pencil 
chamber was positioned within the center bore of the CTDI head phantom such that in-air 
measurements could be acquired.  The Radcal pencil ionization chamber was connected to 
the Radcal electrometer by triaxial cable, and the electrometer was set to acquire 
measurements in auto dose mode (in units of mR).  After the ionization chamber/phantom 
assembly was secured to the scanner head-holder attachment with tape, the table was 
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moved such that the center of the active volume of the pencil chamber was located at 
isocenter.  The CT scanner was then set to the zero position ((0,0,0) in the frontal, sagittal, 
and axial planes) (see Figure 3-1).    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-1.  Using a CTDI head phantom on the head-holder attachment to place the pencil 
ionization chamber at isocenter of the CT scanner bore for in-air measurements. 
 
With the pencil ionization chamber in-air at isocenter, the CT scanner was placed in 
service mode, and the x-ray tube was set to remain stationary through a scan (i.e. such that 
it did not rotate when the tube was on) at the bottom position of the gantry (in the 180 
degree position) (see Figure 3-2).  The scanner was otherwise set such that the x-ray tube 
irradiated the ionization chamber to the same technique as that used by MD Anderson 
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Cancer Center for VC described in Table 1-1:  120 kVp, 100 mA, the default trigger rate of 
984 Hz, large (body) bowtie filter, small focal spot, effective beam width of 40 mm, and the 
default calibration vector setting of “full”.  Exposure times of one second were used for 
these exposures to achieve a total of 100 mAs as opposed to the 0.5 second rotation head 
time described in Table 1-1 (yielding 50 mAs) because VC at MD Anderson Cancer Center 
utilizes two CT scans (one each with the patient in a prone and in a supine position).  Since 
each scan provides 50 mAs of exposure to the patient, and since dose is linearly related to 
mAs (37), these two exposures were combined into one 100 mAs exposure for the purpose 
of these beam quality measurements.   
 
 
 
 
 
 
 
 
 
 
 
Figure 3-2.  X-ray tube held stationary at the 180 degree (bottom) position of the CT scanner. 
 
Exposure measurements were acquired for three separate scans, and the average 
of the three exposures (in mR) was determined to be the I0 value (see Figure 3-3).  One of 
the measured sheets of Al 1100 alloy (x1 = 6.36 mm thick) was then set on the gantry over 
the Mylar window and exposure measurements were again acquired for three scans (with 
 
Mylar Window 
Beam Collimator 
73 
 
the average being considered the I1 value).  Finally, a second 13.48 mm thick sheet of Al 
1100 alloy was added to the beam filtering, providing a total filter thickness of x2 = 19.84 
mm.  Exposure measurements were acquired for three scans in this third configuration (see 
Figure 3-4), and the average of these measurements was determined to be the I2 value.  
With all of the measurements complete, the HVL and QVL values of the MDCT scanner 
were determined for 120 kVp using the VC protocol using Equations 3-4, 3-5, 3-6 and 3-7. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-3.  Configuration used to measure the unattenuated exposure (I0). 
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Figure 3-4.  Configuration used to measure the x1 and x2 attenuated exposures (I1 and I2). 
 
3.2.1.2 (CTDI100)air, CTDIw, and CTDIvol Determination 
 With the CT scanner in normal image acquisition mode (i.e. such that the x-ray tube 
rotated when on), and the pencil ionization chamber located in air at isocenter (as was the 
case for the HVL and QVL measurements displayed in Figure 3-1 above), the CT scanner 
was set to the following technique to approximate (for CTDI measurement purposes) 
irradiation conditions experienced in VC at MD Anderson Cancer Center:  axial scan, 0.5 
sec per rotation of the x-ray tube, an effective beam width of 40 mm, 120 kVp, 200 mA, 
standard reconstruction algorithm, large (body) bowtie filter, large body scan field of view 
(SFOV) and 50 cm display field of view (DFOV).  In a manner similar to the scan technique 
utilized in the beam HVL and QVL measurements, 100 mAs was used to acquire these 
CTDI measurements to simulate the combined dose received by patients undergoing VC 
from the prone and supine CT scans.  Exposure measurements were acquired (in mR) for 
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three scans using this technique, the average of these exposure measurements was 
calculated, and the (CTDI100)air was calculated using Equation 1-11: 
 
   ( )( )TN
LECfCTDI air ⋅
⋅⋅⋅=,100    (1-11) 
 
 where f = 0.0087 mGy/mR, C = 1 (the actual temperature and pressure correction factor of 
0.99 was factored into the exposure reading provided by the electrometer, therefore C=1 
was used), E was the average of the three exposure measurements (in mR), L was the 
length of the pencil chamber (L = 100 mm), N was the number of data channels, T was the 
detector width sampled by each channel, and the product N*T was the nominal beam width 
(N*T = 40 mm).  In order to establish the linearity of the MDCT scanner output with mAs, 
(CTDI100)air measurements were acquired using this technique in 10 mAs increments from 
20 mAs (40 mA) to 170 mAs (340 mA).  The results of these linearity measurements gave 
us confidence these measurements would also be linear within the center bore of a CTDI 
body phantom. 
 The final step of characterizing the beam quality was to determine the CTDIw in the 
32 cm CTDI body phantom with the MD Anderson Cancer Center VC protocol.  To do this, 
the CT table padding was peeled back, and the head-holder attachment was removed.  
Next, the phantom was placed on the unpadded MDCT scanner table and positioned by 
laser alignment such that the gantry isocenter was located at the phantom’s center bore 
and such that the other bores were located at the 12, 3, 6, and 9 o’clock positions.  The 
scanner was zeroed (0,0,0) to the center (in the frontal, sagittal, and axial planes) of the 
phantom according to the laser alignments, and the phantom was secured in place with 
tape.  The standard acrylic insert rods were inserted into the 8 peripheral bores of the CTDI 
body phantom and the pencil chamber was inserted into the center bore such that the 
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marked center of the ionization chamber corresponded with the center of the phantom (and 
the scanner landmark (zero) point) (see Figure 3-5). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-5.  Configuration used to measure the exposure in the center bore of the CTDI body 
phantom, which was used to calculate (CTDI100)c. 
 
The electrometer was used in the auto dose measurement mode (in mR) and the 
scanner was set to the following technique to represent VC conditions at MD Anderson 
Cancer Center (axial scan, 0.5 sec per rotation of the x-ray tube, nominal beam width of 40 
mm, 120 kVp, 200 mA (totaling 100 mAs to represent combined patient dose from the 
prone and supine CT scans), standard reconstruction, large (body) bowtie filter, large body 
SFOV, and 50 cm DFOV.  Exposure measurements were acquired (in mR) for three scans.  
The average of these measurements was calculated and this average exposure value was 
used to calculate the CTDI100 value for the center bore (CTDI100)c) using Equation 1-11 and 
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the same values for f, C, L, and N*T as those previously used to calculate the CTDI100,air 
values. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-6.  Configuration used to measure the exposure in the 12 o’clock bore of the CTDI 
body phantom, which was used to calculate (CTDI100)12.  A similar configuration was used to 
measure the respective exposures in the determination of (CTDI100)3, (CTDI100)6, and (CTDI100)9. 
     
Next, the pencil ionization chamber was removed from the center bore and placed in 
the peripheral bore in the 12:00 position of the phantom (and the insert rod that formerly 
occupied that bore was placed in the center bore) (see Figure 3-6).  The process used to 
measure the three exposure measurements with the pencil ionization chamber in the 
determination of (CTDI100)c was repeated, yielding the CTDI100 value for the 12 o’clock bore 
position ((CTDI100)12).  Similarly, the process was repeated for the peripheral bores located 
in the 3, 6, and 9 o’clock positions, and the CTDI values for these positions were also 
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determined ((CTDI100)3, (CTDI100)6, and (CTDI100)9, respectively).  These four peripheral 
CTDI100 values were averaged to obtain the (CTDI100)periphery value used in Equation 1-12 to 
calculate CTDIw.  Volume CTDI (CTDIvol) was calculated from this CTDIw value using 
Equation 1-14, and this measurement was compared to the CTDIvol value displayed on the 
scanner console to verify consistency. 
 
   ( ) ( )100 100
1 2
3 3w center periphery
CTDI CTDI CTDI= +  (1-12) 
   wvol
CTDICTDI pitch=     (1-14) 
 
3.2.2 Determination of TLD Dose Linearity Correction Coefficients for Virtual Colonoscopy 
 
3.2.2.1 TLD Irradiation at Exposures Received by Patients Undergoing Virtual Colonoscopy 
The Farmer style ionization chamber was attached to the electrometer and was 
placed in the phantom’s center bore (with the standard PMMA insert rods placed in the 8 
remaining peripheral bores) (see Figure 3-7).  The build-up caps were attached to the 
proximal (wired) end and to the distal (active volume) end of the Farmer chamber (as 
shown in Figure 2-9) such that the entire bore volume was occupied with minimal air gap.  
The CTDI body phantom was positioned at isocenter in the “CT9” GE LightSpeed VCT 
scanner table.  The Farmer ionization chamber was aligned within the center bore such that 
the active volume was at the center (0,0,0 coordinate) of the phantom as shown in Figure 3-
7.      
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Figure 3-7.  Configuration used to measure the exposure in the center bore of the CTDI body 
phantom with the Farmer ionization chamber. 
 
A posterior-anterior (PA) survey (i.e. scout) image was obtained of the phantom 
assembly at 120 kVp and 10 mA.  A helical scan was specified to be conducted from 75 
mm superior to 75.4 mm inferior to the landmarked (0,0,0) coordinate (i.e. through the 
length of the CTDI phantom).  The CT scanner was set to standard MD Anderson VC 
protocols:  full helical scan mode with 0.5 sec rotation time, 1.25 mm image thickness, 
39.37 mm/rotation table speed, 0.984 pitch, 0.8 mm interval, 120 kVp, 100 mA, 0 sec delay, 
and standard reconstruction algorithm.   
The ionization chamber exposure was measured and recorded for two scans under 
the specified CT technique for a total photon output of 100 mAs per x-ray tube rotation 
(representing the cumulated exposure acquired from both the prone and supine 50 mAs 
scans in VC).  In addition to exposure, the scan time (in sec), the scanner estimate of 
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CTDIvol (in mGy), and the scanner estimate of dose length product (DLP) (in mGy*cm) were 
recorded for each scan for reference purposes.  This process was repeated three times, 
and the average of the three iterations of two summed exposure measurements was 
determined to be the exposure value used for comparison with the TLD doses. The 
exposures from the PA scout scans were not measured or documented as this dose is 
known to be small, is often considered negligible compared to that provided by the actual 
CT scan (15), and is not displayed on the scanner console (thus no benchmark for 
comparison is available).  The dose contributions to each patient from the PA and lateral 
scout scans was estimated as described in Chapter 3.3.2.7. 
Next, one double-chambered TLD capsule was inserted into the seating cut in the 
center of the custom-designed insert rod (fabricated by the MD Anderson Cancer Center 
Machine Shop and shown in Figures 2-7 and 2-8).  The Farmer ionization chamber was 
replaced within the CTDI body phantom with the TLD-loaded insert rod, and the TLD was 
placed in the center (in the frontal, sagittal, and axial planes) of the CTDI body phantom 
(with the CT scanner still landmarked to this location as (0,0,0)) (see Figure 3-8).  The 
phantom was then irradiated with the TLD embedded within its center using the same CT 
technique settings as those previously used to irradiate the Farmer ionization chamber 
(including the use of two helical scans in each measurement).  After a TLD was irradiated, 
the TLD-loaded insert rod was removed from the phantom and the irradiated TLD capsule 
was taped to a piece of paper and the paper was carefully labeled to document the study 
number assigned to that TLD and the conditions under which each TLD was irradiated.   
After the two CT scans representative of the two supine and prone scans received 
by a patient undergoing VC had been accomplished, the TLD-loaded insert rod was loaded 
with a second unirradiated TLD capsule within the customized insert rod.  The newly 
assembled TLD-loaded insert rod was identically placed back within the CTDI body 
phantom, and the second TLD was irradiated in the same manner as the Farmer ionization 
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chamber and the first TLD.  TLD readout results from the RPC were provided on the same 
sheet of paper as that on which the irradiated TLDs were labeled to minimize opportunities 
for incorrect results to be reported for a specific scan technique. 
     
 
 
 
 
 
 
 
 
 
 
Figure 3-8.  Configuration used to measure the dose in the center bore of the CTDI body 
phantom with a TLD inserted into the custom-made insert rod. 
 
In order to obtain the TLD dose linearity response for the spectrum of rectal doses 
expected to be encountered in the range of sizes of VC patients, this technique was 
repeated at approximately 0.5 mGy increments from the lowest expected dose to the 
highest expected dose.  Since it is well-known that dose is linearly proportional to mAs (37), 
the scan technique was increased in 10 mAs increments from the estimated lowest rectal 
dose (described in Chapter 1.3.5) of 0.5 mGy (0.7 mGy was measured at 20 mAs) to the 
estimated upper rectal dose of 11.2 (10.8 mGy at 170 mAs) to achieve the approximate 0.5 
mGy dose increments desired.  For the lowest dose levels, where the Farmer chamber 
could not detect exposure in the center of the CTDI body phantom, exposure values were 
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extrapolated based on the linearity of the CTDI values at the mid- and upper range dose 
levels.  These extrapolations were based on the principle of x-ray tube linearity observed in 
the CTDI100,air measurements.   
In order to ensure KL,120 values pertaining to the lowest doses were sufficiently 
quantified, four TLDs (each with two aliquots of TLD-100 powder) were used to measure 
doses at 20, 30, 40, and 50 mAs.  The doses administered at the mid- and upper-range 
tube currents (in 10 mAs increments from 60 mAs to 170 mAs) were each measured with 
two TLDs (each also containing two aliquots of TLD-100 powder). Thus, a total of 16 doses 
were measured (along with 5 background TLDs) for a total of 45 TLDs being used to 
determine the KL,120 values for this TLD batch under VC conditions.  As each TLD capsule 
contained two separate chambers filled with TLD-100 material, either eight or four total TLD 
measurements were therefore obtained at the low and mid/high-dose ranges, respectively.  
The TLDs were read by the RPC a minimum of 14 days after irradiation in order to reduce 
uncertainties caused by fading and drift. 
 
3.2.2.2 TLD Readout and Dose Linearity Correction Factor Calculation 
The RPC conducted the TLD read-out process as described in Chapters 1.2.3 and 
2.4, and provided the following data for each TLD:  charge reading (Q) (in µC), aliquot TLD 
mass (mg) (in mg), sensitivity (KS) (i.e. dose to muscle in cGy/µC/mg, which was converted 
to mGy/µC/mg for the order of magnitude of rectal doses received by patients undergoing 
VC) (see Equation 1-5 for details on KS determination), and fading correction factor (KF) 
(unitless) (see Equation 1-1).  In order to calculate the dose to the acrylic phantom using 
the method outlined in Equation 1-8, the f-factor for acrylic (fAcrylic = 0.78 rad/R) was divided 
by the f-factor for muscle/soft tissue (fMuscle = 0.94 rad/R) (42) in a manner similar to that 
described by Equation 1-7.  Thus, TLD dose to the CTDI body phantom was calculated by 
Equation 3-8: 
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where KL,120 is the dose linearity correction factor for the GE LightSpeed VCT spectrum at 
120 kVp (unitless).  TLD response may not be linear at diagnostic energies or in the dose 
range experienced by patients undergoing VC (25, 26), therefore the two correction 
coefficients cannot be determined independently without additional information being 
available regarding TLD-100 batch response to this energy or dose range.  Therefore, the 
dose linearity correction factor could only be defined for the desired range of doses for each 
desired energy spectrum.  However, it was only necessary for this protocol to define the 
dose linearity correction factor at 120 kVp because that is the only energy specified by MD 
Anderson Cancer Center VC protocols.  Defining KL at additional energies was therefore 
determined to be outside the scope of this project. 
In order to calculate values of KL,120 appropriate for VC, the exposure measurements 
obtained by the Farmer ionization chamber (in mR) had to be converted to dose in the 
acrylic CTDI body phantom (in mGy).  These calculations were made using the appropriate 
conversion factors (100 rad = 1 Gy, 1000 mGy = 1 Gy, 1000 mR = 1R) and an f-factor of 
fAcrylic= 0.78 rad/R (42).  The Farmer ionization chamber measurement represented an 
accumulated dose to the center point within the CTDI body phantom as a result of the direct 
photon beam and from scatter through the phantom.  The average dose of the three Farmer 
ionization chamber exposure measurements for each mAs setting was calculated and 
estimated to be the true dose within the medium (DMedium) for that specific protocol.  Using 
this value as a standard by which to compare the dose response within the TLDs, KL,120 was 
calculated by rearranging Equation 3-8 into Equation 3-9: 
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where Q is the TLD charge reading (in µC), mg is the  aliquot TLD mass (in mg), KS is the 
TLD sensitivity correction factor (in mGy/µC/mg), KF is the fading correction factor 
(unitless), fMuscle = 0.94 rad/R, and fAcrylic= 0.78 rad/R.  These resultant KL,120 values were 
used to establish a third-order polynomial regression curve using Excel software (Microsoft 
Corporation, Redmond, WA) based on apparent TLD dose measurements (i.e. TLD dose 
measurements not corrected by KL,120 values).  This regression equation was used to 
calculate anthropomorphic phantom and in-vivo patient rectal dose from apparent TLD dose 
measurements in VC at MD Anderson Cancer Center in Specific Aim 2. 
 
3.3 Specific Aim 2:  Obtain Rectal Dose Measurements in an Anthropomorphic 
Phantom and In-Vivo in Patients Undergoing VC with TLDs 
With Specific Aim 1 accomplished, both the MDCT beam quality and the TLD 
response had been established for the dose range and energy spectrum received by a 
patient’s rectum when undergoing virtual colonoscopy (VC).  Before obtaining in-vivo rectal 
dose measurements in patients undergoing VC at MD Anderson Cancer Center, rectal dose 
measurements were acquired with thermoluminescent dosimeters (TLDs) (provided by the 
Radiologic Physics Center (RPC), Houston, TX) within an anthropomorphic phantom.  
Performing these measurements allowed for the identification of any potential problems in 
in-vivo measurements through “practice” measurements and allowed for an assessment of 
the accuracy of measurements acquired in a phantom compared to in-vivo measurements.  
MD Anderson Cancer Center Institutional Review Board (IRB) approval was obtained to 
perform in-vivo rectal radiation dose measurements for patients undergoing VC.  IRB 
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approval was granted for this study to affix two TLDs to the inner diameter of the standard 
rectal catheters used in 10 patient VC studies at MD Anderson Cancer Center, but data for 
only 6 of these patients were available at the time of the writing.   
 
3.3.1 Rectal Dose Measurement Simulation in an Anthropomorphic Phantom  
In order to conduct simulated VC measurements in an anthropomorphic phantom, 
an ATOM model 701 adult male phantom (Computerized Imaging Reference Systems, Inc 
(CIRS), Norfolk, VA) was modified by placing a circular cut into the pelvis of the phantom to 
simulate an insufflated rectum during VC.  This simulation also included modification of a 
rectal catheter tip that is used in VC and creation of a plug to lift the rectal catheter tip away 
from the posterior wall of the simulated insufflated rectum within the phantom.  In order to 
increase the relevance of the results obtained from measurements within this phantom that 
was designed according to standardized geometric dimensions (that may not reflect the 
anatomy of many actual patients), additional simulations were performed with layers of 
simulated adipose tissue added to the surface of the anthropomorphic phantom such that 
rectal dose determination could be made to simulate patients of larger habitus. 
 
3.3.1.1 Modifications to the Anthropomorphic Phantom 
Measurement of the Miller™ rectal catheter contained within the E-Z-EM model 
8925 Super XL Enema System (Bracco Diagnostics Incorporated, Princeton, NJ) revealed 
that the tip of the rectal catheter (where the TLDs were placed in this experiment) was 
approximately 25 mm in length. This length correlated well with the 25 mm length of each 
section of the ATOM phantom.  Therefore it was determined that although rectal and 
colonic insufflation during VC extends for the entire length of these organs, irradiation 
conditions where these point measurements would be taken with the TLDs could be 
adequately replicated by only cutting a bore representative of an insufflated rectum into one 
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25 mm section of the ATOM phantom.  Doing so also minimized potential damage to the 
ATOM phantom that may have been detrimental to future dosimetric or imaging 
experiments. 
Selection of the phantom section to be cut was determined through analysis of 
supine CT images obtained from 29 randomly selected VC exams previously performed at 
MD Anderson Cancer Center from 9/22/2009 to 9/10/2010.  In each of these supine CT 
image sets, the images containing the superior, center, and inferior portions of each rectal 
catheter head were evaluated with respect to reference anatomical bony landmarks 
(femoral heads, femurs, acetabulum, coccyx, pubic bone, ischia).  These same bony 
landmarks were observed on the ATOM phantom, and the section of the phantom that most 
closely corresponded to the average location of the rectal catheter head (and therefore the 
average location of the TLDs) was determined.  Among the 29 exams evaluated, the TLDs 
would have been placed in the anatomical location approximately corresponding to ATOM 
phantom section 33 in 9 patients, in section 34 in 15 patients, and in section 35 in 5 
patients (see Figure 3-9).  As the mean, median, and mode of this distribution all equaled or 
rounded to section 34, this ATOM phantom section was determined to contain the average 
location of the rectal catheter head during VC at MD Anderson Cancer Center.  
 
 
 
 
 
 
Figure 3-9.  Representative images of patients with a mean TLD location corresponding to 
section 33, section 34, and section 35, respectively, of the ATOM phantom  
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Figure 3-10.  Illustration of maximum rectal diameter measurements at the superior, central, 
and inferior TLD locations  
 
Determination was also made regarding the size of the insufflated rectum at the 
location corresponding to the placement of the TLDs in this study.  This measurement was 
important in order to resolve the size of the cut to make within section 34 of the ATOM 
phantom.  This estimation was made using two different methods.  The first method for 
determining the size of the insufflated rectum incorporated measurements of the largest 
diameter of the rectum in the supine scan image that corresponded to the superior, central, 
and inferior borders where the TLDs would be located within a patient (see Figure 3-10).  
These measurements were made using the tools available in Philips iSite Enterprise patient 
archiving and communication system (PACS) (Philips Healthcare, Andover, MA).  The 
largest rectal diameter in an exam was chosen to be the reference measurement obtained 
because it was the easiest dimension to determine in each rectum (which varied widely in 
size and shape of insufflation within the population of VC patients analyzed).  The average 
maximum rectal diameter measurement at the superior portion of the TLDs was 59.6 mm, 
the average of the diameter measurements at the center of the TLDs was 69.3 mm, and the 
average of the diameter measurements at the inferior portion of the TLDs was 59.4 mm.  
The average of these three diameters was 62.8 mm, which represented the average 
insufflated rectal diameter as concluded by our first method. 
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The second approach for determining the size of rectal insufflation involved 
estimating the average diameter of the rectum after insufflation while accounting for 
potential differences in these measurements based on rectal catheter head placement 
within the surrounding anatomy and based on the size of the patient.  Of the 15 patients 
that had their respective rectal catheter heads placed in the anatomical position that 
corresponded to section 34 of the ATOM phantom, six of these patients were approximately 
the same size as the ATOM phantom.  This was based on estimating the cross sectional 
shape of each patient and the phantom to be an oval (at the approximate center image 
where TLDs would be located), by measuring the short and long radii (rshort and rlong, 
respectively) of each patient, and by calculating the estimated cross sectional area (Area) 
of each of the 15 patients (see Figure 3-11) using Equation 3-10: 
 
longshort rrArea ⋅⋅= π     (3-10) 
 
 
 
 
 
 
Figure 3-11.  Illustration of the approximation of the cross-sectional area of a patient, the 
ATOM phantom, and the cross-sectional area of the patient’s insufflated rectum, respectively, 
at the mean TLD location  
 
Using this method, the cross sectional area of the ATOM phantom was estimated to 
be 550 cm2, and the average cross sectional area of the six patients was estimated to be 
554 cm2 (within 1%).  Next, the area of the insufflated rectum of each of these six patients 
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was also estimated to be an oval and the area of each insufflated rectum was also 
approximated using Equation 3-10.  The six rectal cross sectional areas were averaged to 
obtain a cross sectional area of 33.5 cm2.  Normalizing this area by the difference between 
the average patient cross sectional area and the phantom cross sectional area, an average 
insufflated rectal cross sectional area was calculated to be 33.2 cm2 for a patient of 
approximately equal cross sectional size to the ATOM phantom.  This area was determined 
to be equivalent to a circle 65.0 mm in diameter, which showed good agreement with the 
62.8 mm average diameter estimate obtained from the first measurement technique.  
Averaging these two diameters yielded a circle of approximately 64 mm in diameter, which 
was determined to be the most appropriate diameter for the circular cut that was placed in 
the phantom to represent an insufflated rectum around the TLDs. 
 
 
 
 
 
 
 
 
Figure 3-12.  Illustration of the determination of the location of an insufflated rectum within 
the axial plane of a patient by establishing reference coordinate axes and acquiring rectum-
to-surface distance measurements along the reference coordinate axes, respectively 
 
With the ATOM phantom section selected and the size of the simulated insufflated 
rectum calculated, it was appropriate to determine proper placement of the cut within the 
phantom slice.  This was accomplished by measuring the distance of the insufflated rectum 
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to the surface of each patient in both the x and y directions.  In these measurements, the 
reference x- and y- coordinate systems were established with respect to the locations of the 
femoral heads in each patient (because not all patients’ femoral heads were lying parallel to 
the CT scanner table and were therefore slightly tilted within the scan) such that the 
reference x-coordinate in each patient was parallel to an imaginary axis through the femoral 
heads.  The center of each reference coordinate axes was established to be the 
approximate center of the insufflated rectum, and the distance measurements from the 
rectal wall to a patient’s skin were taken along this reference coordinate axis.  This 
measurement process is illustrated in Figure 3-12. 
These rectal wall measurements within the six patients that most closely were 
represented by the ATOM phantom showed that the average insufflated rectum lied slightly 
to a patient’s left by an average of 6.6 mm, and towards a patient’s posterior surface by an 
average of 57.5 mm.  Transposing the anticipated 64 mm diameter circular cut onto the 
phantom using these dimensions proved problematic, however, because such a cut within 
the phantom would have cut through the phantom’s coccyx; which would not be a realistic 
scenario for VC gas insufflation.  Therefore, the location of the 64 mm diameter circular cut 
within section 34 of the ATOM phantom was modified to be the approximate center in the 
lateral direction, and 5 mm anterior to the coccyx (which provided a representative posterior 
rectum positioning similar to that demonstrated in the actual patient measurements) (see 
Figure 3-13). 
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Figure 3-13.  ATOM 701 adult male phantom section 34 before modification to include 
simulated insufflated rectum. 
 
The circular cut into section 34 of the ATOM phantom that simulated the insufflated 
patient rectum was made by the MD Anderson Cancer Center Machine Shop (Houston, 
TX).  The cut was designed to be circular to make the cutting process easier. Much of the 
removed phantom plug was spared such that it could be reinserted into the bore to 
accommodate future dosimetric and imaging studies.  Where some phantom material was 
lost during the cutting process (based on the width of the cutting tool), the plug was 
supplemented with a sleeve composed of solid water material to reestablish a functionally 
tight fit when the plug was inserted into the phantom.  Figure 3-14 shows section 34 of the 
ATOM phantom both with the simulated insufflated rectum and with the plug in place. 
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Figure 3-14.  A) ATOM 701 adult male phantom section 34 after modification to include 
simulated insufflated rectum; B) ATOM phantom section 34 with plug for non-VC studies. 
 
3.3.1.2 Modifications to the Rectal Catheter 
With the ATOM phantom appropriately configured to accommodate simulations of 
rectal dose measurements during VC at MD Anderson Cancer Center, it was necessary to 
modify a rectal catheter such that it could be placed within the assembled ATOM phantom.  
A) 
 
 B) 
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This was accomplished by simply excising the superior 24 mm of a rectal catheter head 
from the rest of the rectal catheter as shown in Figure 3-15.  Since a review of the 29 
previous supine VC scans revealed that the rectal catheter rests at various locations within 
the insufflated rectum and rarely against the posterior portion of the rectum (as would be 
the case if the catheter tip was simply placed into the insufflated rectal cavity shown in 
Figure 3-14A), a low-density Styrofoam plug was fabricated to lift the modified rectal 
catheter tip away from the simulated rectal catheter wall to more closely represent VC 
conditions (shown in Figure 3-16).   
 
 
 
 
 
 
 
 
 
Figure 3-15.   Miller™ Enema Air Tip rectal catheter modified for insertion into ATOM phantom 
section 34 for simulated VC. 
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Figure 3-16.  Low density Styrofoam plug designed for insertion into the phantom simulated 
insufflated rectum to lift the rectal catheter tip away from the phantom posterior rectal wall 
during simulated VC. 
 
3.3.1.3 Anthropomorphic Phantom Assembly 
Once the ATOM phantom had been modified to represent VC conditions at MD 
Anderson Cancer Center, the phantom was assembled such that the sections were 
properly aligned and ordered from section 1 at the top of the phantom head descending to 
section 39 at the upper thigh.  For convenience during phantom irradiation, the phantom 
was assembled such that several sections were attached to each other by tape and/or 
nylon straps according to anatomical grouping:  the shoulders/thorax/abdomen (sections 
10-29), the pelvis (sections 30-37), and the upper legs (sections 38-39).  The phantom 
head (sections 1-9) was not utilized because its presence would have only contributed 
minimally to the rectal scatter dose and because of the difficulties associated in positioning 
this portion of the phantom to adjoin to the rest of the phantom torso when the adipose 
 
Low Density 
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tissue layers were attached.  Since the ATOM phantom legs were not available to simulate 
the additional scatter dose that would be present in a real patient, the CTDI body phantom 
and an additional anthropomorphic abdomen and pelvis phantom designed for imaging 
studies (manufacturer unknown) was attached to sections 38-39 as shown in Figure 3-18 
below to approximate such scatter dose contribution to the rectum from a patient’s legs. 
 
3.3.1.4 Phantom Measurements and Determination of Population Percentages 
Represented 
With the phantom assembled, anthropomorphic measurements were acquired to 
determine the percentage of the population represented by the phantom.  A limitation of any 
anthropomorphic phantom is the fact that, although they are designed and fabricated to 
represent a standardized “typical” human in composition and dimension (in accordance with 
ICRP 23 (49) in the case of the ATOM phantom (81, 82)), they are limited in that the results 
rendered from dose measurements obtained in these phantoms only can be considered 
accurate for patients of approximately equal size and body composition as the phantom.  
Therefore, it was important to determine the percentage of the population that was 
represented by the ATOM phantom. 
A limit to the validity of anthropomorphic phantom geometry measurements in their 
correlation to measurements obtained in actual patients undergoing VC exists in that the 
phantom is constructed of rigid epoxy resin materials fashioned after a standing patient, 
and actual patients are composed of materials that shift depending on whether that patient 
is lying either on their dorsal or ventral surfaces during VC.  True patient dimensions 
demonstrate depth measurements that decrease and breadth measurements that increase, 
compared to when standing erect, when a patient is laying on their dorsal or ventral 
surfaces.  Therefore, measurements that quantified dimensions involving patient breadth or 
depth were determined to be inappropriate for comparison between patient and phantom 
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dimensions.  Patient circumference measurements can also vary based on patient position 
(specifically regarding whether a patient is standing or lying), especially in the buttocks 
region on most patients (as well as in other regions in obese patients) where folds in the 
skin can make true circumference measurements difficult to achieve and where the 
distribution of excess weight can shift along the axial direction of a large patient.  The 
changes in patient circumference with patient position, however, are not as significant as 
changes in patient breadth or depth; therefore circumference measurements were 
determined to be most appropriate for comparison between true patient measurements and 
phantom measurements. 
PeopleSize 2008 Professional software (version 1.1) (Open Ergonomics Ltd, 
Leicestershire, UK) was used to determine the percentage of US adults (aged 18-64) 
represented by the ATOM phantom.  This software provided anthropomorphic data for six 
trunk circumferential measurements, including:  chest circumference at the armpits (axillae), 
waist circumference at the midpoint, abdominal waist circumference, mid-hip 
circumference, hip circumference around the buttocks, and maximum hip circumference. 
The locations on the ATOM phantom corresponding to each of these locations are shown in 
Figure 3-17.  The results of these measurements, and the percentile of the US adults aged 
18-64 represented by these measurements, are shown in Table 3-1.   
In order to expand the applicability of measurements obtained in the 
anthropomorphic phantom to patients of different habitus, CIRS has manufactured 
additional layers of adipose tissue-equivalent material in order to conduct dosimetry studies 
for obese patients using the ATOM phantom.  These “fat slabs” were designed to be 
applied to the outer surface of the phantom in up to two layers as described in Chapter 2.  
These fat slabs provided the capability to perform dosimetry studies with the ATOM 
phantom for patients of three sizes.   
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Figure 3-17.  Locations of circumference measurements on the ATOM phantom, including: 1) 
chest circumference at the armpits (axillae), 2) waist circumference at the midpoint, 3) 
abdominal waist circumference, 4) mid-hip circumference, 5) hip circumference around the 
buttocks, and 6) maximum hip circumference. 
 
Table 3-1. CIRS ATOM phantom circumference measurements and corresponding percentage 
of US adults aged 18-64 represented. 
Measurement 
ATOM 
Circumference 
(mm) 
Percentile of US 
Adults (18-64 Years) 
(%) 
Chest circumference at armpits (axillae) 940 20 
Waist circumference, at the mid point 815 23 
Waist circumference, abdominal 850 27 
Mid-hip circumference 890 9 
Hip circumference, around buttocks 890 4 
Hip circumference, maximum 920 5 
Average 884 15 
 
The adipose tissue-equivalent phantom fat slabs were positioned onto the ATOM 
phantom pelvis in a manner similar to that shown in Figure 2-5A such that the fat slabs 
attenuated the primary CT beam before being measured by the TLDs within the modified 
rectal catheter placed in the phantom’s rectum.  The fat slabs were assembled onto the 
 
1) Chest circumference at the armpits (axillae) 
2) Waist circumference at the midpoint 
3) Abdominal waist circumference 
4) Mid-hip circumference 
5) Hip circumference around the buttocks 
6) Maximum hip circumference 
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ATOM phantom by first attaching the hook and latch ends of the large “1B” and “1D” slabs 
such that the labels were facing the same direction.  Next, these attached slabs were slid 
over the lateral portions of the previously assembled ATOM pelvis (sections 30-37) with 
slab “1B” being placed over the phantom’s left side.  Slab “1A” was then slid under the hook 
and latch assembly against the posterior side of the phantom such that the widest surface 
was in contact with the phantom.  The first layer of fat slabs was complete when slab “1E” 
was similarly slid under the hook and latch assembly on the anterior side of the phantom.  
Anthropomorphic measurements were then performed on the fatter ATOM phantom to 
determine the percentage of US adults aged 18-64 that were represented by this habitus. 
 
Table 3-2. Circumference measurements of the first layer of CIRS adipose tissue slabs after 
attachment to the ATOM phantom pelvis and the corresponding percentage of US adults aged 
18-64 represented. 
Measurement 
Fat Layer 1 + ATOM 
Circumference 
(mm) 
Percentile of US 
Adults (18-64 Years) 
(%) 
Mid-hip circumference 1170 92 
Hip circumference, around buttocks 1175 87 
Hip circumference, maximum 1180 81 
Average 1175 87 
 
 
As mentioned in Chapter 2, these fat slabs only provide 20 cm of phantom surface 
coverage.  Therefore only three of the six circumference measurements acquired for the 
ATOM phantom torso were able to be acquired for the two additional phantom 
configurations, including:  mid-hip circumference, hip circumference around the buttocks, 
and maximum hip circumference. The results of these measurements and the percentiles of 
US adults aged 18-64 represented by these dimensions are provided in Table 3-2.  
Averaging the percentiles of US adults aged 18-64 represented by these three 
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circumference measurements yielded an approximation that the 87th percentile was 
represented by the phantom configuration with the first layer of fat slabs attached to the 
pelvis.   
 
Table 3-3. Circumference and thickness of supplemental fat material to add to 
anthropomorphic regions of the ATOM phantom corresponding to the 87th percentile of US 
adults aged 18-64. 
Anthropomorphic Region 
87th Percentile 
of US Adults 
(18-64 yr) 
Circumference 
(mm) 
Supplemental 
Circumference 
to be Added to 
Phantom  
(mm) 
Supplemental 
Thickness to 
be Added to 
Phantom 
(mm) 
Chest circumference at armpits (axillae) 1155 215 34 
Waist circumference, at the mid point 1135 320 51 
Waist circumference, abdominal 1135 285 45 
Average 1142 273 44 
 
 
Using this phantom configuration to approximate the rectal dose received by a 
patient undergoing VC at MD Anderson Cancer Center was problematic because where the 
fat slabs only extended 20 cm along the phantom’s pelvis, an appropriate VC scan of a 
person whose torso length equaled that of the phantom would have been much longer.  
Therefore, in order to appropriately represent the conditions experienced by a patient 
undergoing VC, additional application of adipose tissue-equivalent material to the external 
surface of the ATOM phantom was necessary.  The amount of additional fat material 
necessary to represent a patient in the 87th percentile of US adults aged 18-64 was 
determined by calculating the 87th percentile measurements of the three additional 
circumferences measured for the ATOM phantom without the fat slabs in place (but which 
were not measureable due to the short length of the fat slabs).  These three additional 
circumferences included: chest circumference at armpits (axillae), waist circumference at 
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the midpoint, and abdominal waist circumference.  The results of these circumference 
values provided by PeopleSize 2008 Pro, the amount of fat circumference required to be 
added, and the amount of additional fat required to be added to the ATOM phantom to 
achieve these circumferences are provided in Table 3-3.   
Upon completion of the analysis required for the ATOM phantom with the first fat 
layer attached, the second fat layer was added to the exterior of the first fat layer in a 
manner similar to that shown in Figure 2-5B.  This was accomplished by first attaching the 
hook and latch pads located at the ends of the large “2B” and “2D” slabs such that the 
labels were facing the same direction.  Next, these attached slabs were slid over the lateral 
portions of the previously assembled 87th percentile ATOM pelvis (sections 30-37) with slab 
“2B” being placed over the phantom’s left side.  Slab “2A” was then slid under the hook and 
latch assembly on the posterior side of the phantom such that the widest surface was in 
contact with the first fat layer.  The second layer of fat slabs was complete when slab “2E” 
was similarly slid under the hook and latch assembly on the anterior side of the phantom.  
The same three pelvis circumference measurements as were performed on the first layer of 
fat slabs when attached to the ATOM phantom were then performed on the phantom with 
the second fat layer attached to determine in PeopleSize 2008 Pro software the percentage 
of US adults aged 18-64 this third habitus represented.  These measurements and 
percentiles are provided in Table 3-4, and the average of these measurements was 
approximated to be representative of the 99th percentile of US adults aged 18-64 years.   
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Table 3-4. Circumference measurements of the second layer of CIRS adipose tissue slabs 
after attachment to the ATOM phantom pelvis, and the corresponding percentage of US 
adults aged 18-64 represented by this phantom configuration. 
Measurement 
Fat Layer 2 + ATOM 
Circumference 
(mm) 
Percentile of US 
Adults (18-64 Years) 
(%) 
Mid-hip circumference 1410 99.9 
Hip circumference, around buttocks 1435 99.5 
Hip circumference, maximum 1465 99.99 
Average 1437 ≈99 
 
 
In a manner similar to that performed for the first fat layer, the average amount of 
additional fat material was determined with PeopleSize 2008 Pro that was required to be 
added to:  the phantom chest circumference at the armpits (axillae), the waist 
circumference at the midpoint, and the abdominal waist circumference; such that the 
phantom configuration represented the 99th percentile of US adults aged 18-64.  These 99th 
percentile circumferences, the amount of additional circumference, and the amount of 
additional thickness to add to the built-up phantom (with the first fat layer and supplemental 
fat material) are provided in Table 3-5.  Obtaining 99th percentile patient measurements was 
useful for this study because such measurements should represent minimum rectal dose 
limits (due to maximum attenuation by surrounding fatty tissue), which insured that the 
lower limits of administered rectal doses would be detectable with the TLDs in this study.  
We did not expect to perform many (if any) in-vivo measurements in patients large enough 
to be considered within the 99th percentile of US adults aged 18-64. 
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Table 3-5. Circumference and thickness of supplemental fat material to add to 
anthropomorphic regions of the CIRS ATOM phantom (with the first layer of supplemental fat 
already in place), corresponding to the 99th percentile of US adults aged 18-64. 
Anthropomorphic Region 
99th Percentile 
of US Adults 
(18-64 yr) 
Circumference 
(mm) 
Supplemental 
Circumference 
to be Added to 
Phantom  
(mm) 
Supplemental 
Thickness to 
be Added to 
Phantom  
(mm) 
Chest circumference at armpits (axillae) 1352 197 31 
Waist circumference, at the mid point 1481 346 55 
Waist circumference, abdominal 1469 334 53 
Average 1434 292 47 
 
 
With the amount of supplemental fat material to be added to the chest 
circumference at the phantom’s armpits (axillae), to the phantom’s waist circumference at 
the midpoint, and to the phantom’s abdominal waist circumference calculated for the two 
larger phantom configurations, the issue of appropriate selection of supplemental fat 
material to utilize became a relevant decision.  It was determined that the most practical, 
workable, and cost effective material that could be implemented to create a realistic scatter 
medium was pig adipose material in the form of lard.  Therefore 207 pounds of lard were 
purchased and repackaged into 8 space-saver plastic luggage bags (ITW Space Bag®, 
San Diego, CA) and two zipper-style resealable two-gallon bags that could be molded into 
shape and sealed after forcing air out of the bags.  As an added precaution against soiling 
the CT scanner or phantom with this adipose material, a plastic sheet was placed between 
the CT scanner table and the phantom assembly.  Each two-gallon bag was filled with 2-3 
pounds of lard material, each medium-sized plastic luggage bag was filled with 15-18 
pounds, and each large-sized luggage bag was filled with 30-35 pounds such that the 
appropriate thickness of fat material (shown in Tables 3-3 and 3-5) could be added to the 
exterior of the ATOM phantom at the appropriate locations both superior and inferior to the 
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CIRS fat tissue layers (over the thorax/abdomen and leg regions of the phantom).  During 
the simulated VC procedures with the ATOM phantom, the bags of adipose tissue were 
secured in place around the appropriate phantom circumferences with duct tape.  
 
3.3.1.5 Virtual Colonoscopy Simulation in an Anthropomorphic Phantom 
Before acquiring any TLD measurements during simulated VC in the ATOM 
phantom, the “CT9” GE VCT scanner at MD Anderson Cancer Center was evaluated to 
determine the beam half-value layer (HVL), quarter-value layer (QVL), weighted computed 
tomography dose index (CTDIw), volume CTDI (CTDIvol), and 100 cm in-air CTDI 
(CTDI100,air) as described in Chapter 3.2.1.  These beam quality measurements were 
obtained for comparison purposes with those beam quality measurements that were 
acquired when the TLDs were irradiated during the calibration procedure (Specific Aim 1).  
HVL and QVL measurements were also performed upon the completion of in-vivo dose 
measurements on all three GE VCT scanners upon which measurements were performed 
to verify the consistency of the beam output of the x-ray tubes.  Once the x-ray tube beam 
quality had been initially characterized by each of these entities on the “CT9” scanner, the 
ATOM phantom was prepared for simulated rectal dose measurements during VC. 
Before placing the ATOM phantom onto the CT scanner, a plastic sheet was placed 
onto the table to reduce the risk of the simulated adipose material soiling the scanner.  
Next, each of the previously established ATOM phantom regions were placed onto the 
scanner table and assembled such that the respective regions (i.e. thorax and abdomen, 
pelvis, upper legs/leg simulation medium) abutted to one another.  The 15th percentile 
configuration phantom was placed on the scanner table such that it was lying in a supine 
position and no additional fat slabs were attached (see Figure 3-18).  The MDCT scanner 
was then landmarked to the (0,0,0) coordinate at the center of the phantom in the coronal 
plane (which had previously been marked on the phantom with tape), in the approximate 
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center of the phantom in the sagittal plane, and in the center of phantom section 34 in the 
axial plane (87.5 mm from the inferior edge of the phantom pelvis region).  A piece of tape 
was placed on the scanner table in the axial direction at section 34 and a mark was placed 
on the tape along the laser marking the axial plane for consistency in alignment between 
the phantom and the CT scanner in the repeated scans.  A posterior-anterior (PA) scout 
image of the assembled phantom was acquired at 120 kVp and 10 mA to determine the 
superior and inferior borders of the VC scan, which corresponded superiorly with section 18 
at the base of the lungs and inferiorly at section 36 at the ischium.  This scan length was 
based on the same landmarks used to determine scan length of actual patients undergoing 
VC at MD Anderson Cancer Center. 
 
 
 
 
 
 
 
 
 
 
Figure 3-18.  Phantom assembly utilized in simulated VC rectal dose assessment. 
 
With the scan length established, the strap connecting the pelvic region of the 
phantom was disconnected, and section 34 was removed from the rest of the pelvis 
assembly.  The custom-cut insufflated rectum plug was then removed from the phantom 
section and the Styrofoam plug was inserted into the bore.  The modified rectal catheter tip 
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was then inserted into the Styrofoam plug, and two double-chambered TLDs (obtained from 
the RPC) were inserted into the modified rectal catheter tip.  The TLDs were not attached to 
the rectal catheter wall or subjected to extensive quality assurance (QA) measures to 
ensure patient safety (as would be the case for in-vivo measurements) because such steps 
were unnecessary within the inanimate phantom. 
When the two TLDs had been inserted into the modified rectal catheter, the ATOM 
phantom pelvis was reassembled, the strap holding the region together was refastened, 
and the entire ATOM phantom was carefully reassembled by aligning the marks on the 
scanner table and section 34 such that the phantom was in the same position as during the 
acquisition of the scout image.  The MDCT scanner was then set to MD Anderson Cancer 
Center VC scan protocols:  full helical scan mode with 0.5 sec rotation time, 1.25 mm image 
thickness, 39.37 mm/rotation table speed, 0.984 pitch, 0.8 mm image interval, 120 kVp, 100 
mA, 0 sec delay, and standard reconstruction algorithm.  The phantom was then irradiated 
in the supine position using this CT scan technique.  Since CT dose is well known to be 
linearly proportional to mAs (37), and since this experiment was not concerned with 
obtaining the diagnostic benefits described in Chapter 1.1.2 that are associated with 
acquiring both supine and prone CT scans in VC, the ATOM phantom was not rolled over to 
a prone position but rather simply irradiated a second time with the same technique to 
simulate the prone scan. 
Once the two double chambered TLDs had been irradiated with both supine VC 
scans, the pelvic region of the phantom was again disassembled and section 34 was 
removed.  The two TLDs were then extracted from this phantom section and were taped to 
a sheet of paper that was carefully labeled with TLD identification information and the 
irradiation conditions of the TLDs.  Next, a second set of two double chambered TLDs were 
inserted into the modified rectal catheter and the phantom was reassembled.  The phantom 
was identically placed on the MDCT scanner using the alignment lasers and marks placed 
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on both the table and the phantom (see Figure 3-19); and the phantom was irradiated using 
the same MD Anderson Cancer Center method used to irradiate the previous TLDs.  When 
the second set of TLDs had been irradiated, they were replaced with a third set of two 
double chambered TLDs within the ATOM phantom.   
 
 
 
 
 
 
 
 
 
 
Figure 3-19.  Placement of the anthropomorphic phantom on the MDCT scanner such that a 
mark designating the location of the TLDs within the phantom align via laser with a mark 
placed on the scanner table 
 
After a total of three sets of two double chambered TLDs had been irradiated within 
the initial (15th percentile) ATOM phantom configuration (i.e. without the additional fat slabs 
and supplemental fat material), a fourth set of TLDs were inserted into the phantom and the 
first fat layer was added to the external circumference of the pelvis.  For alignment 
purposes, a mark was placed on the surface of the fat slab that was 87.5 mm from the 
inferior edge of the phantom pelvis region to correspond to the center of phantom section 
34.  Next, a medium-sized space-saving bag containing lard was placed on the CT scanner 
table abutting to both the inferior and superior ends of the pelvis fat slabs (see Figure 3-
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20A).  The superior and inferior portions of the phantom were then placed on top of the 
bags filled with lard and were each covered with a second medium-sized bag.  The two 
lard-filled bags were abutted around the respective lateral portions of the phantom and 
were attached at that end with two pieces of duct tape (see Figure 3-20B).  The bags of 
adipose tissue were then wrapped around the respective portions of the phantom and were 
connected by two more pieces of duct tape on the opposite lateral portion of the phantom 
(see Figure 3-20D).  On the phantom thorax and abdomen, the two bags were too short to 
connect on the opposite side; so an additional zipper-style two-gallon bag containing 2-3 
additional pounds of adipose tissue was placed between the respective space-saver bags 
(see Figure 3-20C).   
   With the superior and inferior portions of the lard wrapped around the phantom, 
significant efforts were made to ensure the connecting regions of the phantom correctly 
abutted to one another.  At times, this required placing towels and pillows under portions of 
the adipose material to correctly position the phantom.  Once the regions of the phantom 
were adequately adjoined, the adipose tissue within the bags surrounding the phantom 
were then manipulated by hand such that the lard within the combined bags was 
approximately 51 mm thick at the abdomen and tapered down to approximately 34 mm 
thick at the abdomen in accordance with Table 3-3. 
The adipose material attached to the leg region of the phantom was manipulated by 
hand to be an approximately uniform 40 mm throughout because this thickness equaled 
that of the fat slabs manufactured by CIRS (and anthropometric data for upper leg 
circumference was not available in PeopleSize 2008 Pro software).  It should be noted, 
though, that manipulation of the fat to desired thickness was inexact and even after 
extensive efforts, certain portions remained thicker than others (for example, the central 
portions of the lard-filled bags supporting the phantom weight were unavoidably thinner 
than the lateral portions of those bags due to the effects of gravity). 
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Figure 3-20.  A) Placement of the phantom onto a medium-sized bag filled with adipose tissue 
to represent the 87th percentile of US adults aged 18-64; B) Attachment of two abutting 
adipose tissue-filled bags with duct tape at the lateral portion of phantom; C) The use of a 
zipper-style two-gallon bag filled with adipose tissue to connect opposing bags surrounding 
the phantom thorax and abdomen; D) Attachment of the abutting adipose tissue-filled bags 
with duct tape at the opposite lateral portion of phantom after pulling the bags tightly around 
the phantom. 
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109 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-21.  ATOM phantom assembled to represent the 87th percentile of US adults aged 18-
64 for simulated VC. 
  
When the respective regions had been supplemented with sufficient adipose 
material to represent the 87th percentile of US adults aged 18-64 (the percentile 
corresponding to the pelvic circumference attained when the first fat layer was added to the 
ATOM phantom pelvis), the phantom was reassembled (see Figure 3-21) onto the MDCT 
scanner such that the mark placed on the pelvic fat slab at phantom section 34 aligned with 
the mark placed on the scanner table.  This phantom configuration was then irradiated 
twice (both times with the phantom in the supine position) using the MD Anderson Cancer 
Center CT scan technique for VC provided above.  The pelvis region of the phantom was 
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then rolled away from the rest of the phantom assembly, disassembled, the TLDs within 
section 34 were replaced with two more double chambered TLDs, the phantom 
configuration was reassembled, and the process was repeated such that a total of three 
measurement sets of two double chambered TLDs were acquired in the 87th percentile 
phantom configuration. 
Upon the completion of measurements acquired to represent the rectal dose 
received by the 87th percentile of US adults aged 18-64 while undergoing VC, the phantom 
was modified to accommodate for measurements representing the dose received by the 
99th percentile (the percentile corresponding to the pelvic circumference attained when the 
second fat layer was additionally added to the ATOM phantom pelvis) during VC.  This was 
accomplished by disassembling the entire phantom used to represent the 87th percentile 
and by placing two double chambered TLDs into the ATOM phantom pelvis.  Next, the 
second fat layer was added to the ATOM phantom pelvis and the pelvis assembly was 
placed on the CT scanner table.   
In order to ensure consistency in phantom placement between iterations and 
configurations, a piece of tape was placed on the external surface of the second pelvic fat 
slab and a line was placed on the tape 87.5 mm from the inferior surface of the pelvic 
region.  This line represented the location of the center of ATOM phantom section 34 and 
the location of the TLDs, and the pelvis assembly was adjusted on the scanner table such 
that this line was in alignment to the line previously placed on the scanner table.  A large-
sized bag of lard was then placed onto the CT scanner table both superiorly and inferiorly to 
the phantom pelvis such that both bags abutted to the second fat slab layer encompassing 
the phantom pelvis.  A medium-sized bag of lard was additionally placed on top of each 
large-sized bag, and the 87th percentile phantom configuration was assembled using these 
medium-sized bags on top of the large-sized adipose tissue bags.    
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Once the 87th percentile phantom configuration had been reassembled, a second 
large-sized bag of adipose tissue was placed on top of the superior and inferior regions of 
the 87th percentile phantom configuration, and the two large-sized bags were attached at 
one lateral portion of each region of the phantom by two pieces of duct tape.  In a manner 
similar to that used to assemble the 87th percentile configuration, the large-sized bags were 
then pulled tightly around the phantom and secured at the opposite lateral side of the 
phantom by two additional pieces of duct tape (incorporating an additional zipper-style two-
gallon bag of adipose tissue to connect the large-sized bags on the thorax/abdomen portion 
of the phantom).  In a manner also similar to that incorporated to assemble the 87th 
percentile phantom configuration, considerable care was taken to ensure the adjoining 
portions of the ATOM phantom were correctly mated to one another by using additional 
towels and pillows to prop up portions of the phantom as appropriate.   
When the ATOM phantom was correctly aligned, the bags of adipose tissue were 
adjusted to ensure they abutted to the pelvic fat slabs, and then the lard within the large-
sized bags were manipulated by hand such that the abdominal thickness of lard was 
approximately 54 mm thick and tapered to approximately 31 mm thick at the chest (in 
accordance with Table 3-5).    As with the 87th percentile phantom configuration, the large-
sized bags of lard surrounding the leg portion of the phantom assembly were additionally 
manipulated to be approximately 40 mm thick throughout.  Such hand manipulation of the 
adipose tissue within the bags was inexact, and portions of the respective bags unavoidably 
accumulated more lard (i.e. the lateral portions of the bags) than other portions (i.e. the 
portion of the bags supporting the weight of the phantom).   
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Figure 3-22.  ATOM phantom assembled to represent the 99th percentile of US adults aged 18-
64 for simulated VC. 
 
Figure 3-22 shows the final phantom assembly used to represent the body habitus 
of the 99th percentile of US adults aged 18-64.  In order to acquire multiple measurements 
within a phantom configuration, the pelvic region of the phantom was rolled away from the 
rest of the phantom assembly (see Figure 3-23), disassembled, irradiated TLDs were 
harvested and replaced with unirradiated TLDs within the ATOM phantom pelvis, and the 
entire phantom was reassembled for each measurement set.  This process became very 
time consuming and required patience.  As was the case with the two previous phantom 
configurations simulating VC using the MD Anderson Cancer Center protocol, the three 
measurement sets of two double chambered TLD measurements were acquired for the 
phantom configuration simulating the rectal dose received by the 99th percentile of US 
adults aged 18-64 undergoing VC.  
 
 
113 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-23.  Disassembly of 99th percentile phantom configuration for repeated TLD 
measurements during simulated VC; with the two layers of CIRS simulated phantom fat 
disattached from the ATOM phantom pelvis region (held in-tact during simulated VC by the 
black nylon strap shown). 
 
 Simulation of in-vivo rectal dose measurements in an ATOM phantom was 
completed after the three sets of two double chambered TLDs were irradiated within the 
phantom configuration simulating the 99th percentile of US adults aged 18-64.  In total, 
three sets of two double chambered TLD measurements were accomplished for three 
phantom configurations equaling 12 TLD dose measurements per habitus for a total of 36 
TLD measurements with the ATOM phantom.  The RPC conducted the TLD read-out 
process a minimum of 14 days after irradiation as described in Chapters 1.2.3 and 2.4. 
 
3.3.1.6 Simulated Virtual Colonoscopy Data Analysis 
 
ATOM Phantom 
Pelvis Region 
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The results provided by the RPC included the following data for each TLD:  charge 
reading (Q) (in µC), aliquot TLD mass (mg) (in mg), sensitivity (KS) (i.e. dose to muscle in 
cGy/µC/mg, which was converted to mGy/µC/mg for the order of magnitude of rectal doses 
received by patients undergoing VC) (using Equation 1-5), and fading correction factor (KF) 
(unitless) which was adjusted according to Equation 1-1 to account for the time delay 
between TLD irradiation and readout.  The linearity and energy correction factors (KL,120) 
used to calculate dose for these measurements were those established in Specific Aim 1.  
These dose measurements were used to fit a regression model estimating rectal dose 
based on a patient’s effective diameter; and 95% confidence intervals and an R2 goodness 
of fit coefficient were calculated for this regression analysis.  The average of the 12 dose 
measurements at each simulated habitus was determined to be the dose received by a 
specific patient habitus, and these average dose values were used to accomplish Specific 
Aim 3 in comparing the TLD dose measurements to CTDIvol-based size specific dose 
estimate (SSDE) and Farmer chamber dose measurements taken in a uniform CTDI body 
phantom. 
 
3.3.2 In-Vivo Rectal Dose Measurements during Virtual Colonoscopy 
MD Anderson Cancer Center Institutional Review Board (IRB) approval was 
obtained to perform in-vivo rectal radiation dose measurements for patients undergoing VC.  
IRB approval was granted for this study to affix two TLDs to the inner diameter of the 
standard rectal catheters used in 10 patient VC studies at MD Anderson Cancer Center.  At 
the time of this writing, however, data was only available for six VC patient measurements, 
and therefore data will only be presented in this work for those six patients.  As mentioned 
above, each of the TLDs used in this study contained two measurement chambers; and 
therefore four total rectal radiation dose measurements were obtained for each patient.  Per 
standard VC procedure, the rectal catheters were not used for more than one patient (which 
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significantly reduced the opportunity for infection in patients as a result of participation in 
this study); therefore 6 different rectal catheters were used in this study.   
The only deviation from the standard MD Anderson Cancer Center protocol for VC 
(described in Chapter 1.1.2) introduced by this study was the measurement of the radiation 
dose received by the rectum by affixing the two small TLDs inside the same rectal catheter 
used as a part of the standard VC procedure.  Four measurements were obtained per 
patient of the accumulated dose administered to that patient’s rectum from four scout 
images and both prone and supine CT scans.  In order to reduce the chances of TLD-100 
material coming in direct contact with patients, of TLDs becoming dislodged from the rectal 
catheter, or of patients or researchers receiving an infection as a result of participation in 
this study, a quality assurance (QA) system was established covering five stages of quality 
control (QC).  These QC steps were implemented into the TLD/catheter assembly and VC 
processes.   
 
3.3.2.1 QC Step 1:  Testing TLD Capsules for Leakage  
The first stage of QC was designed to ensure that the plastic encapsulating the 
TLDs remained watertight while in a patient.  These measures were important because 
although LiF toxicity data shows that initial GI symptoms may appear with quantities of LiF 
ingestion as low as 120 mg (97) (and this amount is greater than the total amount of LiF 
used per patient in this study), irritation of the mucosal cells of the rectum and large 
intestine may result from contact with LiF (97-99).   However, as the tissues of the rectum 
and distal portions of the large intestine only permit trace amounts of most materials to be 
absorbed (98), it was determined that there was little risk of notable side effects in the very 
unlikely event that LiF escaped encapsulation.  
In order to ensure the integrity of the TLD encapsulation, the following steps were 
accomplished for each TLD/rectal catheter assembly: 
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1. Two double chamber TLDs obtained from the Radiologic Physics Center (RPC) were 
visually inspected with a magnifying glass to ensure there were no cracks in the plastic 
capsule and that the wax plug was firmly in place. 
2. The TLDs were submersed in a tap water bath within a small container for a period no 
less than 24 hours (see Figure 3-24). 
3. After at least 24 hours had passed, LiF powder within the TLD capsule was carefully 
examined for any condensation or nonuniformities.  As LiF is hygroscopic (97), it readily 
absorbs water within its environment and should provide visually obvious signs of any 
such water intake.  The appearance of the TLD capsule was compared to that of a 
control TLD that had not been submerged.   
4. Any TLD that would have absorbed water would be deemed to have an insufficient seal 
for this project and therefore returned to the RPC.   
 
 
 
 
 
 
 
 
 
 
Figure 3-24.  QA test #1:  Place TLDs in a water bath for 24 hours. 
 
3.3.2.2 Attaching TLDs to the Rectal Catheter 
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Once the integrity of the TLD plastic encapsulation was established, two double-
chambered TLDs were inserted into the inner lumen of the rectal catheter and secured by 
Silicone II (General Electric Corporation, Huntersville, NC) silicone glue and suture string 
(Tyco Healthcare, Norwalk, CT).  Both of these agents had previously established a history 
of being bio-inert in other applications at MD Anderson Cancer Center (with this silicone 
glue used in the assembly of eye plaques treating ocular melanomas with brachytherapy 
and the suture being used surgically).  These TLDs were secured inside this rectal catheter 
tip as illustrated in Figure 3-25 using the method described below. Although the placement 
of the TLDs within the catheter decreased its inner diameter, care was taken to ensure the 
function of the device was not substantially altered. 
 
 
 
Figure 3-25. Cross section diagram of TLD placement within the rectal catheter 
 
The following steps were accomplished to assemble the two TLDs to the inner 
lumen of the rectal catheter: 
1. One end of the bag in which the E-Z-EM Super XL Enema Delivery System (Model 
8925) was packaged was carefully cut using scissors (see contents of the bag in Figure 
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1-2).  Although the catheter assembly was not a sterile device, care was taken when 
handling the device to minimize contamination and protect the components. 
2. A pea-sized amount of silicone glue was placed onto the tip of an unfolded paperclip 
and this glue was dabbed onto the inner lumen of the rectal catheter tip (see Figure 3-
26) through the superior opening just proximal to (and on the same axis as) the balloon 
inflation extrusion (as labeled in Figure 2-13).  This application of glue was repeated 
with several pea-sized applications of silicone glue applied to the same area such that 
the interior of the catheter head was similar in appearance to Figure 3-27. 
3. Two 10 cm lengths of 2-0 (0.3 mm diameter) polypropylene suture string (Tyco 
Healthcare, Norwalk, CT) were weaved through the external ports of the rectal catheter 
such that they bridged the bed of silicone glue (without becoming embedded into the 
bed of glue) and the two ends were loosely tied with the first throw of a surgeon’s knot 
(the right end of the suture was tied over the left end twice yielding a double overhand 
knot) as shown in Figure 3-28. 
4. One TLD was then inserted into the superior opening of the rectal catheter and carefully 
navigated to the applied glue bed (under the suture bridge) using an unfolded paperclip 
fed through the superior and exterior bores of the rectal catheter.  When the TLD was in 
position along the inner surface of the rectal catheter tip abutting to the superior lip of 
the rectal catheter lumen (adjacent to the superior opening), the TLD was pressed into 
the glue using the paper clip and the double overhand knots were drawn taught.  The 
Surgeon’s knots were then completed with the second throw such that the TLD was 
secured into position.  With the TLD secure, most of the excess suture was removed, 
and the knots were rotated into the interior of the rectal catheter as shown in Figure 3-
29. 
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Figure 3-26. Application of a pea-sized amount of silicone glue to the interior of the rectal 
catheter. 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-27. Proper amount of silicone glue applied to the inner lumen of the rectal catheter 
tip. 
 
 
Bed of Silicone Glue 
120 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-28. Two 10 cm lengths of suture string tied in the first throws of surgeon’s knots. 
 
 
 
 
 
 
 
 
 
 
Figure 3-29. Proper placement of the first TLD to the inner lumen of the rectal catheter tip. 
 
5. The excess glue within the rectal catheter was smoothed over using a paperclip to 
ensure that no more than one of the external holes on the rectal catheter head was 
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occluded (to ensure that the functionality required of the rectal catheter was 
maintained). 
6. While slightly pinching the tip of the rectal catheter such that the superior bore assumed 
an oval shape, the second TLD was inserted into the rectal catheter head such that the 
end of the TLD that contained the wax plug was the last portion of the TLD to enter the 
rectal catheter (see Figure 3-30).  Inserting the TLD in this manner ensured that the 
TLD was placed with minimal effort and that the TLD would remain within the rectal 
catheter during the VC procedure due to the tapered geometry of the TLD capsule (with 
the plugged end of the TLD having the largest diameter).  This TLD was not secured 
with silicone glue or suture because the partial occlusion of the superior opening of the 
catheter by the secured TLD prevented the escape of the unglued TLD. 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-30. Proper insertion of the second TLD into the rectal catheter head. 
 
7. Excess glue was wiped from the exterior of the rectal catheter tip. 
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8. The rectal catheter/TLD assembly was placed in a warm and dry environment, and the 
silicone glue was permitted to dry for a minimum of 24 hours. 
9. After at least 24 hours had passed, the assemblies were visually inspected to verify the 
placement of the TLD within the rectal catheter head and to verify that the TLDs and 
glue did not occlude more than one external hole on the rectal catheter head.  The final 
TLD/rectal catheter assembly is shown in Figure 3-31. 
10. As a final check of the functionality of the rectal catheter assembly, air was forced 
through the open end of the blue insufflation tube to verify that the gas insufflation port 
within the rectal catheter was not accidentally occluded with silicone glue.  If it was 
discovered that this hole was occluded, a hole was punctured and reamed out in the 
silicone glue at the gas insufflation port (shown in Figure 2-13) to reestablish gas 
insufflation capability. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-31. Proper final placement of two TLDs within the rectal catheter. 
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3.3.2.3 QC Step 2:  Testing for Secure TLD Attachment to the Rectal Catheter 
The second stage of QC was designed to ensure that the TLDs would remain 
attached to the rectal catheter at all times while in a patient. This was accomplished by 
applying compression and flexion conditions to the exterior surface of the rectal catheter 
with forces exceeding those encountered in the rectal environment; and by water flow 
testing the apparatus with pressures exceeding those encountered in the contrast 
administration process.  The second stage of QC was not executed until the glue had been 
permitted to dry for at least 24 hours, and execution of this QC stage was conducted with 
the following steps:  
1. Observing the TLDs through the superior opening of the catheter, the rectal catheter 
head was physically compressed several times by hand force such that the two TLDs 
came into contact with one another.   During compression, the secured TLD was 
observed for movement away from the catheter wall as the tension within the tip of the 
rectal catheter was applied and relieved.  If little or no TLD movement from the catheter 
lumen wall was observed, additional compression forces were applied to the catheter 
head such that the TLDs both came in contact with the opposite catheter wall 
(completely collapsing the catheter tip).  Again, the secured TLD was observed for 
movement away from the wall to which it was glued. 
2. If little or no TLD movement was observed, the catheter head was again compressed 
such that the TLDs came in contact with the respective opposite walls, and the 
assembly was then rolled/flexed three or four times by hand force such that the TLDs 
were leveraged against each other and forced to peal the secured TLD away from the 
rectal catheter wall.  While doing this, the secured TLD was observed for movement 
away from the catheter wall to which it was attached.   
3. If little or no TLD movement was observed, tap water was poured into the contrast 
agent bag and the cap on the bag was closed.  The rectal catheter tip was directed into 
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a sink and the contrast bag was held several feet higher than the rectal catheter tip.  
The contrast bag containing the tap water was then squeezed such that water was 
forced through the rectal catheter at pressures greater than those encountered by 
hydrostatic means (i.e. at pressures greater than those experienced during VC).   
4. If the TLDs remained within the rectal catheter, the catheter assembly was determined 
to have passed the second QC step.  If, however, a catheter assembly failed any of 
these tests, the assemblies were immediately dried and the TLDs were reapplied using 
the same process described above (Section 3.3.2.2).  No TLD/catheter assembly was 
be used clinically unless it passed each of these tests. 
 
3.3.2.4 QC Step 3:  Disinfection of Rectal Catheter Assembly 
The third stage of QC was implemented to ensure patients did not receive an 
infection as a result of participation in this study. In spite of the fact that VC is a clean 
procedure (and not a sterile procedure), the TLD/rectal catheter assemblies underwent 
disinfection after successfully completing the first two stages of QC (and before being 
inserted into patients). Careful handling ensured disinfection was maintained until the 
catheter came in contact with a patient.  To conduct this QC procedure, the following steps 
were accomplished: 
1. 70% isopropyl alcohol solution (Target Corporation, Minneapolis, MN) was poured into 
an appropriately sized container to 10 cm of depth. 
2. The contrast agent bag, tubes and rectal catheter were coiled into a circle 
approximately 25 cm in diameter, similarly to the configuration in which it was packaged 
by the manufacturer. 
3. The contrast agent tubing was grasped, exposing the rectal catheter (the portion that 
was to be inserted into the rectum), and the rectal catheter was submerged 9 cm into 
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the 70% isopropyl alcohol (up to the bulge on the shaft).  The catheter assembly 
remained in the alcohol solution for at least 10 seconds. 
4. After the alcohol bath was completed, the catheter tip was removed from the alcohol 
solution and excess alcohol was gently shaken from the rectal catheter back into the 
container. 
5. With the assembly still coiled, the disinfected assembly was returned to the original E-Z-
EM Double Contrast Enema Delivery System packaging in a similar manner as 
originally packaged for storage until used clinically.  Careful handling ensured 
disinfection was maintained until the catheter came into contact with a patient.  The 
enema packaging was secured with packing tape to ensure the contents of the bag 
remained secure while in storage.  
6. The disinfected rectal catheter assemblies were stored in a dark location that was 
secure from outside radiation sources. 
 
3.3.2.5 Irradiating TLDs during VC and QC Step 4:  Maintenance of Control of TLDs at All 
Times 
Once the TLD/rectal catheter assemblies, preparatory QA steps, and disinfection 
were completed, 6 patients were recruited for the study in accordance with the conditions 
established for IRB approval.  This study was limited to those patients whom were already 
approved for VC by their primary physician and their insurance.  Patient recruitment, 
informed consent, and evaluation were conducted by one of two board certified radiologists 
experienced in VC interpretation (Drs. David Vining and Priya Bhosale). The process of 
obtaining informed consent for this protocol was overseen by the Office of Translational and 
Clinical Research within the Division of Diagnostic Imaging at MD Anderson Cancer Center.  
The criteria for inclusion in this study included:  those patients scheduled for VC as 
part of routine standard-of-care (including both screening and diagnostic VC exams), an 
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ability to provide informed consent, and an ability to read and speak English (because the 
team was unable to conduct the informed consent process in any other language). Criteria 
for exclusion from this study included: women of childbearing age (unless a negative urine 
or serum pregnancy test was obtained within 48 hours prior to participating in the study), a 
history of allergic reaction to iodinated‐contrast agents, and patients under the age of 18.  
Eligible participants were asked to participate in this research study between one and 30 
days before the VC CT scan was conducted. Participants were made aware that if for any 
reason during the procedure the participant wished to cease their involvement with the 
study, their desires would be adhered to without prejudice and that their VC examination 
would be conducted in the usual manner.   
Once a patient had agreed to participate in this study and provided informed 
consent, a disinfected and sealed rectal catheter/TLD assembly was removed from storage 
for the scheduled VC appointment and provided to the radiologist at the MDCT scanner.  
Although the typical VC protocol at MD Anderson Cancer Center does not require a 
physician to administer the rectal catheter, appropriately trained radiologists conducted all 
enema tip administration and removals for this study.  The fourth stage of QC was 
incorporated to ensure that the radiologist maintained control of the TLDs at all times. This 
was accomplished by adhering to the following procedures: 
1. The bag was opened, but not disposed of, using standard infection control personal 
protective equipment (PPE) (gloves).   
2. When beginning the procedure, the catheter assembly was carefully removed from the 
bag and the inner lumen of the rectal catheter visually inspected through the superior 
opening to verify that two TLDs could be visualized within the catheter (verifying an 
appearance similar to that shown in Figure 3-31).  The VC procedure was not to 
proceed unless both TLDs were present. 
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3. Upon verification of the presence of two TLDs within the catheter tip, the contrast bag 
was clamped at the tubing and filled with the iodinated contrast agent by the CT 
technologist.  Additionally, the gas insufflation pump was connected to the blue tube by 
the technologist and the rectal catheter was inserted into the patient by the radiologist 
for the VC procedure (see Figure 1-4). 
4. Upon completion of the CT scan, the catheter was removed from the patient’s rectum 
and the radiologist immediately verified that two TLDs were present within the catheter.  
If both TLDs were discovered to not be present within the catheter, it would be up to the 
discretion of the radiologist to determine whether active retrieval actions should be 
taken (i.e. Fleet’s enema).  If such an event were to occur, active retrieval actions would 
not typically be necessary after VC as all contents of the rectum and bowel are 
discharged from the patient into a toilet almost immediately upon the completion of the 
exam.  
5. In the very unlikely event that one or both TLDs became dislodged from the rectal 
catheter during a VC procedure, only the TLD that remained (if any) was to be used for 
data acquisition purposes.  If the situation were to arise, any dislodged TLDs were not 
to be pursued due to infection control reasons. 
6. Upon the completion of the VC procedure and verification of the presence of both TLDs 
within the catheter, the radiologist held the rectal catheter such that it could be cut with 
scissors and separated from the rest of the enema delivery system.  The enema 
delivery system was disposed as medical biohazardous waste.  The rectal catheter was 
closed within a zipper-style bag and this bag was enclosed into an additional bag for 
infection control purposes.  A folded piece of paper was placed between the two bags 
containing the patient’s medical record number, the date of the exam, and the patient’s 
study number (1-10). 
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The CT scans were performed in accordance with the standard MD Anderson 
Cancer Center VC procedure outlined in Chapter 1.1.2, with each patient receiving CT 
scans in both a supine and prone position using a standard technique.  As discussed 
above, the two scans are necessary during VC to evaluate segments of the colon that may 
be collapsed during one of the scans, as well as to shift residual feces/water that may mask 
or simulate colonic lesions.  During each VC procedure, the two affixed TLDs acquired a 
total of four measurements of the accumulated absorbed radiation dose delivered to that 
patient’s rectum during the two PA scout scans, the two lateral scout scans, and the two CT 
scans.   
 
3.3.2.6 TLD Retrieval and QC Step 5:  Disinfection of Rectal Catheter Assembly and TLD 
Capsules 
The fifth stage of QC was incorporated to ensure the investigators and RPC staff did 
not receive an infection as a result of participation in this study. This step involved a 
thorough disinfection of the TLD/rectal catheter assembly, the harvesting of irradiated TLDs 
from the rectal catheters, and an additional thorough disinfection of these TLD capsules.  
To do so, the following procedures were conducted: 
1. A suitable work environment was established with a deep sink and running water.  Anti-
microbial soap, disinfection wipes (containing bleach), 70% isopropyl alcohol in a 
container, and appropriate personal protective equipment (PPE) (non-latex gloves, eye 
protection, and disposable coat/covering) were collected.   
2. With PPE donned, the bag containing the used rectal catheter was opened and the 
paper containing patient identity information was also removed from the bag.  
3. The exterior of the rectal catheter was then scrubbed for 30 seconds (with PPE donned) 
with anti-microbial soap, disinfection wipes and copious warm tap water.   
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4. The sutures holding the superior TLD to the rectal catheter were then cut, and the TLDs 
were squeezed from the rectal catheter with hand pressure into the container containing 
the 70% isopropyl alcohol solution; where they remained for several minutes.   
5. When the TLDs had been retrieved from a catheter, that catheter was inserted back into 
the zipper-style plastic bags and discarded as standard waste.   
6. Upon completion of the TLD disinfection within the isopropyl alcohol, the TLDs were 
dried with paper towels, securely attached to a sheet of paper labeled only with the 
patient’s study number (1-6) and the date of the VC scan, and stored as appropriate 
(i.e. in a dark place away from outside radiation sources) for at least 14 days before 
being delivered to the RPC for reading. 
7. Upon completion of these TLD resection and disinfection steps, the workspace and sink 
were thoroughly disinfected with disinfection wipes.  When workspace disinfection was 
completed, the PPE were disposed as standard waste (except the eye protection, which 
was disinfected as appropriate). 
8. When clean-up and disinfection were accomplished, the patient study number (1-6) was 
listed along with the patient medical record number and the date of the exam in a 
password-protected study data collection Excel spreadsheet (Microsoft Corporation, 
Redmond, WA) located on a secure computer at MD Anderson Cancer Center that was 
password protected and located in a locked room.  The spreadsheet columns 
containing the patient identifiers were additionally hidden when not in use (to prevent 
unnecessary personnel from incidentally viewing this information).  When the necessary 
information was recorded, those papers containing the patient identifiers that were 
placed in the bags immediately after the VC scans had occurred were shredded.  
Medical record numbers were only used when necessary to preserve data integrity, and 
all involved research staff that had access to these records completed training for 
130 
 
maintaining confidentiality of health information.  Complete confidentiality was 
maintained during this study and during manuscript preparation. 
 
3.3.2.7 Patient Rectal Dose Determination 
Once at least 14 days had passed from a VC procedure and TLD readout had been 
accomplished, the RPC provided the following information for the purpose of calculating 
patient rectal dose:  TLD aliquot charge reading (in µC), aliquot TLD mass (in mg), 
sensitivity correction factor (in cGy/µC/mg) and fading correction factor (unitless).  These 
values, along with the regression model for the dose linearity correction factor at 120 kVp 
(KL,120) established in Specific Aim 1, were used to calculate the four rectal dose 
measurements (in mGy) obtained for each of the 6 VC patients using Equation 3-8.  Since 
each of these TLD measurements included the rectal dose administered by the four to five 
scout scans and two CT scans administered in each VC, additional efforts were made to 
estimate the contribution of the scout scans to the measured doses. 
Estimation of rectal dose from scout scans was performed in a similar manner as 
that published by O’Daniel, et.al. in (15).  First, patient lateral and PA TLD-to-surface 
distance measurements were obtained from patient DICOM images, and the average 
distance of the TLDs from the table during the in-vivo measurements were recorded for 
both the prone and supine scans.  Next, a Farmer style ionization chamber was placed on a 
block on the CT scanner table such that the active volume of the chamber was at the 
measured average supine TLD distance above the CT table.  Lateral and PA scout scan 
lengths were then established such that the active volume of the Farmer style ionization 
chamber was placed in the center of each scout image.  In-air exposure measurements 
were then acquired using the same techniques as those to which the patients were 
exposed (120 kVp, 10 mA).  This process was repeated for the average distance from the 
CT table to the TLDs when patients were placed in a prone position and for the scout 
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technique used for the prone scout scans (120 kVp and 80 mA).  Using the inverse square 
law and patient lateral and PA TLD-to-surface distance measurements obtained from 
patient DICOM images, each patient’s entrance skin exposure was then estimated for both 
the PA and lateral scout scans in both the supine and prone positions.  By assuming an 
effective keV of 60 from the scout image technique of 120 kVp, a mass attenuation 
coefficient of µ/ρ=0.2025 cm2/g (100), and density of 1.04 g/cm3 (90) for soft tissue, the 
attenuated exposure to the rectum for each scout scan was estimated using the Lambert-
Beer equation (Equation 3-2).  These attenuated exposure estimates were added and were 
converted to dose estimates using the f-factor for muscle (fMuscle=0.94 rad/R), thus yielding a 
total rectal dose estimate from the scout scans.  These total scout scan dose estimates 
were subtracted from the four TLD rectal dose measurements obtained in each patient to 
calculate CT rectal dose measurements for each patient.  The average of these four CT 
dose measurements was determined to be the rectal dose to a specific patient from the CT 
scans administered in VC, and these average dose values were used to accomplish 
Specific Aim 3 in comparing the TLD dose measurements to anthropomorphic phantom 
measurements, CTDIvol-based dose estimates (including the size specific dose estimates 
(SSDE)) and Farmer chamber dose measurements obtained in a uniform CTDI body 
phantom. 
 
3.4 Specific Aim 3:  Compare In-Vivo Rectal Dose Measurements to Anthropomorphic 
Phantom Measurements, CTDI-Based Dose Estimates and Point Dose Measurements 
from a Uniform Phantom 
 
3.4.1 Introduction  
When the TLD measurement results were received from the RPC and absorbed 
dose measurements were calculated for every in-vivo dose measurement patient (along 
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with the average rectal dose for each phantom configuration and patient) in Specific Aim 2, 
these average dose measurements were compared to anthropomorphic phantom 
measurements, CTDIvol-based size specific dose estimates (SSDE) estimates and a Farmer 
chamber dose measurement taken in a uniform CTDI body phantom. To do so, the 
following values were tabulated by phantom configuration and patient in a password-
protected Excel spreadsheet (Microsoft Corporation, Redmond, WA) to protect patient 
identity in accordance with IRB and HIPAA requirements:  phantom configuration (P0-P2) 
or patient identifier (a number 1-6), patient medical record number and VC scan date (with 
these columns hidden and password protected for additional patient identity protection), 
patient thickness measurements obtained using Philips iSite Enterprise PACS software 
(Philips Healthcare, Andover, MA) from a supine CT image that was determine to be the 
median location of the TLDs (posterior-anterior (PA), lateral, and circumference 
measurements, along with effective diameter), percentile of US adults aged 18-64 the 
patient represents, the image number that was used to measure patient thickness, the 
number of scout scans in the VC procedure, the number of CT scans in the VC procedure 
(because a prone or supine scan occasionally must be repeated; such as in cases where a 
scan shows that the bowel was not insufflated sufficiently), all rectal doses from TLD 
measurements, average phantom or patient TLD rectal dose measurements, CTDIvol based 
rectal dose estimates, Farmer chamber measurements performed in a uniform CTDI body 
phantom, and SSDE dose estimates (described below).  Mean square errors were 
calculated to compare these dose estimates to the in-vivo dose measurements for each 
patient.  95% confidence intervals (CI) were also established for the in-vivo TLD dose 
measurements, as was the percent coefficient of variation (%CoV) for each patient and for 
the population of patients that participated in this study.  This between-patient %CoV value 
was calculated based on the average rectal dose measurement of each patient as was 
used as an indirect assessment of the size range of patients receiving VC at MD Anderson 
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Cancer Center.  It was hypothesized in chapter 1.4.1 that this between-patient %CoV would 
be greater than 50%.   
 
3.4.2 Size Specific Dose Estimate (SSDE) 
Size specific dose estimate (SSDE) is a dose estimate introduced in AAPM Report 
204 (101) that incorporates a correction factor to account for underestimation or 
overestimation of CTDIvol dose estimates resulting from patient size (with large patient dose 
being overestimated and small patient dose being underestimated by CTDIvol) (42, 101).  
SSDE does not address other problems with CTDI measurements such as CTDI’s lack of 
ability to measure extended scatter dose tails (43).  The SSDE technique includes several 
options for determining patient size.  The approach utilized in this work is that of the 
effective diameter, where AP and lateral measurement are acquired from one cross-
sectional CT image (at the average location of the TLDs within the rectal catheter), 
multiplied together and the square root is taken of this product.  Tables in AAPM Report 
204 provide a specific correction factor based on the phantom used to determine the 
CTDIvol estimate and a specific patient’s size measurement ( PhantomPatientf ) (101).  For example, if 
a patient’s AP and laterial dimensions summed to 22.2 cm such that an effective diameter 
of 10.7 cm is calculated (a small patient), and the CTDIvol estimate (in mGy) provided by the 
scanner was based on the 32 cm CTDI body phantom, the physicist would reference Table 
1A in AAPM Report 204 to obtain a correction factor of 5.2322.22 =
Sf (unitless) (101).  This 
correction factor would be used to calculate the SSDE (in mGy) using Equation 3-11: 
 
Phantom
Patientvol fCTDISSDE ⋅=    (3-11) 
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The importance of this technique to correct CTDIvol dose estimates is underscored in this 
example, where the correction factor of 5.2322.22 =
Sf  implies that the CTDIvol estimate 
provided by the scanner underestimated the actual patient dose by 250% (due to the small 
size of the patient).  
The PhantomPatientf  values published in AAPM Report 204 show an exponential relationship 
between the normalized dose correction coefficient and patient dimension measurements.  
Additionally, the PhantomPatientf  values were independently verified by four different laboratories 
(two involving Monte Carlo calculations and two involving physical measurements in 
phantoms), with the results showing considerable agreement (101).  As SSDE provides 
users with an estimate of patient dose based on patient size and MDCT scanner output, 
this technique theoretically provides a better estimate of the average patient dose than 
standard CTDIvol dose estimates.  
 
3.4.3 Outlier Analysis 
In order to explain potential differences between patient rectal dose measurements 
and anthropomorphic phantom dose measurements due to insurmountable differences that 
may arise during in-vivo sampling (such as differences in TLD placement, amount of iodine 
contrast, and body composition), several additional Hounsfield Unit (HU) measurements 
were performed on the axial images for each patient.  Relative bone density measurements 
were obtained by averaging six HU measurements acquired in supine images of the ATOM 
phantom and in each patient’s femoral heads as illustrated in Figure 3-32.  These 
measurements were acquired in the femoral heads of each patient regardless of the 
location of the TLDs within the rectum in order to provide a consistent assessment of each 
patient’s bone density, and the average HU measurements were plotted in a bar chart (in 
Chapter 4) for comparison purposes. 
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Figure 3-32. Illustration of the assessment of patient relative bone density via HU 
measurements in six ROI measurements encompassing the femoral heads. 
 
The combined effects of differences in iodine contrast present, bone density, and 
TLD placement were assessed through histograms of the supine and prone CT images 
(see Figure 3-33).  The images analyzed for each patient and the ATOM phantom were 
chosen on the basis of being the average location of the two TLDs in each scan series.  
Since iodine and bone provided the highest HU numbers in each VC image, the histogram 
of each of these images were thresholded to those values greater than 200 HU, and that 
number of pixels was divided by the total number of pixels in an image (512x512=262,144 
pixels).  For comparison purposes between patients, each of these percentages were then 
normalized to a display field of view (DFOV) of 50 cm (such that the pixel areas were equal 
in each image) by multiplying the ratio of the pixel area in an image by the pixel area at 50 
cm DFOV (0.0095 cm2).  Such quantification of highly attenuating material provided insight 
into the effects of such factors as TLD placement, iodine contrast, and bone density on the 
TLD rectal dose measurements.  
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Figure 3-33. A) Histogram of a supine VC image of a patient. B) Patient supine VC image after 
being thresholded to include only those voxels with HU values greater than 200. 
 
3.4.4 Statistical Analysis 
Regression analysis was used to establish a rectal dose predictive model from 
anthropomorphic phantom measurements.  A multiple-order polynomial regression equation 
and R2 goodness of fit coefficient were also established for this anthropomorphic phantom 
regression analysis.  These predictive rectal dose values were compared to the in-vivo 
patient rectal dose measurements obtained in Specific Aim 2.   
Understanding the size of patients undergoing VC at MD Anderson Cancer Center 
was determined to be important based on the fact that the dose delivered to a patient’s 
rectum using this fixed CT technique will be a function of the size of that patient.  As an 
indirect assessment of the size distribution of VC patients participating in this study, a 
between-patient percent coefficient of variation (%CoV) value was determined by dividing 
the standard deviation of the average rectal dose measurements from the six patients by 
A)
 
B)       
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the average measured rectal dose for the study population.  This %CoV value was 
assessed to determine whether it exceeded 50%, as stated in the hypothesis.   
Mean square error (MSE) calculations were performed to compare the in-vivo rectal 
dose measurements to anthropomorphic phantom measurements, SSDE dose estimates, 
and uniform CTDI phantom-based dose estimates (including Farmer chamber dose 
measurements, measured CTDIvol for the beam output received by patients undergoing VC, 
and CTDIvol,center (providing a CTDI dose estimate that did not consider the peripheral pencil 
chamber measurements)).  Calculations were also performed to determine if the differences 
between the mean TLD rectal dose measurements, the anthropomorphic phantom, the 
SSDE estimates, the CTDIvol-based estimates, and the Farmer chamber measurements in 
a CTDI body phantom were outside the 95% confidence interval (as stated in the 
hypothesis).  The results of these analyses are provided in Chapter 4. 
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CHAPTER 4.0:  RESULTS 
  
4.1 Introduction 
 The results from the phantom and patient virtual colonoscopy (VC) rectal dose 
measurements are reported in the order presented in Chapter 3 and arranged according to 
the specific aims outlined in Chapter 1.  First, in accordance with Specific Aim 1, 
thermoluminescent dosimeter (TLD) linearity correction factors were established for a range 
of doses at 120 kVp for a multi-detector computed tomography (MDCT) scanner using VC 
scan parameters in a 32 cm CT dose index (CTDI) body phantom.  Next, in accordance 
with Specific Aim 2, rectal dose measurements using TLDs were obtained in VC 
simulations within an anthropomorphic phantom and in-vivo within patients undergoing VC.  
Finally, in accordance with Specific Aim 3, in-vivo rectal dose measurements were 
compared to anthropomorphic phantom measurements, CTDIvol-based dose estimates, and 
point dose measurements obtained in a CTDI body phantom.  These specific aims were 
accomplished in order to test our hypotheses:  In-vivo rectal dose measurements obtained 
during virtual colonoscopy will have a rectal dose coefficient of variation that will be greater 
than 50%, and the differences between the anthropomorphic phantom measurements, 
CTDIvol-based dose estimates, and Farmer chamber measurements in a CTDI body 
phantom will exceed the 95% confidence interval of in-vivo rectal dose measurements. 
 
4.2 Specific Aim 1:  Establish TLD Linearity Correction Factors for VC Scan 
Parameters on a MDCT 
As stated earlier, although the Radiologic Physics Center (RPC) (Houston, TX) 
typically provides energy and dose linearity correction coefficients to customers as a 
standard service, their established correction factors pertain to those doses and energies 
encountered in photon or electron cancer therapy by linear accelerator and are specifically 
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defined for higher energies (a minimum of 1 MV) and doses (a minimum of 200 mGy) than 
those obtained by MDCT dose to a patient’s rectum during a VC exam.  Therefore Specific 
Aim 1 characterized baseline x-ray beam performance and provided correction factors 
relevant for MDCT at the energy and dose range encountered in VC.   
 
4.2.1 MDCT Beam Characterization 
In order to identify any discrepancies in TLD readings and actual dose 
measurements between MDCT scanners used for VC or in the event of a change in the 
MDCT x-ray tube between TLD irradiation and anthropomorphic phantom or in-vivo patient 
VC measurements, several x-ray beam quality factors were measured.  These 
measurements were conducted in the same CT sessions as when the TLDs were irradiated 
to establish the dose linearity correction factors for VC conditions, and upon completion of 
in-vivo patient dose measurements.  These measured beam factors included:  the half-
value layer (HVL), quarter-value layer (QVL), CTDI in-air measured with a 100 mm pencil 
chamber ((CTDI100)air), weighted CTDI (CTDIw), and volume CTDI (CTDIvol) for the MD 
Anderson Cancer Center VC technique.   
 
4.2.1.1 HVL and QVL Measurement 
 The HVL and QVL measurements were made using the method described by 
Mathieu, et al (95) incorporating the Lambert W function described in Chapter 3.2.1.1 for 
the polyenergetic spectrums encountered in CT.  These HVL and QVL measurements were 
obtained on the two scanning occasions where the TLD dose linearity correction factors 
were established for a 120 kVp MDCT photon beam.  This technique required the 
acquisition of in-air exposure measurements using a 100 mm pencil ionization chamber of 
unattenuated and attenuated stationary (i.e. non-rotating) beams specified to approximate 
conditions used in VC at MD Anderson Cancer Center (120 kVp, 100 mA, 1 sec exposure 
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time, large body filter, small focal spot, 40 mm nominal beam). The total beam quanta 
output per rotation of 100 mAs was used to simulate the combined beam output from both 
the prone and supine scans used in VC.  The results of the three exposure measurements 
obtained with each amount of beam filtration on each testing date (in mR); the average, 
standard deviation, and percent coefficient of variation (%CoV) of those exposure 
measurements; the values for λ and µ0 calculated from Equations 3-6 and 3-7, respectively; 
and the HVL and QVL (both in mm Al) values calculated from Equations 3-4 and 3-5, 
respectively, are provided in Table 4-1. 
These results demonstrated excellent measurement precision, with all exposure 
measurements at a given filtration having a %CoV less than 0.1% and with the HVL and 
QVL values demonstrating consistent x-ray tube quality on different days five months apart 
and across 3 MDCT scanners.  The HVL values also corresponded well with the HVL 
measured during acceptance testing of the scanner (7.96 mm Al).  This 2% difference may 
be the result of a small drift in tube output, or may be caused by inherent uncertainties in 
the measurement of the filtration thickness or of the ionization chamber measurements.  No 
standards currently exist stating an amount of allowable change in HVL measurements a 
tube may experience before requiring replacement.  The effect of these differences in x-ray 
tube output between the respective dates and scanners likely had a minimal impact on the 
TLD doses calculated based on the linearity correction factors determined at 120 kVp on 
the “CT9” MDCT at MD Anderson Cancer Center, regardless of the CT scanner used to 
accomplish a VC. 
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Table 4-1. Results of HVL and QVL measurements obtained on the MDCT scanners at MD 
Anderson Cancer Center used for VC procedures under VC simulation conditions; where 
Date is the date the measurements were obtained (corresponding to the dates used to 
determine the TLD correction factors), CT is the MD Anderson Cancer Center nomenclature 
for the MDCT scanner on which the exposure measurements were performed, Filtration is the 
thickness of aluminum 1100 alloy used to attenuate the primary beam, Exp represents the 
respective exposure measurements obtained at each thickness, Avg Exp is the average of the 
exposure measurements, St Dev is the standard deviation of the exposure measurements, 
%CoV is the percent coefficient of variation of the exposure measurements, λ and µ0 are 
coefficients utilized by Lambert W interpolation, HVL is the half-value-layer, and QVL is the 
quarter-value-layer. 
Date CT Filtration (mm Al) 
Exp 
#1 
(mR) 
Exp 
#2 
(mR) 
Exp 
#3 
(mR) 
Avg 
Exp 
(mR) 
St Dev 
(mR) 
%CoV 
(%) λ µ0 
HVL 
(mm Al) 
QVL 
(mm Al) 
1/17/11 CT9 
0 1263 1263 1264 1263 0.577 0.05 
0.0412 0.0683 7.79 17.63 6.36 706.6 705.9 706.4 706.3 0.361 0.05 
19.84 272.7 273.1 272.9 272.9 0.200 0.07 
4/2/11 CT9 
0 1269 1271 1269 1270 1.155 0.09 
0.0411 0.0685 7.78 17.60 6.36 709.1 710.0 709.8 709.6 0.473 0.07 
19.84 273.4 273.3 273.7 273.6 0.173 0.06 
6/18/11 CT9* 
0 1306 1305 1305 1305 0.577 0.04 
0.0420 0.0685 7.75 17.56 6.36 727.7 727.8 727.6 727.7 0.100 0.01 
19.84 280.6 280.4 280.8 280.6 0.200 0.07 
6/18/11 CT12 
0 1303 1302 1303 1303 0.577 0.04 
0.0429 0.0692 7.65 17.35 6.36 721.3 721.3 721.4 721.3 0.058 0.01 
19.84 275.8 275.6 276.0 275.8 0.200 0.07 
6/18/11 CT5 
0 1277 1277 1276 1277 0.577 0.05 
0.0419 0.0686 7.74 17.52 6.36 711.5 711.4 710.9 711.3 0.321 0.05 
19.84 273.8 273.7 273.8 273.8 0.058 0.02 
*The x-ray tube on this scanner was replaced between the time the last in-vivo VC was performed and before the final HVL 
and QVL measurements could be acquired. 
   
4.2.1.2 (CTDI100)air, CTDIw, and CTDIvol Determination 
 (CTDI100)air measurements were acquired using the same pencil ionization chamber 
configuration as that used to determine the HVL and QVL.  (CTDI100)air required slightly 
different scan settings, however, as the scans were performed in axial mode (as opposed to 
the tube remaining stationary while the beam was on).  In order to replicate beam 
conditions during VC at MD Anderson Cancer Center, the CT scan settings used to 
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determine (CTDI100)air via Equation 1-11 were:  axial scan, 0.5 sec per rotation of the x-ray 
tube, a nominal beam width of 40 mm, 120 kVp, 200 mA, standard reconstruction algorithm, 
large (body) bowtie filter, large body scan field of view (SFOV) and 50 cm display field of 
view (DFOV).  In a manner similar to the scan technique utilized in the beam HVL and QVL 
measurements, 100 mAs was used to acquire these CTDI measurements to simulate the 
combined dose received by patients undergoing VC from the prone and supine CT scans.  
The results of the exposure measurements (in mR), the average and standard deviation of 
those exposures (in mR), the percent coefficient of variation (in %), and the calculated 
(CTDI100)air values (in mGy) for the two scanning sessions that determined the TLD 
correction factors specific to MDCT are provided in Table 4-2. 
 
Table 4-2. Results of in-air exposure measurements and corresponding (CTDI100)air 
calculations obtained on MD Anderson Cancer Center “CT9” MDCT under conditions 
simulating VC at MD Anderson Cancer Center; where Date is the date the measurements were 
obtained (corresponding to the dates used to determine the TLD correction factors and 
completion of in-vivo measurements), Exp represents the respective exposure measurement 
iteration obtained in each day, Avg Exp is the average of the exposure measurements, St Dev 
is the standard deviation of the exposure measurements, %CoV is the percent coefficient of 
variation, and (CTDI100)air is the corresponding in-air CTDI100 value. 
Date Exp #1 
(mR) 
Exp #2 
(mR) 
Exp #3 
(mR) 
Avg Exp 
(mR) 
St Dev 
(mR) 
%CoV 
(%) 
(CTDI100)air  
(mGy) 
1/17/11 1032 1034 1034 1033 1.155 0.1 22.25 
4/2/11 1028 1028 1028 1028 0 0 22.36 
6/18/11* 1066 1069 1069 1068 1.732 0.2 23.23 
*The x-ray tube on this scanner was replaced between the time the last in-vivo VC was performed and before the final HVL 
and QVL measurements could be acquired. 
 
 The results of these (CTDI100)air measurements also showed excellent precision with 
the %CoV being 0.2% or less, and good agreement between respective (CTDI100)air 
measurements on the different days and different x-ray tubes (which was replaced on the 
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“CT9” scanner in the three days between the last in-vivo patient measurement being 
acquired and the exposure tube measurements).  The 0.5% difference between the 
(CTDI100)air measurements acquired on the same x-ray tube may be the result of inherent 
uncertainties in the measurement process and likely had a minimal impact on the TLD dose 
linearity correction factors determined at 120 kVp for the “CT9” MDCT at MD Anderson 
Cancer Center.  The 4% difference between the (CTDI100)air measurements acquired on the 
different x-ray tubes was likely the combined result of changes in  respective tube 
performance and inherent uncertainties in the measurement process, but these results still 
demonstrated good agreement between the outputs of several x-ray tubes and provided 
confidence in the uniformity of the in-vivo doses measured on multiple MDCT scanners 
during VC. 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-1.  Linear relationship between MD Anderson Cancer Center “CT9” beam 
administered dose (measured in the form of (CTDI100)air) and mAs. 
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In order to establish the linearity of the MDCT scanner dose output with mAs, 
(CTDI100)air measurements were acquired using this same scan technique in 10 mAs 
increments from 20 mAs (40 mA) to 170 mAs (340 mA),.  These linearity measurements 
were helpful in extrapolating doses at the center of the CTDI body phantom that were 
sufficiently low as to be undetected with a Farmer ionization chamber (without this data, 
TLD dose linearity correction coefficients at 120 kVp could not be obtained for administered 
point doses less than 2.1 mGy).  The linear relationship between these (CTDI100)air 
measurements and increasing mAs is demonstrated in Figure 4-1.  The R2 value of 0.999 
demonstrates a very strong goodness of fit of the linear regression between the scanner 
mAs and the (CTDI100)air calculations. 
 In order to measure the weighted CTDI (CTDIw) and volume CTDI (CTDIvol), the 
pencil ionization chamber was placed within the CTDI body phantom and exposure 
measurements were acquired within the center bore and in the peripheral bores located in 
the 12, 3, 6, and 9 o’clock positions using the same scan technique as that used to 
determine (CTDI100)air at 100 mAs.  These exposure measurements were used to calculate 
CTDI100 values at each of these locations ((CTDI100)c, (CTDI100)12, (CTDI100)3, (CTDI100)6, 
and (CTDI100)9, respectively).  The peripheral CTDI values were averaged to calculate the 
CTDI100 value at the periphery of the phantom ((CTDI100)periphery), and this value was used 
with (CTDI100)c to calculate CTDIw via Equation 1-12.  CTDIvol was calculated from CTDIw 
using Equation 1-14.  Each of these CTDI values are provided in Table 4-3 for the two 
sessions used to determine the TLD dose linearity correction coefficients at 120 kVp and in 
a session that was conducted upon the conclusion of in-vivo dose measurements (where 
the “CT9” MDCT scanner contained a newly replaced x-ray tube).   
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Table 4-3. Results of exposure measurements within a CTDI body phantom and 
corresponding CTDI calculations obtained on the MD Anderson Cancer Center “CT9” MDCT 
scanner under conditions simulating VC at MD Anderson Cancer Center; where Date is the 
date the measurements were collected (corresponding to the dates used to determine the 
TLD correction factors), Pos is the position of the pencil chamber within the CTDI phantom, 
Exp represents the respective exposure measurements obtained at each position, Avg Exp is 
the average of the exposure measurements, St Dev is the standard deviation of the exposure 
measurements, %CoV is the percent coefficient of variation, (CTDI100)pos is the corresponding 
CTDI100 value at that position, CTDIw is the weighted CTDI, CTDIvol is the measured volume 
CTDI, and Scanner CTDIvol is the volume CTDI value provided by the CT scanner console. 
Date Pos 
Exp 
#1 
(mR) 
Exp 
#2 
(mR) 
Exp 
#3 
(mR) 
Avg 
Exp 
(mR) 
St Dev 
Exp 
(mR) 
%CoV 
Exp 
(%) 
(CTDI100)pos 
(mGy) 
CTDIw 
(mGy) 
CTDIvol 
(mGy) 
Scanner 
CTDIvol 
(mGy) 
1/17/11 
Center 217.6 216.8 216.8 217.1 0.462 0.21 4.72* 
7.99 8.12 8.26 
12:00 447.9 465.0 461.1 458 8.96 1.96 9.96 
3:00 451.0 457.4 450.5 453.0 3.85 0.85 9.85 
6:00 406.5 407.4 408.5 407.5 1.00 0.25 8.86 
9:00 452.3 451.6 451.8 451.9 0.361 0.08 9.83 
Periph       9.63 
4/2/11 
Center 215.5 216.0 215.9 215.8 0.265 0.12 4.69* 
8.14 8.27 8.26 
12:00 459.3 461.5 461.6 460.8 1.30 0.28 10.02 
3:00 480.5 479.6 475.9 478.7 2.44 0.51 10.41 
6:00 431.3 427.1 424.6 427.7 3.39 0.79 9.30 
9:00 447.0 447.3 447.0 447.1 0.173 0.04 9.72 
Periph       9.86 
6/18/11† 
Center 223.2 222.3 222.8 222.8 0.451 0.20 4.85* 
8.24 8.37 8.26 
12:00 473.5 482.0 478.5 478.0 4.27 0.89 10.40 
3:00 464.8 463.4 461.1 463.1 1.87 0.40 10.07 
6:00 415.7 415.5 421.3 417.5 3.29 0.79 9.08 
9:00 468.7 467.9 469.0 468.5 0.569 0.12 10.19 
Periph       9.94 
* Approximate position of the rectum within a patient 
† Measurements were performed on the same MDCT scanner with a replaced x-ray tube 
 
 The results of these CTDI100 measurements also demonstrated good precision, with 
the %CoV being 2% or less, and good agreement between the respective CTDIw and 
CTDIvol measurements.  The 2% difference between the CTDIw and CTDIvol measurements 
obtained with the same x-ray tube may be the result of inherent uncertainties in the 
measurement procedures.  The 2% difference between the average CTDIw and CTDIvol 
measurements obtained with different x-ray tubes may be the result of slight differences in 
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performance between the x-ray tubes and inherent uncertainties in the measurement 
equipment.  These CTDIvol values also corresponded well with the CTDIvol value provided 
by the MDCT scanner for this scan technique (CTDIvol=8.26 mGy), with an average percent 
difference of 0.08%.  The effect of these differences in x-ray tube output between the 
respective dates and x-ray tubes likely had a minimal impact on the TLD dose linearity 
correction factors determined at 120 kVp for the “CT9” MDCT at MD Anderson Cancer 
Center, and provided confidence regarding the dose measurements obtained from different 
MDCT scanners of the same model.  
 
4.2.2 Determination of TLD Dose Linearity Correction Coefficients for Virtual Colonoscopy 
With the x-ray tube beam output well characterized at 120 kVp for the TLD 
irradiation sessions that would determine dose linearity response correction factors of the 
TLDs at 120 kVp (KL,120), the pencil ionization chamber was replaced with a Farmer style 
ionization chamber in the center of the 32 cm CTDI body phantom.   Using a scout image, 
the scan length was specified to be conducted from 75 mm superior to 75.4 mm inferior to 
the center of the CTDI body phantom.  The CT scanner was set to standard MD Anderson 
VC protocols (also listed in Table 1-1 above):  full helical scan mode with 0.5 sec rotation 
time, 1.25 mm image thickness, 39.37 mm/rotation table speed, 0.984 pitch, 1/64 channel 
setting, 0.8 mm interval, 120 kVp, 100 mA, 0 sec delay, and standard reconstruction 
algorithm.  The ionization chamber exposure was measured and recorded for two scans 
under the specified CT technique for a total photon output of 100 mAs per x-ray tube 
rotation (representing the cumulated exposure acquired from both the prone and supine 50 
mAs scans in VC).    
The exposure measurements obtained by the Farmer ionization chamber (in mR) 
were converted to dose in the acrylic CTDI body phantom (in mGy) using an f-factor of 
fAcrylic= 0.78 rad/R.  This process was repeated three times and the average of these three 
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acrylic dose measurements was used to calculate the dose at the center of the CTDI body 
phantom at 100 mAs.  This entire process was repeated for scanner photon outputs per 
rotation ranging from 20 mAs to 170 mAs in 10 mAs increments to administer doses to the 
center of the CTDI body phantom ranging from 0.6 mGy to 8.9 mGy (using the f-factor for 
acrylic), approximately reflecting the expected range of rectal doses administered in VC at 
MD Anderson Cancer Center as estimated in Chapter 1.3.5 (0.7-10.8 mGy when an f-factor 
appropriate for rectal dose is used, fMuscle= 0.94 rad/R).  Doses were extrapolated based on 
the linear relationship between Farmer ionization chamber measured doses and mAs and 
assigned to those tube output values where doses were too low to be directly measured by 
the Farmer chamber (i.e. at 20 and 30 mAs).  The principle of linearity between 
administered dose and mAs was demonstrated in Figure 4-1.  
 
 
 
 
 
 
 
 
 
 
Figure 4-2.  Fourth-order polynomial regression curve predicting Farmer ionization chamber 
response for the RPC’s B09 TLD-100 batch from apparent TLD dose measurements (those 
uncorrected for dose linearity or energy) on MD Anderson Cancer Center “CT9” MDCT 
scanner. 
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After determining the average Farmer chamber dose at each respective mAs 
technique, double chambered TLDs were placed within the center of the CTDI body 
phantom (in a custom-designed insert rod), and the TLDs were irradiated under the same 
conditions as the Farmer ionization chamber.  After TLD readout, the RPC provided the 
following information:  measured TLD aliquot charge reading (Q) (in µC), TLD aliquot mass 
(mg) (in mg), sensitivity (KS) (which was converted to mGy/µC/mg for the order of 
magnitude of rectal doses received by patients undergoing VC), and fading correction factor 
(KF) (unitless).  An f-factor for acrylic (fAcrylic = 0.78 rad/R) was divided by the f-factor for 
muscle/soft tissue (fMuscle = 0.94 rad/R), and the uncorrected TLD dose to the CTDI body 
phantom was calculated by Equation 3-8 for each TLD chamber.  The results of the Farmer 
ionization chamber measurements are plotted with a fourth-order polynomial regression 
against the resultant apparent (i.e. uncorrected) TLD dose measurements in Figure 4-2.   
KL,120 values were calculated for every TLD chamber in this dose range by dividing 
the Farmer measured dose by the apparent TLD dose as demonstrated in Equation 3-9.  
The average KL,120 value and the %CoV were determined for every mAs setting.  These 
TLD charge and mass measurements, the KS and KF correction coefficients, the calculated 
TLD doses (not corrected for dose linearity or photon energy), the Farmer ionization 
chamber measured doses, the KL,120 values and the average KL,120 values at each mAs 
setting, and the %CoV for the KL,120 values at each mAs setting are provided in Table 4-4.   
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Table 4-4. Results of Farmer ionization chamber determined dose measurements, TLD dose 
measurements, and TLD dose linearity correction factors at 120 kVp obtained in a 32 cm 
diameter CTDI body phantom under identical conditions simulating VC on MD Anderson 
Cancer Center “CT9” MDCT; where mAs represents the scanner setting used, Charge 
represents the measured reading, Mass is the mass of TLD aliquot read, KS is the sensitivity 
correction factor, KF is the fading correction factor, TLD Dose represents the apparent dose 
predicted by the TLD, Farmer Dose represents the dose measured by a Farmer chamber or 
extrapolated from data demonstrating dose linearity with mAs, KL,120 represents the TLD dose 
linearity correction factor at 120 kVp, Avg KL,120 is the average of the KL,120 values at a mAs 
value, and %CoV is the percent coefficient of variation of the KL,120 values. 
mAs Charge (µC) 
Mass 
(mg) 
KS  
(cGy/ 
µC/mg) 
KF 
TLD 
Dose 
(mGy) 
Farmer 
Dose 
(mGy) 
KL,120 Avg KL,120 
%CoV 
KL,120  
(%) 
20 
0.07693 21.69 110.0 1.042 3.373 0.565 0.167 
0.169 2.07 
0.07878 21.92 110.0 1.042 3.418 0.565 0.165 
0.07465 21.22 110.0 1.042 3.346 0.565 0.169 
0.07301 21.27 110.0 1.042 3.265 0.565 0.173 
0.07430 22.03 110.0 1.042 3.208 0.565 0.176 
0.07564 21.30 110.0 1.042 3.378 0.565 0.167 
0.07758 21.98 110.0 1.042 3.357 0.565 0.168 
0.07530 21.35 110.0 1.042 3.354 0.565 0.168 
30 
0.08889 21.99 108.7 1.048 3.821 1.176 0.308 
0.291 3.56 
0.09289 22.09 108.7 1.048 3.975 1.176 0.296 
0.09111 22.37 108.7 1.048 3.850 1.176 0.305 
0.09484 21.80 108.7 1.048 4.112 1.176 0.286 
0.09250 21.99 110.0 1.042 4.001 1.143 0.286 
0.09147 21.57 110.0 1.042 4.033 1.143 0.283 
0.09337 22.14 110.0 1.042 4.011 1.143 0.285 
0.09258 21.66 110.0 1.042 4.065 1.143 0.281 
40 
0.1063 21.70 110.0 1.042 4.659 1.722 0.370 
0.369 1.98 
0.1073 21.39 110.0 1.042 4.771 1.722 0.361 
0.1068 21.82 110.0 1.042 4.655 1.722 0.370 
0.1110 21.81 110.0 1.042 4.841 1.722 0.356 
0.1045 21.72 110.0 1.042 4.576 1.722 0.376 
0.1066 22.00 110.0 1.042 4.609 1.722 0.374 
0.1050 21.83 110.0 1.042 4.575 1.722 0.376 
0.1063 21.57 110.0 1.042 4.687 1.722 0.367 
50 
0.1308 21.74 108.7 1.048 5.687 2.282 0.401 
0.432 3.15 
0.1217 22.10 108.7 1.048 5.205 2.282 0.438 
0.1198 21.40 108.7 1.048 5.292 2.282 0.431 
0.1214 21.69 108.7 1.048 5.291 2.282 0.431 
0.1192 21.76 110.0 1.042 5.210 2.300 0.441 
0.1225 21.64 110.0 1.042 5.384 2.300 0.427 
0.1222 22.46 110.0 1.042 5.175 2.300 0.444 
0.1201 21.77 110.0 1.042 5.247 2.300 0.438 
60 
0.1373 21.81 108.7 1.048 5.951 2.848 0.479 
0.482 1.74 0.1361 21.72 108.7 1.048 5.923 2.848 0.481 
0.1347 22.11 108.7 1.048 5.759 2.848 0.494 
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0.1381 21.80 108.7 1.048 5.988 2.848 0.476 
70 
0.1507 21.98 108.7 1.048 6.481 3.404 0.525 
0.526 2.28 0.1510 22.61 108.7 1.048 6.313 3.404 0.539 0.1499 22.06 108.7 1.048 6.423 3.404 0.530 
0.1459 20.68 108.7 1.048 6.669 3.404 0.510 
80 
0.1683 22.02 108.7 1.048 7.225 3.954 0.547 
0.543 1.00 0.1631 21.28 108.7 1.048 7.245 3.954 0.546 0.1661 21.25 108.7 1.048 7.389 3.954 0.535 
0.1681 21.84 108.7 1.048 7.276 3.954 0.544 
90 
0.1773 21.72 108.7 1.048 7.716 4.517 0.585 
0.577 1.75 0.1810 21.98 108.7 1.048 7.784 4.517 0.580 0.1888 22.22 108.7 1.048 8.032 4.517 0.562 
0.1832 22.25 108.7 1.048 7.783 4.517 0.580 
100 
0.1941 22.17 108.7 1.048 8.280 5.076 0.613 
0.605 1.47 0.1922 21.67 108.7 1.048 8.384 5.076 0.605 0.1918 21.80 108.7 1.048 8.317 5.076 0.610 
0.1958 21.62 108.7 1.048 8.561 5.076 0.593 
110 
0.2059 21.38 108.7 1.048 9.103 5.640 0.620 
0.623 0.62 0.2115 21.96 108.7 1.048 9.104 5.640 0.619 0.2090 21.88 108.7 1.048 9.029 5.640 0.625 
0.2102 22.10 108.7 1.048 8.991 5.640 0.627 
120 
0.2294 22.20 108.7 1.048 9.768 6.184 0.633 
0.633 0.76 0.2207 21.53 108.7 1.048 9.690 6.184 0.638 0.2278 21.82 108.7 1.048 9.869 6.184 0.627 
0.2195 21.29 108.7 1.048 9.746 6.184 0.634 
130 
0.2415 22.04 108.7 1.048 10.358 6.736 0.650 
0.648 1.18 0.2429 21.86 108.7 1.048 10.504 6.736 0.641 0.2307 21.30 108.7 1.048 10.238 6.736 0.658 
0.2428 21.90 108.7 1.048 10.480 6.736 0.643 
140 
0.2523 21.82 108.7 1.048 10.930 7.281 0.666 
0.664 1.91 0.2534 22.26 108.7 1.048 10.761 7.281 0.677 0.2508 21.66 108.7 1.048 10.945 7.281 0.665 
0.2614 21.93 108.7 1.048 11.267 7.281 0.646 
150 
0.2659 21.31 108.7 1.048 11.795 7.754 0.657 
0.658 0.78 0.2755 21.91 108.7 1.048 11.886 7.754 0.652 0.2671 21.65 108.7 1.048 11.662 7.754 0.665 
0.2736 21.94 108.7 1.048 11.788 7.754 0.658 
160 
0.2854 21.94 108.7 1.048 12.296 8.314 0.676 
0.677 0.41 0.2730 20.89 108.7 1.048 12.353 8.314 0.673 0.2893 22.36 108.7 1.048 12.230 8.314 0.680 
0.2874 22.13 108.7 1.048 12.276 8.314 0.677 
170 
0.3037 21.89 108.7 1.048 13.115 8.934 0.681 
0.694 2.03 0.2997 21.84 108.7 1.048 12.972 8.934 0.689 0.3049 22.30 108.7 1.048 12.924 8.934 0.691 
0.2948 22.27 108.7 1.048 12.513 8.934 0.714 
Bkg 
0.04755 22.30 104.7 1.059 1.962 0 0 
0 4.39 
0.05089 21.78 104.7 1.059 2.150 0 0 
0.04804 22.16 104.7 1.059 1.995 0 0 
0.05071 22.32 104.7 1.059 2.090 0 0 
0.04692 21.98 104.7 1.059 1.964 0 0 
0.05224 21.79 104.7 1.059 2.206 0 0 
0.04690 22.33 110.0 1.042 1.998 0 0 
0.04664 21.99 110.0 1.042 2.017 0 0 
0.04538 22.11 110.0 1.042 1.952 0 0 
0.04963 22.23 110.0 1.042 2.123 0 0 
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The KL,120 values were used to establish a third-order polynomial regression curve 
based on apparent TLD dose measurements (i.e. TLD dose measurements not corrected 
by KL,120 values).  The results of this regression analysis are shown in Figure 4-3.  Although 
Chapter 1 discussed several of the inherent difficulties involved with using TL-100 material 
to measure doses at diagnostic energies and doses, the TLDs demonstrated good 
reproducibility with all %CoV values for an administered mAs setting being 3.56% or less 
(with several %CoV values being less than 1%).  The TLDs also demonstrate a general 
increase in %CoV values at lower administered doses.  The R2 value of 0.992 
demonstrates a very strong goodness of fit of the third-order polynomial regression 
between the uncorrected TLD predicted doses and the KL,120 calculations.  This third-order 
polynomial regression equation was used to calculate anthropomorphic phantom and in-
vivo patient rectal doses from apparent TLD dose measurements in VC at MD Anderson 
Cancer Center in Specific Aim 2. 
 
 
 
 
 
 
 
 
 
 
Figure 4-3.  Third-order polynomial regression curve predicting KL,120 values for the RPC’s 
B09 TLD-100 batch from apparent TLD dose measurements (those uncorrected for dose 
linearity or energy) on MD Anderson Cancer Center “CT9” MDCT scanner. 
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 From Table 4-3, by approximating that the rectum is located in the center of the 
phantom, the estimated dose to a patient’s rectum from CTDI measurements is provided by 
the average CTDIvol,center measurements (the average (CTDI100)center measurements 
corrected for pitch), which yields a dose estimate of 4.78 mGy.  Similarly, the dose to a 
patient’s rectum estimated by the Farmer style ionization chamber measurements in the 
center of a CTDI body phantom is provided by the measurements displayed in Table 4-4 at 
100 mAs, which average to be 6.12 mGy after applying the f-factor for dose to muscle 
(f=0.94 rad/R) to the exposure measurements.  These uniform phantom-based dose 
estimates (summarized in Table 4-5) were compared in Specific Aim 3 to the dose 
estimates provided by the TLD measurements within the anthropomorphic phantom and 
within patients undergoing VC in Specific Aim 2 to assess whether the differences between 
the mean TLD rectal dose measurements, the CTDIvol-based SSDE estimates, and the 
ionization chamber measurements in a CTDI body phantom exceeded 10% of a 95% 
confidence interval (as stated in the hypothesis). 
 
Table 4-5. Summary of rectal dose estimates obtained in a uniform CTDI body phantom, 
where CTDIvol is the volume CTDI value determined from pencil chamber measurements 
simulating the technique used in virtual colonoscopy, CTDIvol,center is the volume CTDI 
estimate only considering the center bore measurement in the CTDIw calculation, and Farmer 
is the dose measured by the Farmer chamber in the center bore. 
CTDIvol  
(mGy) 
CTDIvol,center  
(mGy) 
Farmer 
(mGy) 
8.3 4.8 6.1 
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4.3 Specific Aim 2:  Obtain In-Vivo Rectal Dose Measurements in Patients 
Undergoing VC with TLDs 
With Specific Aim 1 accomplished, both the MDCT beam quality and the TLD 
response had been established for the dose range and energy spectrum received by a 
patient’s rectum when undergoing virtual colonoscopy (VC).  With this data, rectal dose 
measurements were obtained in an anthropomorphic phantom during simulated VC and in-
vivo rectal dose measurements were obtained in actual patients undergoing VC at MD 
Anderson Cancer Center.  All of these rectal dose measurements were acquired with 
thermoluminescent dosimeters (TLDs) (provided by the Radiologic Physics Center (RPC), 
Houston, TX). 
 
4.3.1 Rectal Dose Measurement Simulation in an Anthropomorphic Phantom  
 Two double chamber TLDs were inserted within a rectal catheter that was placed in 
a simulated insufflated rectum within an anthropomorphic phantom.  The 15th percentile 
phantom configuration was then placed on the MD Anderson “CT9” MDCT scanner in a 
supine position irradiated twice with the standard MD Anderson Cancer Center VC protocol 
to simulate patient scans in both a prone and a supine position:  full helical scan mode with 
0.5 sec rotation time, 1.25 mm image thickness, 39.37 mm/rotation table speed, 0.984 
pitch, 0.8 mm image interval, 120 kVp, 100 mA, 0 sec delay, and standard reconstruction 
algorithm.  The two irradiated TLDs were then replaced with a set of two un-irradiated TLDs 
within the phantom; and this process was repeated twice for a total of three sets of virtual 
colonoscopy rectal dose measurements.   
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Table 4-6. Results of TLD dose measurements during simulated VC in an anthropomorphic 
phantom configured to represent patients of three sizes of US adults aged 18-64 (15th 
percentile, 87th percentile, and 99th percentile); %ile represents the population percentile at 
the TLD location represented by the phantom configuration, Dim is the effective diameter of 
the phantom at the location of the TLDs, Charge represents the measured reading, Mass is 
the mass of TLD aliquot read, KS is the sensitivity correction factor, KF is the fading 
correction factor, Uncorr Dose represents the dose predicted by the TLD before corrections 
for dose linearity and energy were applied, KL,120 represents the TLD dose linearity correction 
factor at 120 kVp, TLD Dose represents the dose predicted by the TLD after corrections for 
dose linearity and energy were applied, Avg Dose is the average of the dose measurements 
for a phantom configuration, and %CoV is the percent coefficient of variation of the TLD dose 
measurements. 
%ile Dim (cm) 
Charge 
(µC) 
Mass 
(mg) 
KS 
(cGy/ 
µC/mg) 
KF 
Uncorr 
Dose 
(mGy) 
KL,120 
TLD 
Dose 
(mGy) 
Avg 
TLD 
Dose 
(mGy) 
%CoV 
TLD 
Dose 
(%) 
15 26.61 
0.2532 21.82 110.0 1.042 13.301 0.677 9.011 
8.804 1.92 
0.2515 21.83 110.0 1.042 13.205 0.676 8.928 
0.2504 21.74 110.0 1.042 13.202 0.676 8.925 
0.2432 21.64 110.0 1.042 12.882 0.672 8.653 
0.2475 21.82 110.0 1.042 13.001 0.673 8.754 
0.2509 21.66 110.0 1.042 13.277 0.677 8.990 
0.2495 22.08 110.0 1.042 12.952 0.673 8.712 
0.2278 20.50 110.0 1.042 12.737 0.670 8.533 
0.2600 22.49 110.0 1.042 13.251 0.677 8.968 
0.2397 21.55 110.0 1.042 12.749 0.670 8.543 
0.2471 21.58 110.0 1.042 13.124 0.675 8.859 
0.2381 20.96 110.0 1.042 13.021 0.674 8.770 
87 34.90 
0.1786 22.11 110.0 1.042 9.259 0.622 5.758 
5.743 2.53 
0.1783 21.49 110.0 1.042 9.510 0.627 5.966 
0.1776 22.14 110.0 1.042 9.194 0.620 5.704 
0.1784 21.35 110.0 1.042 9.578 0.629 6.021 
0.1773 22.20 110.0 1.042 9.154 0.619 5.671 
0.1746 21.81 110.0 1.042 9.176 0.620 5.689 
0.1698 21.72 110.0 1.042 8.691 0.615 5.508 
0.1688 21.05 110.0 1.042 9.191 0.620 5.702 
0.1778 21.71 110.0 1.042 9.387 0.625 5.864 
0.1770 22.08 110.0 1.042 9.188 0.620 5.699 
0.1760 21.83 110.0 1.042 9.241 0.621 5.743 
0.1695 21.44 110.0 1.042 9.062 0.617 5.593 
99 43.75 
0.1269 22.16 110.0 1.042 6.564 0.515 3.383 
3.475 4.33 
0.1278 21.43 110.0 1.042 6.835 0.531 3.631 
0.1288 22.10 110.0 1.042 6.680 0.522 3.489 
0.1329 21.99 110.0 1.042 6.927 0.536 3.714 
0.1258 21.67 110.0 1.042 6.654 0.521 3.465 
0.1288 21.62 110.0 1.042 6.828 0.531 3.624 
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0.1260 22.00 110.0 1.042 6.565 0.515 3.383 
0.1247 21.70 110.0 1.042 6.587 0.517 3.404 
0.1206 21.91 110.0 1.042 6.309 0.499 3.150 
0.1248 21.47 110.0 1.042 6.663 0.521 3.473 
0.1275 22.20 110.0 1.042 6.583 0.517 3.400 
0.1301 21.99 110.0 1.042 6.781 0.528 3.581 
 
 
In order to use the phantom to represent sub-populations of patients of larger 
habitus than the 15th percentile of US adults aged 18-64, bags of simulated phantom 
adipose material were placed around the phantom pelvis and bags of pig adipose material 
(lard) were placed around the thorax, abdomen and legs to represent patients of the 87th 
and 99th percentile of US adults aged 18-64.  The results of the TLD rectal dose 
measurements for each phantom configuration are provided in Table 4-6.  The percent 
coefficients of variation (%CoV) of the 12 measurements obtained at each habitus 
demonstrate good precision (i.e. less than 5%) in the TLD measurements, and demonstrate 
the same trend observed in Specific Aim 1 that lower doses yield higher %CoV values. 
Figure 4-4 plots the mean TLD organ dose, Farmer ionization chamber, SSDE, 
CTDIvol, and CTDIvol,center measurements against patient size measurements (effective 
diameter).  An exponential regression curve for the TLD measurements is also provided 
along with 95% confidence intervals of the regression and of the mean TLD measurements 
at each phantom habitus.  The R2 value of 0.993 demonstrates a very strong goodness of 
fit of the regression equation to the data.  This regression additionally demonstrates the 
exponential relationship between dose and patient size predicted in other studies (101, 
102). 
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Figure 4-4.  Anthropomorphic phantom mean TLD rectal dose measurements as a function of 
phantom effective diameter with an exponential regression curve (including 95% confidence 
intervals of both entities), as well as rectal dose estimates obtained from a uniform CTDI body 
phantom (all in mGy).  CTDIvol is the measured volume CTDI dose estimate, CTDIvol,center is the 
CTDI100 measurement acquired at the center of the CTDI body phantom and corrected for 
pitch, and SSDE is the size specific dose estimate. 
 
4.3.2 In-Vivo Rectal Dose Measurements during Virtual Colonoscopy 
 Once MD Anderson Cancer Center Institutional Review Board (IRB) approval was 
granted for in-vivo rectal radiation absorbed dose measurements during VC, 6 patients 
previously approved by their respective insurances to receive the procedure that met all of 
the criteria outlined in Chapter 1.1.1 were approached for enrollment in the study.  Patient 
rectal dose measurements were obtained from May – June 2011 at MD Anderson Cancer 
Center.  Based on retrospective measurements from patient CT images, the average 
distance from the TLDs (within the rectum) to the table was calculated to be 10.5 cm for 
supine scans and 14.6 cm for prone scans.  These distances were used to estimate the 
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rectal dose administered to each patient from the scout scans as described in Chapter 
3.3.2.7.  The results of these scout rectal dose estimates are provided in Table 4-7, with the 
scout scans accounting for 1.4%-2.2% of the total VC rectal doses measured in each 
patient.   
 
Table 4-7. Results of dose estimates received from scout images during VC within 6 patients; 
where Pt # represents the study specific patient identification number, Supine mA is the tube 
current technique utilized to acquire the PA and lateral scout scans with the patient 
positioned in the supine position, Supine PA Dist is the distance from the TLDs to the 
patient’s surface in the PA direction, Supine PA Dose is the estimated dose administered to 
the TLDs within the rectum from the supine PA scout, Supine Lat Dist is the distance from the 
TLDs to the patient’s surface in the lateral direction, Supine Lat Dose is the estimated dose 
administered to the TLDs within the rectum from the supine lateral scout, Prone mA is the 
tube current technique utilized to acquire the AP and lateral scans with the patient positioned 
in the prone position, Prone AP Dist is the distance from the TLDs to the patient’s surface in 
the AP direction, Prone AP Dose is the estimated dose administered to the TLDs within the 
rectum from the prone AP scout, Prone Lat Dist is the distance from the TLDs to the patient’s 
surface in the lateral direction, Prone Lat Dose is the estimated dose administered to the 
TLDs within the rectum from the prone lateral scout. 
Pt 
# 
Supine 
mA 
Supine 
PA Dist 
(cm) 
Supine 
PA 
Dose 
(mGy) 
Supine 
Lat Dist 
(cm) 
Supine 
Lat 
Dose 
(mGy) 
Prone 
mA 
Prone 
AP 
Dist 
(cm) 
Prone 
AP 
Dose 
(mGy) 
Prone 
Lat 
Dist 
(cm) 
Prone 
Lat 
Dose 
(mGy) 
Total 
Scout 
Dose 
(mGy) 
1 10 10.8 0.016 19.5 0.003 80 11.0 0.130 17.8 0.041 0.190 
2 10 7.4 0.032 18.3 0.005 80 10.0 0.162 14.7 0.078 0.277 
3 10 9.8 0.020 19.0 0.004 80 13.6 0.077 18.0 0.039 0.140 
4 10 9.2 0.022 17.2 0.006 80 11.5 0.117 17.5 0.043 0.189 
5 10 7.7 0.030* 19.0 0.004 80 13.0 0.086 17.6 0.043 0.193 
6 10 8.6 0.025 19.3 0.004 80 11.2 0.124 20.2 0.025 0.178 
*Patient received two supine AP scans  
 
The results of the TLD rectal dose measurements for each patient are provided in 
Table 4-8.  The percent coefficients of variation (%CoV) of the 4 TLD measurements 
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obtained within each patient demonstrate reasonable precision in the TLD measurements, 
but do not necessarily demonstrate the same trend observed in Specific Aim 1 that lower 
doses yield higher %CoV values.  Figure 4-5 plots the in-vivo TLD rectal dose 
measurements as well as the anthropomorphic phantom measurements, SSDE dose 
estimates, and CTDI phantom based dose estimates against patient size measurements 
(effective diameter).   A regression curve is provided for the anthropomorphic phantom 
measurements (as a faint, dotted line), which is the same regression curve provided in 
Figure 4-4.  The in-vivo measurements appeared to include two outlier measurement points 
(Patients 4 and 5) that were not believed to represent standard VC conditions in Specific 
Aim 3, which will be explained in more detail below.  Also provided in Figure 4-5 are the 
95% confidence intervals of the in-vivo rectal dose measurements (which assumed a t-
distribution of the TLD measurements at a patient habitus).   
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Table 4-8. Results of in-vivo TLD rectal dose measurements during VC within 6 patients; 
where # represents the study specific patient identification number, Dim is the effective 
diameter of the patient at the location of the TLDs, %ile is the percentile of US Adults 
represented by the patient circumference at the location of the TLDs, Charge represents the 
measured reading, Mass is the mass of TLD aliquot read, KS is the sensitivity correction 
factor, KF is the fading correction factor, Uncorr Dose represents the dose predicted by the 
TLD before corrections for dose linearity and energy were applied, KL,120 represents the TLD 
dose linearity correction factor at 120 kVp, TLD Dose represents the dose predicted by the 
TLD after corrections for dose linearity and energy were applied, Scout Dose is the estimate 
of patient rectal dose received, Avg Dose is the average of the CT dose measurements for a 
patient (not including the scout scans), and %CoV is the percent coefficient of variation of the 
TLD dose measurements. 
# Dim (cm) 
%ile 
(%) 
Charge 
(µC) 
Mass 
(mg) 
KS 
(cGy/ 
µC/mg) 
KF 
Uncorr 
Dose 
(mGy) 
KL,120 
Scout 
Dose 
(mGy) 
TLD 
Dose 
(mGy) 
Avg 
TLD 
Dose 
(mGy) 
%CoV 
TLD 
Dose 
(%) 
1 30.3 27 
0.2763 21.95 108.5 1.052 14.37 0.674 
0.190 
9.497 
10.13 10.0 0.2659 21.80 108.5 1.052 13.92 0.668 9.113 0.2963 21.67 108.5 1.052 15.61 0.689 10.57 
0.2968 20.54 108.5 1.052 16.49 0.699 11.33 
2 26.2 7 
0.3570 21.52 108.5 1.052 18.94 0.720 
0.277 
13.36 
12.53 5.0 0.3302 21.05 108.5 1.052 17.90 0.712 12.47 0.3475 22.16 108.5 1.052 17.90 0.712 12.46 
0.3091 20.56 108.5 1.052 17.16 0.705 11.82 
3 30.5 31 
0.2760 21.47 108.5 1.050 14.65 0.678 
0.140 
9.788 
9.78 1.8 0.2543 20.19 108.5 1.050 14.35 0.674 9.532 0.2833 21.85 108.5 1.050 14.77 0.679 9.896 
0.2611 20.10 108.5 1.050 14.80 0.680 9.920 
4 26.9 11 
0.2685 21.92 108.5 1.049 13.94 0.668 
0.189 
9.131 
8.96 5.6 0.2481 21.89 108.5 1.049 12.90 0.653 8.231 0.2587 21.23 108.5 1.049 13.87 0.667 9.068 
0.2709 21.63 108.5 1.049 14.25 0.673 9.401 
5 28.4 31 
0.3644 22.08 108.5 1.049 18.78 0.719 
0.193 
13.31 
13.05 5.6 0.3164 20.63 108.5 1.049 17.46 0.708 12.16 0.3716 21.73 108.5 1.049 19.46 0.724 13.90 
0.3250 20.26 108.5 1.049 18.26 0.715 12.85 
6 28.0 35 
0.3362 21.96 108.5 1.039 17.26 0.706 
0.178 
12.01 
11.37 4.7 0.3138 21.05 108.5 1.039 16.81 0.702 11.62 0.3046 21.53 108.5 1.039 15.95 0.693 10.88 
0.3156 22.11 108.5 1.039 16.09 0.695 11.00 
 
 
 
160 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-5.  In-vivo mean TLD rectal dose measurements (with the 95% confidence intervals) 
as a function of patient effective diameter, as well as rectal dose estimates obtained from an 
anthropomorphic phantom and a uniform CTDI body phantom (all doses are provided in 
mGy).  SSDE is the size specific dose estimate, Anthro Phantom is the anthropomorphic 
phantom TLD rectal dose measurement, CTDIvol is the measured volume CTDI dose estimate 
based on the x-ray tube output in VC, Farmer is the Farmer chamber measurements within 
the center bore of the uniform CTDI body phantom, CTDIvol,c is the CTDI100 measurement 
acquired at the center of the CTDI body phantom and corrected for pitch.  The data for 
Patients 1, 4, and 5 are specified for outlier analysis purposes as they represent those data 
measurements that were close to, below, and above, respectively, those dose prediction 
made by the SSDE technique.  The faint dotted line is the regression of the anthropomorphic 
phantom dose measurements (also provided in Figure 4-4). 
 
4.4 Specific Aim 3:  Compare In-Vivo Rectal Dose Measurements to Anthropomorphic 
Phantom Measurements, CTDI-Based Dose Estimates and Point Dose Measurements 
from a Uniform Phantom 
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4.4.1 Introduction 
Once all TLD measurement results were received from the RPC and absorbed dose 
measurements were calculated for every phantom configuration and patient (along with the 
average rectal dose for each phantom configuration and patient) in Specific Aim 2, the 
average in-vivo rectal dose measurements were compared to anthropomorphic phantom 
measurements, CTDIvol-based dose estimates (including the size specific dose estimates 
(SSDE)) and Farmer ionization chamber dose measurements obtained in a uniform CTDI 
body phantom.  Figures 4-4 and 4-5 display the measurements within the anthropomorphic 
phantom at each phantom configuration and within each patient and compare these 
measurements with the CTDI-based and Farmer chamber measurements.  Each of these 
values are additionally tabulated in Table 4-9 by phantom configuration and patient:  
phantom configuration percentile (a number P0, P1, P2) or patient identifier (a number 1-6), 
phantom or patient effective diameter measurements from a CT image that contained both 
TLDs, the percentile of US adults aged 18-64 represented by each phantom or patient 
circumference, the average phantom or patient TLD rectal dose measurements, the upper 
and lower 95% confidence intervals of the average measurements (based on a t-distribution 
assumption), Farmer chamber measurements in a CTDI body phantom, CTDIvol,center dose 
estimates, CTDIvol dose estimates, SSDE dose estimates, and the percent differences of 
each of these dose estimates from the confidence interval of the measured rectal dose 
estimates.  As can be seen in Figures 4-4 and 4-5 and Table 4-9, SSDE is the only 
homogeneous phantom-based predictive model that varies with patient size; with the SSDE 
predictions appearing to run approximately parallel with the exponential regression line for 
the anthropomorphic phantom and concurrently with most of the in-vivo VC rectal dose 
measurements.   
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Table 4-9. Results of anthropomorphic phantom and in-vivo TLD dose measurements during 
VC within 3 phantom sizes and 6 patients; where # represents the study specific phantom or 
patient identification number, %ile represents the percentage of US adults aged 18-64 
represented by the circumference of a specific phantom or patient, Dim is the effective 
diameter of the patient at the location of the TLDs, TLD Dose is the average of the dose 
measurements for a phantom configuration or patient, Low 95% CI is the lower 95% 
confidence interval of the mean dose measurement, Up 95% CI is the upper 95% confidence 
interval of the mean dose measurement, Farmer is the dose estimate obtained by Farmer 
chamber measurement in a CTDI body phantom, Farmer % Diff is the percent difference of the 
Farmer chamber measurement from the confidence interval of the mean TLD dose value, 
CTDIvol,c is the (CTDI100)center measurement corrected for pitch, CTDIvol,c % Diff is the percent 
difference of the CTDIvol,center measurement from the confidence interval of the mean TLD dose 
value, CTDIvol is the volume CTDI measurement (accounting for the tube output experienced 
by a patient in both the supine and prone scans), CTDIvol % Diff is the percent difference of 
the CTDIvol measurement from the confidence interval of the mean TLD dose value, SSDE is 
the size specific dose estimate, and SSDE % Diff is the percent difference of the SSDE 
estimate from the confidence interval of the mean TLD dose value.  If a % Diff value is not 
provided (-), that value indicates that the dose estimate is within the 95% CI for the average 
TLD measurement. 
# %ile Dim (cm) 
Low 
95% 
CI 
(mGy) 
TLD 
Dose 
(mGy) 
Up 
95% 
CI 
(mGy) 
Farmer 
(mGy) 
CTDIvol,c 
(mGy) 
CTDIvol 
(mGy) 
SSDE 
(mGy) 
Farmer 
% Diff 
(%) 
CTDIvol,c 
% Diff 
(%) 
CTDIvol 
% Diff 
(%) 
SSDE 
% Diff 
(%) 
P0 15 26.6 8.418 8.804 9.189 6.12 4.83 8.25 12 -27.3 -42.6 -2.0 25.4 
P1 87 34.9 5.358 5.743 6.129 6.12 4.83 8.25 9 - -9.8 34.6 39.1 
P2 99 43.8 3.089 3.475 3.860 6.12 4.83 8.25 6 58.5 25.1 113.7 60.4 
1 27 30.3 9.699 10.13 10.56 6.12 4.83 8.25 10 -35.2 -48.9 -12.7 - 
2 7 26.2 12.10 12.53 12.96 6.12 4.83 8.25 12 -48.3 -59.2 -30.3 -0.4 
3 31 30.5 9.355 9.784 10.21 6.12 4.83 8.25 10 -32.8 -46.9 -9.4 - 
4 11 26.9 8.529 8.958 9.387 6.12 4.83 8.25 12 -26.1 -41.6 -0.3 19.8 
5 31 28.4 12.63 13.05 13.48 6.12 4.83 8.25 11 -50.5 -61.0 -33.3 -13.3 
6 35 28.0 10.94 11.37 11.80 6.12 4.83 8.25 11 -42.8 -54.8 -22.8 - 
 
 
4.4.2 Percent Coefficient of Variation (%CoV) 
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The percent coefficient of variation (%CoV) was calculated to be 14.2% for the in-
vivo TLD rectal dose measurements.  This between-patient %CoV value was based on the 
mean TLD dose measurements of the six in-vivo patients, and was calculated to assess 
whether the between-patient rectal dose %CoV was greater than 50% (as stated in the 
hypothesis).  The calculated %CoV value was much lower than expected, which is a 
reflection of the distribution of the sizes of patients that participated in this study.  As can be 
seen in Figure 4-6, the distribution of patients that participated in this study was skewed 
toward the smaller percentiles of US adults aged 18-64; and more Gaussian distribution of 
patient sizes would likely have increased the between-patient %CoV.  Therefore, the 
between-patient %CoV value of rectal dose measurements would likely increase with a 
larger sample population that would include patients of a larger habitus.   
 
 
 
 
 
 
 
 
 
Figure 4-6.  Distribution of VC patient percentiles participating in this study. 
 
4.4.3 Outlier Analysis 
The results of the relative bone density quantification via Hounsfield Unit (HU) 
numbers is provided in Figure 4-7.  As can be seen from this figure, the anthropomorphic 
phantom demonstrates considerably higher bone density than any of the patients, with 
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Patients 4 and 5 demonstrating the highest relative bone density of the in-vivo 
measurement patients.  This was not surprising considering the age and gender of Patient 
4 (23 year old male), compared to that of the other patients who underwent VC in this study 
(ages ranging from 61 years to 78 years with an average age of 71.4 years among the four 
females and one male remaining); but was somewhat surprising for Patient 5 (78 year old 
female).  It is likely that these differences in bone density impacted the in-vivo dose 
measurements provided in Figure 4-5, and Figure 4-7 perhaps only partially explains the 
outlier measurement point that appeared considerably lower than the rest of the in-vivo 
dose measurements (Patient 4).  Further explanation regarding this outlier point is provided 
in Chapter 5. 
 
 
 
 
 
 
 
 
 
 
Figure 4-7.  Patient and anthropomorphic phantom relative bone density quantified as the 
average HU values of six femoral head region of interest HU measurements within supine VC 
images.  The gender of each patient is also provided. 
 
 
 
 
0
100
200
300
400
500
600
700
800
900
1000
ATOM 1 2 3 4 5 6
Av
er
ag
e 
H
U
Phantom or Patient
Average HU Measurement at Femoral Heads
TLD Dose 
Below 
SSDE 
TLD Dose 
Above 
SSDE 
TLD 
Dose At 
SSDE 
TLD Dose 
Below 
SSDE 
F M M F F F 
165 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-8.  Average percent of pixels containing highly attenuating material as determined 
from histograms of the median location of the TLDs within the rectum in supine and prone VC 
scans.  These measurements provided understanding regarding the effects of factors such as 
amount of iodine contrast agent present, bone density, and placement of TLDs with respect 
to surrounding anatomy have on in-vivo dose measurements. 
 
 
 
 
 
 
 
Figure 4-9.  Visual comparison of CT images of Patients 4 and 5 at the mean TLD location; 
which represent the high and low extremes, respectively, of the amount of highly attenuating 
material at the mean TLD location present among the patients enrolled in this study. 
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The results of the determination of the percentage of highly attenuating material via 
histogram of supine and prone images containing the median TLD placement within the 
anthropomorphic phantom and each patient are provided in Figure 4-8.  As can be seen 
from this figure, the anthropomorphic phantom and Patient 4 demonstrate considerably 
higher percentages of highly attenuating material than the rest of the patients.  It can also 
be observed from this figure that Patient 5 (represented by the data point that considerably 
exceeded the rest of the in-vivo patient measurements) provided the lowest percentage of 
highly attenuating material of any of the patients at the level of the TLDs (somewhat inferior 
relative to the other patients).  A visual comparison of the CT images at the average TLD 
location for Patients 4 and 5, which represent the high and low extremes of amount of 
highly attenuating material at the mean location of the TLDs, is provided in Figure 4-9.  
Although it is observed in Figure 4-7 that this Patient 5 did not have the lowest relative bone 
density, analysis of the VC scan images revealed that the TLDs were placed inferior within 
the rectum compared to the other patients such that the x-rays within the primary beam 
were only attenuated by the femurs and ischia (where the other patients’ TLDs received 
more attenuation by the pelvis, as suggested by the higher percentages of highly 
attenuating material displayed in Figures 4-8 and 4-9).  It additionally appears in Figure 4-9 
that the ratio of soft tissue to fat within Patient 4 was greater at the TLD level than within 
Patient 5 (with soft tissue providing more beam attenuation than fat). As the 
anthropomorphic phantom and Patient 4 were of similar size (26.6 cm and 26.9 cm effective 
diameter, respectively) and percentage of highly attenuating material (3.06% and 3.17%, 
respectively), it was not surprising that the TLD dose measurements for the 
anthropomorphic phantom and Patient 4 were similar; and lower rectal doses were 
measured within these two entities than in the rest of the VC patients.  Further, as the x-
rays incident on the TLDs within Patient 5 underwent less attenuation from such highly 
attenuating materials as iodine contrast and pelvic bone, higher doses were measured in 
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this patient than in the rest of the VC patients.  Further explanation regarding these outlier 
points is provided in Chapter 5. 
 
4.4.4 Statistical Analysis 
Mean Square Error (MSE) analysis was conducted to assess the quality of the rectal 
dose estimates provided by anthropomorphic phantom measurements, SSDE dose 
estimates, and uniform CTDI phantom based dose estimates (including Farmer chamber 
dose measurements, CTDIvol, and CTDIvol,center) to the in-vivo rectal dose measurements.  
The results of this analysis are provided in Table 4-10, with the best prediction model for 
each patient being highlighted.  It can be seen from this table that the SSDE provided the 
best fit to the in-vivo dose measurements for all patients except one (the patient that was 
considerably younger than the rest of the population), where the anthropomorphic phantom 
regression provided the best dose estimate for that patient.  As the Farmer chamber 
estimate, the CTDIvol, and the CTDIvol,center dose estimates provided models that did not 
change with changing patient size, these models do not provide an adequate fit to rectal 
dose data for an entire population. 
Calculations were also performed to determine whether the differences between the 
anthropomorphic phantom rectal dose measurements, the SSDE dose estimates, the 
CTDIvol-based estimates, and the Farmer chamber measurements in a CTDI body phantom 
was outside the 95% confidence interval of the in-vivo rectal dose measurements during VC 
(as stated in the hypothesis).  This analysis (summarized in Table 4-9) determined that the 
rectal dose delivered to Patients 1, 3, and 6 during VC was predicted within the 95% CI by 
the SSDE model (with a 1.4%, 1.2%, and -4.3% difference from the mean TLD dose 
measurements, respectively) and not within the 95% confidence interval by any other 
method.  Patient 2 exceeded the 95% CI by -0.4%.  The rectal dose delivered to Patient 4 
during VC was predicted within the 95% CI by the anthropomorphic phantom regression 
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model (2.0% from the mean TLD dose measurement), and the measured CTDIvol dose 
estimate at the VC beam output was -0.3% outside the 95%CI.  The rectal dose delivered 
to Patient 5 was not predicted within the 95% CI by any dose estimation model, but was 
most closely estimated by the SSDE model (15.1% from the CI).  Discussions regarding 
these results are provided in Chapter 5. 
 
Table 4-10. Results of the mean square error (MSE) assessment of the quality of the 
predictions of patient rectal dose during VC provided by the anthropomorphic phantom 
measurement regression, the SSDE, and the uniform CTDI phantom-based dose estimate 
models compared with the in-vivo TLD dose measurements; where SSDE is the MSE of the 
size specific dose estimate model to the in-vivo dose measurements, Anth is the MSE of the 
anthropomorphic phantom measurement regression to the in-vivo dose measurements, 
Farmer is the MSE of the Farmer chamber measurement model to the in-vivo dose 
measurements, CTDIvol,c is the MSE of the (CTDI100)center measurement model (corrected for 
pitch) to the in-vivo dose measurements, CTDIvol is the MSE of the measured volume CTDI 
(based on beam output during VC) dose estimate model to the in-vivo dose measurements.  
The highlighted fields indicate the superior patient rectal dose prediction technique. 
Patient Mean Square Error (MSE) (in mGy) Farmer CTDIvol,c CTDIvol SSDE Anth 
1 2.00 2.65 0.94 0.07 1.41 
2 3.20 3.85 2.14 0.36 1.73 
3 1.83 2.48 0.77 0.06 1.30 
4 1.42 2.06 0.35 1.30 0.09 
5 3.47 4.11 2.40 1.16 2.52 
6 2.63 3.27 1.56 0.24 1.57 
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CHAPTER 5.0:  DISCUSSION 
  
5.1 Introduction 
 Discussion of the results from the phantom and patient virtual colonoscopy (VC) 
rectal dose estimates, and the steps that led to the accomplishment of these 
measurements, are within this chapter and are reported in the order presented in Chapters 
3 and 4.  First, in accordance with Specific Aim 1, thermoluminescent dosimeter (TLD) 
linearity correction factors were established for a range of doses at 120 kVp for a multi-
detector computed tomography (MDCT) scanner using VC scan parameters in a 32 cm CT 
dose index (CTDI) body phantom.  Next, in accordance with Specific Aim 2, in-vivo rectal 
dose measurements using TLDs were obtained in VC simulations within an 
anthropomorphic phantom and in patients undergoing VC.  Finally, in accordance with 
Specific Aim 3, rectal dose measurements were compared to CTDIvol-based dose estimates 
and point dose measurements obtained in a CTDI body phantom.  This specific aim was 
accomplished in order to test our hypotheses:  in-vivo rectal dose measurements obtained 
during virtual colonoscopy will have a rectal dose coefficient of variation that will be greater 
than 50%; and the differences between the anthropomorphic phantom measurements, the 
CTDIvol-based dose estimates, and Farmer chamber measurements in a CTDI body 
phantom will be outside the 95% confidence interval of in-vivo rectal dose measurements 
during VC. 
 
5.2 Specific Aim 1:  Establish TLD Linearity Correction Factors for VC Scan 
Parameters on a MDCT 
 Specific Aim 1 was accomplished in two phases:  CT beam characterization and 
TLD dose correction factor determination at 120 kVp (KL,120) for the photon spectrum 
produced by GE LightSpeed VCT scanners at MD Anderson Cancer Center.  The beam 
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characterization phase was accomplished in order to assess the reproducibility of this 
technique of determining the TLD KL,120 values as time progressed (i.e. as the performance 
of the x-ray tube changed with time), to assess consistency of beam output on several 
MDCT scanners that may be used for VC, to help explain potential variations in TLD 
response, to assess potential effects of KL,120 values in the event of a change in the x-ray 
tube as a part of scanner maintenance, and to better characterize the equivalent source 
model output for future Monte Carlo rectal dose calculations (60).  The KL,120 value 
determination phase was necessary because neither the dose linearity correction factor nor 
the energy correction factor were established by the Radiologic Physics Center (RPC) 
(Houston, TX) for the dose and energy ranges encountered during VC; and these data 
values could not reasonably be extrapolated from the correction factors established by the 
RPC due to the well-documented potential for non-linear response of TLD-100 material in 
this dose and energy range (25, 26, 28, 31). 
 
5.2.1 MDCT Beam Characterization 
 As stated in Chapters 3 and 4, the beam quality measurements obtained within the 
first phase of Specific Aim 1 included:  the half-value layer (HVL), quarter-value layer 
(QVL), CTDI in-air measured with a 100 mm pencil chamber ((CTDI100)air), weighted CTDI 
(CTDIw), and volume CTDI (CTDIvol) for the MD Anderson Cancer Center VC technique on 
the institution’s “CT9” GE LightSpeed VCT scanner.  HVL and QVL measurements were 
also obtained upon the completion of the in-vivo measurements on “CT5”, “CT9”, and 
“CT12” scanners.  As the x-ray tube was not replaced on any of the scanners until the 
completion of all in-vivo dose measurments, the value of these beam quality measurements 
were perhaps somewhat reduced.  Reevaluation of HVL and QVL values with the replaced 
x-ray tube was conducted to investigate the differences between the hardness produced by 
a new x-ray tube and one at the end of its lifespan.  The value of the beam output 
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measurements was increased in this study in the fact that the variability observed in the 
TLD measurements (and accordingly the KL,120 values) was correctly assigned to the TLD 
process and not to the MDCT scanner output as the MDCT precision was characterized 
with these beam quality measurements.  Additional value will result from these 
measurements if they are applied to the characterization of an equivalent source model in 
future Monte Carlo simulation.  Ultimately, it was better to have an abundance of 
measurements that were not used than to desire such measurements retrospectively. 
 
5.2.1.1 HVL and QVL Measurement 
 As mentioned in Chapter 4, the HVL and QVL measurements demonstrated good 
precision with all exposure measurements at a specific filtration on a specific day, with a 
percent coefficient of variation (%CoV) less than 0.1% being achieved.  The HVL 
measurements between the three dates (approximately five months apart) and in the three 
MDCT scanners (with a total of four x-ray tubes) demonstrated a %CoV of 0.73% from one 
another, which was within the range of HVL measurement precision values for GE VCT 
scanners published by Mathieu et al (103) (0.20%-2.19% %CoV, with a mean of 0.42% for 
quarterly between-run precision measurements).  Further, the QVL measurements between 
the two dates demonstrated a %CoV of 0.62% from one another, which was slightly greater 
than the range of QVL measurement precision values for GE VCT scanners published by 
Mathieu (103) (0.11%-0.50% %CoV, with a mean of 0.43% for quarterly between-run 
precision measurements). 
 During acceptance testing of the “CT9” MDCT scanner at MD Anderson Cancer 
Center in August 2008, the measured HVL with the large body bow-tie filter was 7.96 mm 
Al.  The 2% difference observed between our HVL measurements and this measurement 
may be the result of differences in the methods used to obtain the HVL measuremetns, may 
be caused by inherent uncertainties in the measurement of the filtration thickness (using 
172 
 
several measurements with electronic calipers compared to the nominal thickness), or even 
of the ionization chamber measurements themselves (with a published uncertainty of ±4% 
after temperature and pressure condition corrections have been applied when using Co-60 
as the calibration source).  No standards currently exist stating an amount of allowable 
change in HVL measurements a tube may experience before requiring replacement.  These 
results suggest that the effect of these observed differences in x-ray tube output between 
the respective dates and MDCT scanners likely had a minimal impact on the calculated 
TLD KL,120 values or on the rectal dose measurements acquired during VC; and any 
variation observed in measured TLD dose between the MDCT scanner utilized in the VC 
scan, or between the phantom configuration and patients of equivalent size, are likely the 
result of uncertainties inherent within the TLDs’ ability to measure dose at diagnostic-level 
doses and energies. 
 
5.2.1.2 (CTDI100)air, CTDIw, and CTDIvol Determination 
The exposure measurements used to calculate respective (CTDI100)air values on the 
two dates the KL,120 values were determined (approximately 3 months apart) demonstrated 
a %CoV ranging from 0.00-0.20% from one another with a mean %CoV of 0.06%.  This 
range of precision values for GE VCT scanners was slightly greater than that published by 
Mathieu et al (103) (0.04%-0.11% %CoV, with a mean of 0.05% for within-run precision 
measurements obtained within seconds of one another).  As stated in Chapter 4, the results 
of the (CTDI100)air measurements also demonstrated very good agreement between 
respective (CTDI100)air measurements, with a %CoV of 0.08% between the (CTDI100)air  
measurements taken approximately 3 months apart.  This precision was less than the 
quarterly between-run range of precision values for GE VCT scanners published by 
Mathieu (103) (a range of 0.47%-1.04% %CoV, with a mean of 0.58%).    
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The need to acquire (CTDI100)air measurements in order to verify the linearity of the 
MDCT scanner dose output with mAs became obvious retrospectively after the first 
scanning session designed to establish KL,120 values.  Ideally, this linearity would have been 
established during both irradiation sessions for the entire dose range in which the KL,120 
values were determined, but this was not accomplished.  We are confident, however, that 
the x-ray tube output was linear during both irradiation sessions because of the well-
documented linear relationship between dose and mAs (37) and the good precision 
between the irradiation sessions.  Although these (CTDI100)air measurements established 
that the beam dose output was linear with mAs, the regression equation correlating the two 
entities for (CTDI100)air was not used to extrapolate the doses used to determine the KL,120 
values at 20 and 30 mAs.  Rather, the linearity of the Farmer chamber measurements in the 
CTDI body phantom with mAs were used to extrapolate these lowest doses using the linear 
regression shown in Equation 5-1; where FarmerDose is the extrapolated point dose 
estimated in the center of the CTDI body phantom (in mGy), and mAs is the scan technique 
used. 
 
5912.00578.0 −⋅= mAsFarmerDose   (5-1) 
 
As stated in Chapter 4, the results of the CTDI100 measurements within the CTDI 
body phantom also demonstrated good precision, with the %CoV ranging from 0.04-1.96%.  
Further, the %CoV of the CTDIw values measured approximately three months from one 
another was 1.31%, which was within the range published by Mathieu (103) (a range of 
0.61%-1.84% %CoV, with a mean of 0.84%).  Good agreement was also observed between 
the respective CTDIw and CTDIvol measurements.  The measured CTDIvol values 
corresponded well with the CTDIvol value provided by the MDCT scanner console for this 
scan technique (CTDIvol=8.26 mGy), with a total %CoV of 1.03%.   
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The observed 0.5% difference between the respective (CTDI100)air measurements 
and the 2% difference between the respective (CTDI100)w and (CTDI100)vol measurements 
may have been the result of inherent uncertainties in the measurement device (with a 
published uncertainty of ±4% after temperature and pressure condition corrections have 
been applied when using Co-60 as the calibration source).  These results further reinforce 
the belief that the effect of these observed differences in x-ray tube output between the 
respective dates likely had a minimal impact on the uncertainties observed in the calculated 
TLD KL,120 values or on the TLD-measured rectal doses administered during VC, and any 
such uncertainties observed in the measured TLD doses obtained within a single phantom 
configuration or within patients are likely the result of uncertainties inherent within the use of 
TLD-100 powder as a measurement technique at diagnostic doses and energies. 
 
5.2.2 Determination of TLD Dose Linearity Correction Coefficients for Virtual Colonoscopy 
 The results of the characterization of the RPC’s B09 TLD-100 batch to diagnostic 
doses at the 120 kVp spectrum administered by MD Anderson Cancer Center’s “CT9” 
scanner are provided in Figure 4-2 and Figure 4-3.  With the determination of Figure 4-2, 
which directly converts the apparent TLD dose (uncorrected for energy or dose linearity) it 
was not technically necessary to determine the KL,120 values for the dose range 
encountered in VC, since KL,120 was calculated by dividing the Farmer chamber dose by the 
uncorrected TLD dose.  However, in keeping with the traditional method of calculating TLD 
dose of multiplying the charge per mass reading by correction factors for sensitivity, fading, 
dose linearity and energy, KL,120 values were determined for the dose range encountered in 
VC (shown in Figure 4-3). 
It appears from the direct conversion of apparent (i.e. uncorrected) TLD dose to 
Farmer chamber dose displayed in Figure 4-2 that the TLD dose response at the 120 kVp 
spectrum is still within the linear region of the TLD-100 material’s dose response for all 
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doses administered to the TLDs above background.  In fact, if the background TLD 
measurements were to be omitted from the dataset, a linear regression equation is 
achieved that is characterized by a goodness of fit factor of R2=0.998.  This observed 
linearity is consistent with published lower dose limits of linearity for TLD-100 material, with 
the low-dose supralinearity region being published to approximately begin at doses less 
than or equal to 1 mGy (26).   
The supralinearity observed in the regression line between the lowest dose 
measured by TLD and the background measurements necessitated that a non-linear 
regression line be created to completely characterize the relationship between the apparent 
TLD dose and the Farmer chamber measured dose.  Therefore a fourth-order polynomial 
was used to characterize this relationship because it was found to be the minimally ordered 
regression that provided a goodness of fit factor (R2=0.999) that was greater than that of 
the linear regression when the background apparent TLD doses were not considered.  
Without characterizing the background apparent TLD dose, a linear regression would 
certainly have been appropriate (R2=0.998).   
The observed linearity of the TLD dose response is not immediately apparent, 
however, by viewing the KL,120 values provided in Figure 4-3.  This figure demonstrates a 
third-order polynomial regression being necessary to describe the relationship between the 
apparent TLD dose and KL,120 value that corrects the apparent TLD dose to the Farmer 
chamber dose (with a goodness of fit factor of R2=0.992).  This observed nonlinearity of the 
KL,120 values is a mathematical consequence of the added complexity inherent within the 
KL,120 value determination.   KL,120 is calculated by dividing the Farmer chamber dose 
measurement by the apparent TLD dose measurement.  Establishing a regression equation 
where the dependent variable (KL,120) is inherently a function of the independent variable 
(apparent TLD dose) is analogous to raising the order of the regression polynomial.  In 
other words, if an embedded independent variable were to be removed from the dependent 
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variable of a linear regression by multiplication, the result would be a second-order 
polynomial regression.  This mathematical reality was the reason the KL,120 values did not 
display a linear trend with increasing apparent TLD dose. 
Typically, under conditions where the RPC must determine the TLD dose linearity 
correction factor (KL) for orthovoltage energies, they do so by first estimating the energy 
correction factor (KE) based on data previously collected by the RPC that predicts 
appropriate KE values based on photon beam hardness (half-value layer) and then by 
irradiating the TLDs to the dose range desired with Co-60 photons to determine KL.  This 
published data correlating orthovoltage KE values to beam hardness describes the 
relationship as a non-linear function.  Based on this data, an appropriate energy correction 
factor for the HVL measured in Specific Aim 1 would be approximately KE=0.7.  However, 
this estimate is not specific to the RPC’s B09 batch of TLD-100 material and therefore 
subject to error.  Since both the dose and energy dependence had not been previously 
characterized for the RPC’s batch of B09 TLD-100 powder at the 120 kVp spectrum 
produced by MD Anderson Cancer Center’s “CT9” scanner, it was impossible to separate 
the dose linearity correction from the energy correction to determine the proximity of the 
calculated energy correction to this predicted energy correction for this batch of TLD-100 
powder. 
Regarding the characterization of the TLD dose response at diagnostic-level energy 
doses, the goodness of fit factors of R2=0.992 and 0.999 obtained for the KL,120 correction 
factors and the direct conversion from apparent TLD dose to Farmer dose, respectively, 
provided confidence in the ability of the TLDs to determine the rectal doses delivered by 
VC.  Additionally, although the TLDs perhaps introduced the primary source of error into our 
rectal dose measurements, the percent coefficient of variation values were determined to 
be 3.56% or less for all doses greater than background.  This degree of precision provided 
additional confidence in the rectal dose measurements obtained in Specific Aim 2. 
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5.3 Specific Aim 2:  Obtain Rectal Dose Measurements in an Anthropomorphic 
Phantom and In-Vivo in Patients Undergoing VC with TLDs 
Specific Aim 2 was accomplished in two phases: measurement of rectal doses in an 
anthropomorphic phantom during simulated VC and in-vivo rectal dose measurements in 
patients undergoing actual VC procedures.  The simulations within the anthropomorphic 
phantom were performed in order to provide dry runs for the in-vivo measurements (to 
ensure the process was well understood before any patients were subjected to the 
measurement process), to obtain additional rectal dose estimates, and to make preliminary 
determination regarding the legitimacy of using an anthropomorphic phantom to estimate 
patient organ dose (which is commonly done and is considered the benchmark for other 
indirect dose measurement techniques such as Monte Carlo simulation).  Once doses had 
been measured within the anthropomorphic phantom during simulated VC and IRB 
approval had been obtained from MD Anderson Cancer Center, in-vivo rectal dose 
measurements were performed for 6 patients undergoing VC. 
 
5.3.1 Rectal Dose Measurement Simulation in an Anthropomorphic Phantom  
As mentioned in Chapter 1, anthropomorphic phantoms contain many inherent 
approximations; such as assuming all soft tissue organs interact with radiation in an equal 
manner, using “standardized” anatomical geometry that may or may not reflect a true 
patient’s anatomy, using proprietary materials that provide simulated bony tissue radiation 
interactions across a wide range of ages and for multiple types of bones, etc.  Therefore the 
use of anthropomorphic phantoms to estimate patient doses is limited in many ways that 
are not yet fully understood.  Therefore, in a similar manner in which Monte Carlo 
simulations are benchmarked against phantom measurements, one of the intents of this 
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study was to provide a first step toward benchmarking Monte Carlo estimates and phantom 
measurements against in-vivo measurements.   
In order to accomplish this intent for phantoms within the parameters of this study 
where internal in-vivo measurements were to be acquired during VC, the anthropomorphic 
phantom had to be appropriately modified to represent patients undergoing VC.  Since 
patients present in a variety of sizes, and because VC at MD Anderson Cancer Center is 
accomplished using a fixed technique, a patient’s girth was assumed to be the primary 
determinate of the rectal dose received in VC.  Therefore, efforts were made to utilize a 
single anthropomorphic phantom to simulate patients of several sizes.  The rectal dose 
measurements obtained during the simulated VC were analyzed to ensure that the TLDs 
provided adequate precision for this study such that reliable rectal dose measurements 
during VC were accomplished, and a regression analysis was performed investigating the 
behavior of measured rectal doses with increasing patient habitus.  This model, along with 
rectal dose predictions obtained from a uniform phantom, was compared to internal in-vivo 
measurements in an effort to assess the legitimacy of using a phantom to estimate true 
patient rectal dose during VC. 
 
5.3.1.1 Modifications to the Anthropomorphic Phantom 
The primary necessary modification to the anthropomorphic phantom was the 
creation of an insufflated rectum within the phantom.  Many assumptions and 
approximations were requisite to determine an appropriately representative size, shape, 
and location of the insufflated rectum within the phantom.  The fact that each of these 
approximations were based on generalizations regarding patient rectum size and shape 
after gas insufflation, the bony landmarks surrounding the location of the rectal catheter, 
and the focus on those patients whose size was approximately equal to that of the phantom 
introduced some of the same limitations that have always plagued the use of 
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anthropomorphic phantoms and therefore necessarily introduced potential rectal dose 
measurement differences from those obtained within actual patients. 
Confidence is gained regarding the selected size and location of the insufflated 
rectum within the anthropomorphic phantom based on the population size and diverse 
techniques incorporated to determine these entities.  The use of anatomical measurements 
from VC scans of 29 total patients when performing this analysis enabled anthropomorphic 
or positional irregularities observed in one or two patients to not greatly influence decision 
making (for example, a pelvis positioned in an asymmetric manner which would affect the 
determination of the location of the TLDs with respect to the body landmarks).  Further, due 
to the fact that two separate methods were incorporated to determine the size and location 
of the insufflated rectum with respect to the surrounding bony landmarks, and that each of 
the two methods provided similar results, we are confident that the approximations made in 
creating the insufflated rectum within the phantom were appropriate for simulated VC at MD 
Anderson Cancer Center. 
The decision to cut a 6.4 cm diameter bore into one section of this pricy phantom 
was not made lightly, and only done with the stipulation that efforts be made to salvage as 
much of the removed material as possible to plug the bore when not being used in 
simulated VC.  The use of “solid water” plastic material to supplement the plastic plug 
where phantom material was unavoidably lost in the cutting process proved to be a good 
approximation to the proprietary soft-tissue equivalent material.  CT scans of the phantom 
with the solid water/phantom plug in-place revealed that the solid water was sufficiently 
equivalent to the surrounding phantom material that no discernable difference in contrast 
was observed at any window width or level setting (see Figure 5-1).  A comparison analysis 
of HU values between the solid water and the surrounding phantom material was not 
possible, however, because the thin size of the solid water material would not permit the 
creation of a sufficiently large ROI to attain stable consecutive HU measurements.   
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Figure 5-1.  Visual comparison between ATOM phantom image without and with the rectal 
plug (including the solid water) in place, respectively. 
 
As a preliminary assessment of the ability of the ATOM phantom to adequately 
represent a patient undergoing VC at MD Anderson Cancer Center, five ROI 
measurements of rectal tissues imaged in supine VC scans of 3 true MD Anderson Cancer 
Center patients (of approximately equal size to the ATOM phantom and who were chosen 
at random) yielded an average of 27.09 HU.  Similarly, ATOM phantom soft tissue ROI 
measurements during simulated VC yielded an average measurement of 26.53 HU.  This 
2.06% difference in HU values represented a difference in linear attenuation coefficient of 
0.05% between the actual VC patient rectal tissue and the phantom simulated soft tissue.  
Therefore, based on these measurements, the ATOM phantom appeared to provide an 
appropriate substitute for patient rectal tissue using the VC imaging technique. 
An additional modification made to the anthropomorphic phantom involved the low-
density Styrofoam plug that was inserted into the phantom to represent the carbon dioxide 
gas within the insufflated rectum while appropriately positioning the rectal catheter away 
from the posterior rectal wall.  Although the location of the rectal catheter within the 
insufflated rectum was not consistent among the 29 patient VC scans analyzed, none of the 
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patients demonstrated rectal catheter placement against the posterior portion of the rectal 
wall.  The simulated VC scans of the anthropomorphic phantom with the low-density 
Styrofoam plug inserted into the simulated rectum provided an average measurement of     
-931.66 HUs from five averaged ROIs within the insufflated rectum.  This value compares 
well to true carbon dioxide ROI measurements obtained within insufflated rectums of 3 
patients receiving VC scans at MD Anderson Cancer Center who were of approximately 
equal size to the ATOM phantom and who were chosen at random.  The average of these 
measurements was -947.60 HU, which was only 1.68% larger than the HU value provided 
by the low-density Styrofoam plug.  Therefore it was determined that the choice of the low-
density Styrofoam plug to support the rectal catheter appeared to be a good choice of 
materials that only minimally attenuated the photons that were measured by the TLDs 
within the simulated rectum.   
In order to use the ATOM phantom to obtain rectal dose estimates for patients of 
several sizes, fat substitutes were wrapped around the phantom in a manner that was 
consistent with population anthropomorphic data.  The fat materials used included porcine 
adipose material (lard) and a simulated phantom fat kit manufactured by CIRS.  The use of 
lard as a fat substitute during diagnostic imaging procedures was not a new scientific 
development (104-106).  Many studies have been published that incorporated the use of 
lard in dual energy x-ray absorbtiometry (DEXA) (107-117), ultrasound (118, 119) and in 
magnetic resonance imaging (MRI) (120-123).  A literature review did not, however, reveal 
any previous research using this material for CT scans for the estimation of patient dose.  
Therefore, in addition to patient rectal dose measurements, a preliminary assessment of the 
use of lard as a low-cost scatter mechanism in anthropomorphic phantom VC dosimetry 
studies was conducted.  Due to the novel nature of this approach, this material was only 
used as a scatter medium and did not attenuate the direct beam that was measured by the 
182 
 
TLDs.  Therefore, speculation can be made that the use of lard in this study contributed to 
perhaps only 5% of each TLD reading. 
An analysis of the scans that resulted from the simulated VC studies demonstrated 
that the lard provided photon attenuation that was similar to that of patient adipose tissue 
under VC conditions.  Averaging five ROI measurements from the anthropomorphic 
phantom undergoing VC and 3 randomly selected patient VC scans at MD Anderson 
Cancer Center of similar size to the ATOM phantom yielded: a lard average measurement 
of -156.97 HU, a CIRS manufactured simulated phantom fat measurement of -79.54 HUs, 
and a true patient adipose tissue average measurement of -112.06 HUs.  While these 
average ROI measurements yielded a 40.08% difference in HU number between the lard 
and the VC patient adipose tissue and a 29.02% difference in HU number between the 
CIRS phantom fat and the VC patient adipose tissue, the measured difference in HU 
numbers translated into a 5.06% difference between the linear attenuation coefficients of 
the lard and the patient adipose tissue, and a 3.66% difference between the CIRS phantom 
fat and the patient adipose tissue linear attenuation coefficients.  This 3.66% difference 
between the CIRS fat and patient fat exceeded the 1% difference in tissue equivalence 
published by CIRS (83) for all diagnostic and therapeutic doses and energies.   
These measurements suggest that the lard and the CIRS phantom fat provided 
similar deviations in linear attenuation coefficient from actual patient adipose tissue during 
VC.  This fact, along with the simple advantage in cost that lard has over the CIRS phantom 
fat (around $1 per lb of lard versus several thousand dollars for the CIRS simulated 
phantom fat system), suggest that lard could perhaps prove to be a reasonable substitute 
for patient fat in anthropomorphic phantom VC dosimetry studies.  It should be stated, 
however, that the packaging and use of lard as a scatter medium was a labor intensive 
process.  The value provided by the CIRS simulated fat material over lard was most 
apparent in the ease of use of the material (especially compared to the difficulties 
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encountered with the phantom set-up and packaging of the lard), the ability of the simulated 
fat material to support the weight of the phantom (where the lard was pushed laterally by 
the weight of the phantom), and the uniform coverage of the phantom fat material around 
the circumference of the phantom provided by the structure of the gelatinous phantom 
material and tapered design of the phantom fat.  In contrast, the adjoining bags of lard were 
abutted by duct tape and included air gaps at the juncture.  This design flaw of the lard 
system could be overcome with additional design efforts (such as tapering the lard within 
the bags and overlapping such bags when assembling them onto the phantom). 
 
5.3.1.2 Anthropomorphic Phantom Assembly 
During simulated VC with the anthropomorphic phantom, the most difficult and time 
consuming portion of the phantom irradiation process was the phantom set-up and tear-
down between consecutive measurements at a single phantom habitus.  The most 
complicated portion of this endeavor was aligning the respective sections of the phantom to 
one another.  This process was made difficult by the design flaws inherent within the bags 
of lard as the semi-solid substance was forced laterally within the bags by the weight of the 
phantom.  In order to adjoin the respective phantom portions as accurately as possible to 
create a uniform phantom scatter medium), supporting towels were frequently inserted 
between the table and the bags of lard; most notably in the lumbar and cervical areas of the 
phantom.  Although the use of these towels slightly redistributed the lard within the bags, it 
is unlikely this redistribution had a significant effect on the measured rectal doses; also, the 
proper alignment of the respective ATOM phantom sections was considered a higher 
priority than ideal lard distribution. 
Two additional approximations to true patient anatomy that were made regarding 
the ATOM phantom involved the phantom head and the phantom legs.  The phantom head 
was not used during these simulated VC scans because this structure was difficult to 
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support (especially at the larger phantom sizes).  It was believed that the phantom head 
would only minimally contribute to the scatter dose administered to the rectum, and 
therefore it is unlikely that the omission of this portion of the phantom had a significant 
impact on the doses measured by the TLDs within the rectum.   
Regarding the legs of the anthropomorphic phantom, true ATOM phantom legs were 
not available for this study.  Therefore this scatter medium was approximated by the use of 
two additional phantoms:  an anthropomorphic torso phantom, and a CTDI body phantom.  
In order to achieve the best possible continuity in scatter material between the ATOM pelvis 
and the simulated legs in the 15th percentile configuration, the CTDI body phantom was 
abutted to the ATOM phantom and the anthropomorphic abdomen/pelvis phantom was 
placed inferior to the CTDI body phantom.  This order of was reversed, however, when the 
layers of fat were applied such that the CTDI body phantom was placed inferior to the 
anthropomorphic abdomen/pelvis phantom.  This change was made because the bags that 
were filled with lard were not large enough to wrap around the CTDI body phantom and 
because the anthropomorphic pelvis phantom could be elevated with towels to mate 
appropriately with the ATOM phantom pelvis once the bags of lard were wrapped around 
the simulated legs.  As with the head of the ATOM phantom, it is believed that the specific 
geometry of the simulated phantom legs had a minimal impact on the rectal doses 
measured by the TLDs since they were not subjected to the primary beam at any time 
during the simulated VC (and they therefore acted solely as a scatter medium).   
 
5.3.1.3 Phantom Measurements and Determination of Population Percentiles Represented 
The determination of the percentile of US adults aged 18-64 represented by a 
phantom configuration was based on circumference measurements of the phantom and the 
population percentile data available in PeopleSize 2008 Pro software.  The population of 
US adults considered in this study was limited to those between 18-64 years of age 
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because this demographic represented the population data that was most available within 
the software, and it represented a reasonable approximation to the actual population that 
receives VC at MD Anderson Cancer Center (which includes those older than 64 years of 
age).  Additionally, the demographic used in this study was not a default population 
available in PeopleSize 2008 Pro software.  This population was manually defined as 49% 
of US males aged 18-64 and 51% of US females aged 18-64, with a “mixed adults” 
correlation table.  These manually defined settings were previously used in other studies 
assessing US adult sizes (124).  
Circumference measurements were perhaps not the ideal technique to use for the 
determination of the population of US Adults represented by a phantom configuration, but it 
provided the best option available.  Lateral and anterior-posterior (AP) dimensions are 
highly susceptible to shifts (especially in patients with a higher percentage of body fat) 
when a patient is lying down (e.g. while undergoing VC) versus when the patient is standing 
up (which was the posture for which data was available in PeopleSize 2008 Pro software).  
Realistically, circumference measurements are also subject to redistribution based on a 
patient’s posture (with dimensions shifting in a direction parallel to the CT scan table for 
patients with a higher body fat percentage); but of the options available, circumference 
presented the option with the least variation between the two postures and was therefore 
utilized in this study.  Such potential redistribution in body fat based on position may have 
impacted this study’s regression analysis between measured rectal dose and effective 
diameter (especially if patients were to present in this study with larger habitus), but it is 
believed that any such impact was minimal and would be observed on a patient-by-patient 
basis (as no two people truly have the exact same body measurements and fat distribution). 
A limitation of the data contained in PeopleSize 2008 Pro software is the lack of 
specific anatomical locations (i.e. anatomical landmarks) to which specific anthropometric 
measurements apply.  While the user interface of the software provided helpful clues, more 
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specific anatomical landmarks would have made the measurement process more accurate.  
As stated above, though, due to the fact that no two people yield exactly identical 
anthropometric measurements at every anatomical location, this lack of specific information 
likely had a minimal effect on the rectal dose to effective diameter regression analyses 
contained within this study.  These limitations likely had an impact, however, on the 
population percentiles provided for each patient participating in this study as there 
appeared to be some discrepancies between effective dose and percentiles for several 
patients in Table 4-8. 
Although PeopleSize 2008 Pro software did not provide specific anatomical 
landmarks on which measurements should be based, the software did provide 
anthropometric measurement data resolution to the millimeter.  This number of significant 
figures did not, however, improve the accuracy of the anthropometric measurements of the 
phantom; especially with regard to the measurements that encompassed the bagged lard.  
Although considerable efforts were undertaken to ensure that the lard within the bags was 
correctly distributed to match the distribution within a theoretical patient characterized by a 
percentile of US adults aged 18-64 (for example, ensuring that the thickness of the lard in 
the abdominal portion of the 87th percentile phantom configuration was 45 mm and was 34 
mm at the armpits), it was ultimately unfeasible to go to the lengths necessary to ensure 
these exact measurements were obtained.  Therefore, a ruler was simply used to obtain 
several measurements at each end of a bag to approximate that the lard was distributed in 
an appropriate manner.  These measurements were complicated when the bags of lard 
were attached to the phantom during the simulated VC procedures as the weight of the 
phantom and the wrapping of the bags around the phantom unavoidably forced a lateral 
redistribution of the semi-solid lard within the bags.  Although some of this fat redistribution 
realistically represented observed fat movement within patients when in a prone or supine 
position, obtaining and maintaining circumference measurements to the millimeter was 
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unfeasible in this study.  Due to these factors in the lard redistribution, and due to the fact 
that a phantom population percentile was determined by averaging the circumference 
measurements at several anatomical locations, the population percentiles represented by 
each phantom configuration were susceptible to some error. 
 
5.3.1.4 Virtual Colonoscopy Simulation in an Anthropomorphic Phantom 
Besides the approximations inherent within the anthropomorphic phantom and 
within the population percentile represented by a phantom habitus configuration, an 
approximation to a true VC scan was made in the simulated VC in that two supine scans 
were performed on the anthropomorphic phantom (as opposed to a prone and a supine 
scan).  This modification to actual VC procedure was utilized to minimize the difficulties 
associated with phantom set-up.  Performing two supine CT scans was believed to be a 
reasonable approximation to a true VC exam where a prone and a supine scan are 
performed, but it also introduced opportunities for discrepancies between anthropomorphic 
phantom measurements and in-vivo measurements.  Any discrepancies caused by this 
deviation from true VC protocol are believed to be minimal. 
 
5.3.1.5 Simulated Virtual Colonoscopy Data Analysis 
The trend of increasing %CoV observed in the phantom measurements with 
decreasing dose was also observed in Specific Aim 1 when the TLD dose and energy 
response was characterized.  With the %CoV reaching 4.33% for the 99th percentile 
phantom configuration (likely the largest size of patient to undergo a VC), it was determined 
that TLD-100 material displays adequate precision to measure rectal doses during VC at 
MD Anderson Cancer Center.  Additionally, a trend of patient CT dose decreasing in an 
exponential manner with an increase in patient size had been previously reported in other 
studies (101, 102).  This trend was observed in our TLD dose measurements within the 
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anthropomorphic phantom and the calculated goodness of fit factor of R2=0.993 of the 
exponential regression between the phantom effective diameter and the measured dose 
supported this finding. 
The 95% confidence intervals (CI) for the mean phantom TLD measurements 
obtained at each patient size are admittedly difficult to observe in Figure 4-4.  Although not 
displayed in Figure 4-4, a few measured dose values lied outside the 95% CI at each 
phantom effective diameter.  This was likely due to the fact that the CIs displayed in Figure 
4-4 were calculated based on a t-distribution.  With only 12 data points available for each 
phantom habitus, it was very difficult to determine the distribution that was appropriate to 
model this data.  Therefore, although some data lied outside this confidence interval range, 
it is unclear whether this data should (in reality) be considered outside the 95% confidence 
interval of the data. 
The 95% CIs for the exponential regression equation modeling the measured rectal 
doses to the phantom effective diameter are admittedly large.  Based on these confidence 
intervals, two patients’ effective diameter could differ by up to 5 cm and still predict the 
same TLD dose within the 95% confidence interval.  This large confidence interval was 
attributed to the fact that TLD measurements were only obtained at three effective 
diameters.  If this analysis were expanded to include additional effective diameters, the 
coefficients within the exponential regression equation would likely experience small 
changes and the confidence intervals would likely narrow considerably toward the 
regression line. 
The uniform phantom-based dose predictors were included in Figures 4-4 and 4-5 
for illustrative purposes.  With the data presented in this manner, the reader can easily see 
that all of the dose predictors, except the size specific dose estimate (SSDE), provided 
equal dose estimates regardless of the size of the patient; with the SSDE dose prediction 
being approximately parallel with the rectal dose regression developed by the TLD 
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measurements in the anthropomorphic phantom.  Obviously, the dose estimates that do not 
change with patient size are not reliable prediction models of patient rectal dose as such 
models only predict patient dose for those patients of one size.  The reason the SSDE dose 
prediction and the anthropomorphic phantom TLD measurements were not equal (and did 
not overlap) was believed to be due to the fact that the SSDE is based on an average dose 
distributed throughout the phantom (via the CTDIw component contained within SSDE) and 
the TLD measurements were point dose measurements obtained in a position slightly 
posterior to the center of a phantom.  Therefore, because the dose within a phantom was 
higher at the phantom’s surface than at the phantom’s center, and since such higher dose 
measurements were included in the SSDE calculations and not in the TLD measurements, 
SSDE values should always be higher than dose measurements obtained near the center 
of a phantom.     
For larger, more superficial organs in an anthropomorphic phantom that are 
completely within a scan volume, SSDE may be able to provide a reasonable first 
approximation to the dose administered to that phantom’s organ.  However, specific organ 
dose measurements would be required to verify this hypothesis.  For organs not entirely 
within a CT scan volume or organs irradiated using dose modulation techniques (such as 
Smart mAs or automatic exposure control (AEC)), SSDE would not likely provide even 
reasonable first approximation estimates of the dose to that organ in an anthropomorphic 
phantom.  In spite of these limitations, SSDE provides a useful adaptation to CTDIvol that 
accounts for patients of various sizes and provides general patient dose estimates within 
10-20% of actual doses (101), and may even provide good approximations of dose 
administered to a point in the superior portion of the rectum within a typical VC patient. 
 
5.3.2 In-Vivo Rectal Dose Measurements during Virtual Colonoscopy 
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The second phase of Specific Aim 2 included internal in-vivo rectal dose 
measurements in 6 patients undergoing VC at MD Anderson Cancer Center.  Based on 
several literature reviews, it was believed that in-vivo dose measurements had never been 
performed inside patients undergoing virtual colonoscopy or even when undergoing MDCT 
scans in general.  As such, significant efforts were made to define the scope of the project 
and to obtain IRB approval at MD Anderson Cancer Center.  This approval was granted 
after the Food and Drug Adminstration (FDA) (Silver Spring, MD) determined that the study 
posed a non-significant risk to patients.  One of the desired outcomes associated with this 
study is that more in-vivo CT dosimetric studies will be conducted in the future, not only 
within the rectum but also within other anatomical locations.  Such studies would be 
important to validate patient or organ dose estimates produced by indirect means such as 
within phantoms, by Monte Carlo simulations, or by cadaveric studies. 
 
5.3.2.1 Maintenance of Control of TLDs during VC Procedure 
No TLDs became dislodged from the rectal catheter while performing in-vivo 
measurements during VC procedures.  This TLD security was attributed to the fact that the 
TLDs were attached to the rectal catheter by both silicone glue and suture.  Disinfection of 
the rectal catheter with 70% isopropyl alcohol may have negatively impacted the strength of 
the silicone glue.  Although no substance is known to completely dissolve silicone glue, 
isopropyl alcohol is known to infiltrate the cells of silicone glue and expand them (rendering 
the bonds weaker).  It is for this reason that the manufacturers of silicone glue recommend 
isopropyl alcohol when trying to remove the glue from surfaces.  Therefore, incorporating 
the additional security of the suture provided sufficient adherence of the TLDs to the rectal 
catheters. 
 
5.3.2.2 Patient Rectal Dose Determination 
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 As demonstrated in Figure 4-7, Patient 4 had a higher relative bone density than the 
rest of patients receiving VC in this study due to the considerably younger age (and male 
gender) of this patient compared to the rest of the sample population.  With this relatively 
high bone density, with a substantial amount of iodine contrast in the rectum, and with the 
TLDs located sufficiently superior within the rectum such that the primary x-ray beam was 
attenuated by the pelvis (as demonstrated in Figures 4-8 and 4-9), the measured readings 
and the 95% CI were lower than those of the rest of the patients.  Conversely, although 
Patient 5 measured at a relatively high bone density as shown in Figure 4-7, the TLDs were 
placed more inferior within the rectum than in the rest of the patients such that the primary 
beam was not highly attenuated by the pelvis; but rather by the femurs and the ischia.  This 
explains the low percentage of highly attenuating material in the axial plane of the TLDs 
observed in Figures 4-8 and 4-9.  Since such relatively low amounts of highly attenuating 
material interacted with the primary beam on its path to the TLDs, the measured doses in 
this patient were understandably higher than in the rest of the study population.  
 Patient 4 had an effective diameter within 1% of that of the anthropomorphic 
phantom, at a comparable percentage of highly attenuating material in the images 
containing the median TLD location, and at similar measured rectal doses (within 1.7% of 
one another).  Although it cannot be proven with just one young male patient with a 
seemingly typical amount of relative bone density, these in-vivo measurements suggest that 
x-ray attenuation in younger and relatively healthy adult populations are correctly 
represented by the ATOM anthropomorphic phantom; and conversely it may be implied that 
the ATOM phantom under-predicts doses in older patients with lower bone density.  More 
patients would be required to definitively support these conclusions, however.  It is 
noteworthy to mention that such younger and relatively healthy adult populations are not 
those typically receiving VCs, or even CT exams in general.  
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 Although other studies (101, 102) (as well as the anthropomorphic phantom 
measurements in this study) predict a regression of patient CT dose decreasing 
exponentially with increasing effective diameter, the outliers within our in-vivo dose 
measurement results (Patients 4 and 5) rendered the calculation of any such regression a 
statistical problem for the in-vivo measurements (since the outliers account for 1/3rd of the 
total number of patients).  Even though the driving factors behind these outlying 
measurements were believed to be known, it would take many more patients and perhaps 
even a mixed effects statistical model to create a regression of sufficient complexity to 
account for these factors and accurately predict patient rectal doses.  Such endeavors 
would be important to undertake if adequate dose prediction models are to be developed. 
It was observed in Chapter 5.3.1.5 that the simulated VC procedure within the 
anthropomorphic phantom provided rectal dose measurements that were considerably 
lower than those of the SSDE dose estimate.  Although the two dose models decrease with 
increasing patient effective diameter in a nearly parallel nature, as stated above the 
differences between these dose models lies in the fact that SSDE is based on a weighted 
average dose throughout a phantom and the anthropomorphic phantom is solely based on 
point dose measurements in the approximate center of the phantom.  It was interesting to 
observe that the higher rectal doses measured in the typical VC patients (due to a lack of 
relative bone density compared to the younger Patient 4 and the anthropomorphic 
phantom) almost exactly coincided with those higher dose estimates provided by the SSDE 
model.  This coincidence is quantified by the mean square error analysis (MSE) provided in 
Table 4-10 that demonstrated that the SSDE model provided the best rectal dose estimate 
for 5 of 6 patients.  Although the overlap of the values predicted in these models is 
somewhat coincidental, it appears that when assessing dose to the superior portion of the 
rectum in patients of approximately average bone density for the typical VC patient, SSDE 
provided dose estimates in this study within ±5% of actual measured rectal doses. 
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 A close look at Table 4-9, in which in-vivo rectal dose measurements are compared 
to phantom dose estimates, may suggest some inconsistencies between the listed effective 
diameters and the provided percentiles of US adults aged 18-64 represented by each 
patient (as stated above in Chapter 5.3.1.3).  One possible source for these apparent 
discrepancies is the fact that the percentiles were based on circumference measurements, 
where effective diameter (calculated by obtaining the square root of the product of the AP 
and lateral dimensions) was not.  Secondarily, while the PeopleSize software does provide 
a simple interface, it does not provide highly descriptive landmarks upon which 
anthropometric measurements should be based.  The dimension within this software used 
to quantify the population percentile was described as “hip circumference, around buttocks”.  
It is possible that the circumference measurements acquired in this study do not completely 
reflect the anatomy intended in the PeopleSize software, and therefore some opportunity 
existed for error in the population percentiles provided in Tables 4-6, 4-8, and 4-9. 
 Additionally, the observed shifts in patient habitus mentioned in Chapter 3 yielded 
effective diameter measurements that were perhaps artificially inflated compared with 
analogous measurements performed on the uniform phantom and compared to the 
population percentiles provided.  This suspicion of inflated effective diameters could 
perhaps also partially explain the apparent mismatch between patient effective diameters 
and population percentiles provided in Table 4-9.  While it was expected that a patient’s 
adipose tissue would distribute laterally as they lay either prone or supine on the CT 
scanner table, the manner of this adipose tissue redistribution observed in patients provided 
a different shape than that of the anthropomorphic phantom; with the actual patients’ MDCT 
images yielding non-uniform lateral protrusions (where the phantom remained 
approximately oval shaped).  Figure 5-2 displays a comparison of the distribution of the 
body mass during a simulated VC within the anthropomorphic phantom and in an actual VC 
within a patient.     
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Figure 5-2.  Visual comparison between A) non-uniform lateral adipose tissue distribution in 
patients, and B) anthropomorphic phantom. 
 
In order to be consistent across all patients when performing patient size 
measurements, the lateral diameter measurements that were acquired to determine a 
patient’s effective diameter were obtained at the maximum lateral distance; even when 
these protrusions were observed laterally.  Therefore, the lateral diameter measurements 
obtained in this study were not indicative of an average lateral distance, but rather of the 
maximum lateral distance.  Thus, it was possible that effective diameters assigned to those 
patients displaying this non-uniform distribution of adipose tissue were biased larger than 
appropriate; and such measurements provided an additional opportunity for disagreement 
between the data sets.  It is possible that circumference measurements would have 
provided a better assessment of patient size than effective diameter in such cases when 
comparing anthropomorphic phantom measurement data to in-vivo patient data; however 
circumference is not readily assessed on CT scanners, and many interfaces to not offer 
tools to perform these measurements.  Ultimately, effective diameter measurements were 
selected due to their utility in AAPM Report 204 (101), which describes SSDE as a function 
of effective diameter.   
A)     
 
B)   
 
Lateral protrusions perhaps inflating 
effective diameter measurements 
195 
 
In order to accurately assess the dose delivered to the rectum as a result of the CT 
scans enlisted in the VC procedure, it was important to quantify the contribution to the TLD 
measured doses from the survey (aka scout) scans.  Each patient, before undergoing both 
the supine and prone scan, received 2-3 scout scans (in both the PA and lateral directions) 
in order to ensure that the patient was appropriately positioned and that the CT scan 
covered all of the necessary anatomy.  The results of the scout scan dose estimates are 
provided in Tables 4-7 and 4-8.  While these administered doses were low (estimated to be 
between 0.140-0.277 mGy or 1.4-2.2% of the total VC rectal dose measurement), they 
introduced an opportunity for disagreement from the TLD measurements performed within 
the anthropomorphic phantom (which was not subjected to scout scans).  These estimated 
scout doses were subtracted from the reported CT scan doses as shown in Figure 4-5 and 
Table 4-8, but as these doses are only estimates some disagreement may have been 
introduced between the anthropomorphic phantom and between the in-vivo measurements.   
An exact comparison between the estimated scout scan entrance exposures 
calculated in this study and those results published by O’Daniel (15) is not possible; as 
O’Daniel did not provide entrance exposures for a GE VCT scanner (64 channels and a 40 
mm beam), for 90° (lateral) scouts, for a tube current of 80 mA, or at an equivalent 
exposure measurement location (a VC patient thickness of 21.6 cm versus 22.5 cm 
thickness in O’Daniel).  The closest comparison with data published in this paper would be 
based on a GE LightSpeed scanner (16 channels), at 10 mA and only for a 180° (PA) 
scout.  Under these conditions, O’Daniel published an entrance skin exposure of 24.4 mR, 
while this study estimated an entrance exposure for a 180° scout at 10 mA to be 15.7 mR. 
It should also be noted that the prone scout scans contributed considerably more 
dose to patients than the supine scout scans.  This was due an oversight in the pre-set 
scanner settings that resulted in the prone scout scans being acquired at 80 mA compared 
to the 10 mA tube current used for the supine scout scans.  While the scout image quality 
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was perhaps superior with the 80 mA technique, both imaging techniques provided images 
that were of sufficient quality to perform the functions required of the CT scout scan.  
Therefore, the prone scout technique could likely be decreased to 10 mA; which would 
have decreased the average scout dose administered to patients participating in this study 
by 59-85%.   
Besides the dose contribution to the TLDs from the scout scans, additional 
consideration was required regarding measured TLD doses exceeding the maximum dose 
to which the TLD response was characterized.  The initial estimates of rectal dose 
administered during VC that were discussed in Chapter 1.3.5 and Chapter 3 were based on 
Farmer chamber measurements as the midpoint dose, and 6 cm of acrylic material 
mathematically subtracted from the radius of the CTDI body phantom as the approximate 
upper dose limit and a simple estimate of 0.5 mGy as the lower dose limit.  This initial rectal 
dose estimate was calculated to range from 0.5 mGy to 11.2 mGy.  In calibrating the TLDs 
to this dose range, 0.7 mGy was administered at 20 mAs, and 10.8 mGy was administered 
at 170 mAs.   
After calculation of the in-vivo TLD dose measurements, it was obvious that the 
doses administered at these mAs extremes did not completely encompass the range of 
doses encountered in the 6 patient measurements. The maximum dose characterized in 
Specific Aim 1 was 10.8 mGy (using an f-factor for dose to muscle), and 13 of 24 in-vivo 
TLD measurements exceeded this value.   Patient 2 represented the minimum sized patient 
for which the TLD doses were measured in this study, and the maximum dose measured in 
the study was that within Patient 5.  Based on the dose measurements from Patient 5, it 
can be estimated that the range of doses for which this batch of TLD-100 material should 
have been characterized in the diagnostic dose range by actual Farmer chamber and TLD 
measurement was 14.3 mGy (including the 95% confidence interval).  This maximum dose, 
along with the measured dose range of 9.86 mGy to 13.05 mGy, suggests that although the 
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initial 11.2 mGy maximum dose estimate was not an entirely bad initial guess, the 11 mGy 
to 18 mGy dose range published by DeMarco (59) (for the entire colon) was more accurate 
for the rectum than initially expected.  Based on the linearity of the administered doses to 
increasing mAs established in Specific Aim 1 with a very high goodness of fit factor (R2), 
the TLD dose response extrapolations performed in this study to determine the rectal doses 
for those measurements exceeding the initial 11.2 mGy maximum rectal dose estimate 
were believed to be appropriate and robust. 
It was also observed when accomplishing Specific Aim 1 and when TLD 
measurements were performed within the anthropomorphic phantom during simulated VC 
that the %CoV of the TLD measurements at a single dose increased with decreasing 
energy.  This phenomena was not observed in the in-vivo measurements, however, as the 
%CoV appeared to maintain a value of approximately 5% for four out of six patients.  The 
%CoV of these two outlier patients were 10% and 1.8% %CoV, even though the average 
dose readings from these two patients were within 0.5 mGy of one another.  It is not known 
why the %CoV for these two patients varied from the others or each other, nor is it known 
why the %CoV for the in-vivo measurements averaged approximately 5% while the %CoV 
for the TLDs in the uniform phantom averaged 2% and the TLDs in the anthropometric 
phantom averaged 3%.  This increase in %CoV was driven by increases in the standard 
deviations of the six patients compared to the phantom measurements, which was also 
reflected in larger 95% CIs than those observed in the respective phantom measurements.  
In spite of this decrease in %CoV and increase in CI, it is believed that the TLDs performed 
with adequate measurement precision in this study to reliably measure patient rectal doses 
during VC.  
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5.4 Specific Aim 3:  Compare In-Vivo Rectal Dose Measurements to Anthropomorphic 
Phantom Measurements, CTDI-Based Dose Estimates and Point Dose Measurements 
from a Uniform Phantom 
 Since there are not yet many established methods to obtain organ dose 
measurements during CT scans, it is important to understand the accuracy of any such 
dose estimates provided by currently established methods.  In an effort to preliminarily 
assess the accuracy of such methods, the in-vivo TLD rectal dose measurements were 
compared in Specific Aim 3 to dose estimates obtained from an anthropomorphic phantom, 
and a uniform CTDI body phantom using the same CT scan technique.  These CTDI body 
phantom-based dose estimation techniques included: Farmer ionization chamber 
measurements within a CTDI body phantom, CTDIvol measurements, (CTDI100)center 
measurements corrected for pitch (assigned the nomenclature “CTDIvol,center“), and SSDE 
dose estimates.   
The Farmer chamber measurements used for comparison with the anthropomorphic 
phantom and in-vivo TLD measurements were based on the same exposure measurements 
used to determine the TLD KL,120 values in Specific Aim 1.  A difference existed, however, in 
the dose estimate used for comparison with anthropomorphic phantom and in-vivo 
measurements and those used to establish TLD response.  The difference observed 
between these measurements was due to the fact that the f-factor that was multiplied by the 
measured Farmer chamber exposure, with the f-factor for muscle (f=0.94 rad/R) being used 
in Specific Aim 3 as opposed to the f-factor for acrylic (f=0.78 rad/R) that was used for the 
determination of the TLD KL,120 values in Specific Aim 1.   
It was necessary to use a common f-factor for both the apparent (uncorrected) TLD 
measurements and the Farmer chamber in Specific Aim 1 such that both f-factors cancelled 
out and were not erroneously factored into the KL,120 determination.  Since the CTDI body 
phantom is constructed of acrylic, this f-factor was utilized.  However, TLD sensitivity (KS) is 
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determined by the RPC in terms of absorbed dose to muscle.  Therefore, in order to 
correctly compare the TLD measurement results to the Farmer chamber measurement 
dose estimate, the Farmer chamber exposure measurements were multiplied by the f-factor 
for muscle instead of that for acrylic. 
The uniform CTDI phantom-based dose estimates were not found to provide dose 
estimates within 95% CI of the mean dose measurements within the anthropomorphic 
phantom.  There were two uniform phantom measurements, however, that provided dose 
estimates with the 95% CI of the regression of the anthropomorphic phantom.  Therefore, 
there may be some (limited) circumstances in which uniform CTDI phantom-based dose 
estimates may be useful in dose estimation.   
Comparing the performance of the anthropomorphic and uniform phantom-based 
dose estimates to in-vivo measurements by MSE calculations showed that the SSDE model 
demonstrated the most consistent agreement to in-vivo measurements; providing the most 
accurate dose estimation for five of six patients, and predictions within the 95% CI for two of 
the patients.  The remaining (younger) patient not conforming to the SSDE model was best 
predicted by the anthropomorphic phantom regression due to the fact that this patient more 
closely represented the phantom size and percentage of highly attenuating bone 
composition.  Surprisingly, in spite of the fact that the CTDIvol dose estimate model does not 
change with changes in patient size, it did provide dose predictions for three patients with 
MSE values less than 1 mGy.  However, with a larger and more uniformly distributed 
patient population, this percentage of relatively low MSE values will decrease because the 
CTDIvol model does not change with patient size; which makes the model generally 
unsuitable for dose predictions pertaining to a large population of individuals.  Further, with 
a larger patient population that would include a representation of larger patients, all of the 
uniform dose predictions used in this study will predict doses for some range of patient 
sizes (as displayed in Figure 4-4). 
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Regarding our assessment of the variety of sizes of patients that undergo VC at MD 
Anderson Cancer Center, the percent coefficient of variation (%CoV) of the mean patient 
rectal doses was calculated to be 14.2%.  This between-patient %CoV value was calculated 
to assess whether the between-patient rectal dose %CoV was greater than 50% (as stated 
in the hypothesis), which was an indirect assessment of the size distribution of patients 
receiving VC at MD Anderson Cancer Center.  As can be seen in Figure 4-6, however, the 
distribution of patients that participated in this study was biased toward the smaller sizes of 
US adults.  Due to the small sample size of this pilot study, it is unclear at this time whether 
this bias reflects a true bias in the population of adults receiving VC at MD Anderson 
Cancer Center; or whether this size distribution is simply a function of the small population 
of patients recruited for this study.  If the size distribution of patients receiving VC at MD 
Anderson Cancer Center is truly smaller than that of the actual population of US adults 
aged 18-64, it could be a result of the fact that the typical patient receiving VC is greater 
than 50 years of age (and obese patients are less likely to survive to more advanced ages); 
or perhaps it could be a result of weight loss stemming from gastrointestinal issues that 
prompted a VC procedure.  It is anticipated that this between-patient %CoV of rectal dose 
measurements would likely increase with a larger sample population. 
The hypothesis of this study was:  in-vivo rectal dose measurements obtained 
during virtual colonoscopy will have a rectal dose coefficient of variation that will be greater 
than 50%; and the differences between the anthropomorphic phantom dose measurements, 
the CTDIvol-based dose estimates, and Farmer chamber measurements in a CTDI body 
phantom will be outside the 95% confidence interval for in-vivo patient VC dosimetry 
measurements.  Based on the measurements obtained in this study, we have failed to 
prove the hypothesis prediction that the between-patient rectal dose coefficient of variation 
would exceed 50% based on our calculation yielding a coefficient of variation of 14.2%.  
Also, we have failed to prove the hypothesis prediction that the differences between the 
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anthropomorphic phantom dose measurements, the CTDIvol-based dose estimates, and 
Farmer chamber measurements in a CTDI body phantom would be outside the 95% 
confidence interval for in-vivo patient VC dosimetry measurements; as the SSDE and 
anthropomorphic phantom provided rectal dose estimates within the 95% confidence 
interval of mean patient dose measurements acquired in this study.  Our data supports this 
hypothesis prediction, however, for the uniform CTDIvol dose models, the CTDI phantom-
based CTDIvol,center, and Farmer chamber rectal dose estimates. 
 
5.5 Potential Future Work 
In addition to the in-vivo measurements obtained for the 6 patients in this study, 
future work should concentrate on collecting in-vivo rectal dose measurements for a larger 
population of patients.  Doing so would allow for a determination of the true distribution of 
rectal dose within a population of VC patients, which would allow for a better determination 
of the 95% confidence intervals than those provided in Figures 4-4 and 4-5.  Future studies 
with a larger population of patients could also allow for an in-depth assessment of the 
validity of the rectal dose regression models developed within this study, even in those 
regression models such as the anthropomorphic phantom that were found to not predict 
typical VC patient dose with a high degree of accuracy, but were suggested to predict rectal 
doses in patients with higher relative bone density. 
Future work related to this project should also focus on validating other indirect dose 
estimates to determine their accuracy compared to these direct TLD dose measurements. 
This could be accomplished by creating digital models of these same patients and 
performing VCs in Monte Carlo simulation to estimate rectal dose administered during the 
procedure.  The groundwork to accomplish such dose comparisons has already been 
created, with the x-ray beam quality being adequately determined for the set-up of a Monte 
Carlo simulation equivalent source; and with 50 cm display field of view (DFOV) 
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reconstructions already available for each of the VC scans conducted in this study.  
Although it would be helpful in the development of such a Monte Carlo simulation 
equivalent source if ionization chamber exposure measurements were available at a 
modeled patient’s surface, entrance surface exposures could be estimated with ionization 
chamber measurements at isocenter for the VC scan protocol by increasing the exposure 
measurements based on inverse square corrections for a patient’s size; similarly to that 
which was done to estimate patient dose from the scout images (15).  Ultimately, 
simulations could be performed based on the data already available without any such 
measurements.  A new IRB approval would be required, however, for such a study as the 
IRB protocol for these measurements did not include exporting data to any other institutions 
where such modeling capabilities exist (such as McNitt-Gray’s model at UCLA (44, 57-62, 
102, 125)). 
In addition to validating Monte Carlo models of dose administration, the techniques 
described in this study could be used to validate other indirect dose estimation techniques, 
such as other uniform or anthropomorphic phantom measurements or even cadaveric 
measurements.  In order to more completely understand the accuracy provided by these 
(and Monte Carlo) dose estimates, however, dose measurements to additional organs 
would need to be acquired.  Admittedly, the opportunities to acquire such measurements 
are primarily limited to those organs which contain accessible lumen structures (such as the 
digestive tract, the urinary tract, and perhaps the circulatory system).  Measurements in 
each of these locations would present challenges and patient risks additional to those 
contained within this study.  If a solid in-vivo benchmark could be established for these 
indirect measurement techniques, dose administered to many of the less accessible organs 
during CT scans could potentially be reliably estimated through refined modeling that 
considered patient size, anatomic composition and geometry, scan parameters, and other 
factors that contribute to patient dose.   
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 Even if such models could be generated through a comprehensive series of direct 
organ dose measurements, the “bottom line” of such measurements is the determination of 
the risk to a patient.  Ultimately, this determination may prove to be much more challenging 
than acquiring organ dose measurements at several sites and developing well-refined 
dosimetric understanding.  A patient’s risk from radiation exposure is not simply a factor of 
the dose that patient receives, but also a factor of many other factors; to include (as an 
incomplete list):  previous radiation exposure, tissues irradiated, genetic pre-disposition to 
cancer, cancer history, stochastic events, deterministic thresholds, etc.  Such a thorough 
understanding of radiation biology does not currently exist to sufficiently determine the risk 
to a patient from CT scans, even with more comprehensive organ dose measurements.  
Therefore, while the performance of in-vivo organ dose measurements is a valuable step 
toward understanding patient risk from a diagnostic CT procedure such as VC, such 
measurements do not completely answer the fundamental question of patient risk.  
Regarding the understanding of “ground truth” rectal organ dose from in-vivo rectal 
dose measurements, in order to completely correlate the TLD rectal dose measurements to 
actual patient rectal dose, consideration must be made regarding the amount of additional 
dose deposited to the rectum as a result of the presence of the iodinated contrast agent.  
Although the contrast agent acts as a highly attenuating material, photoelectric interactions 
likely occur within this material, which could deposit dose in surrounding tissues.  
Therefore, future work should also focus on modeling rectal dose as a function of the 
relative concentration of contrast agent within the rectum at the time of the VC scan.  No 
such data is currently believed to be available; but a previous study (126) determined 
through a combination of liquid scintillation measurements of dose increase at various 
concentrations of iodinated contrast agent, HU measurements to determine the 
concentration of iodinated contrast agent in a medium, and Monte Carlo modeling of organ 
doses in an anthropomorphic phantom that dose to all five tissues analyzed increased with 
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the presence of an iodine contrast agent.  The amount of organ dose increase was 
determined to be based on the concentration of the iodinated contrast agent present in the 
organ and the specific organs subjected to radiation.  The study showed that in some 
tissues, when relatively high concentrations of iodinated contrast agents were present, the 
dose administered to the organ by the CT scan increased by as much as 74%.  Therefore, 
an understanding of the dosimetric effects of the presence of the iodinated contrast agent 
within the rectum must be attained to fully quantify the radiation dose administered to the 
rectum during VC. 
There are a few opportunities currently available to reduce the rectal dose resulting 
from VC procedures.  Some institutions have incorporated the use of automatic exposure 
control (AEC) features such as GE’s “Smart mAs” technology to modulate the dose to an 
appropriate level throughout the scan volume.  Another potential method for reducing 
radiation dose to a patient would be to eliminate one of the two CT scans within the VC 
procedure.  In order to eliminate one of the two CT scans (and still acquire a VC study of 
sufficient diagnostic quality), better computer aided detection (CAD) of polyps, better 
methods for insufflating the bowel, better methods for the removal of residual contrast agent 
while obtaining necessary contrast distribution, and improved ways to identify and see 
through fecal matter would have to be implemented.  Although efforts have been applied to 
address each of these limitations, additional progress must be achieved to eliminate one of 
the two CT scans.   
Radiation dose is eliminated completely when using optical colonoscopy (OC) or 
MRI technology as opposed to CT for VC (known as MR Colonography or MRC) (127-132).  
Although considered the “gold standard” by gastroenterologists, OC has many limitations; 
including:  a relative inability to know exactly where in the colon the endoscope is at a given 
time, patient risks from sedation and bowel injury, and an insufficient number of qualified 
endoscopists to meet demands (screening, diagnosis, treatment, and surveillance).   A 
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more wide-spread implementation of MRC could eliminate radiation dose.   However, MRC 
requires longer scan times, which contributes to additional patient discomfort; and is not as 
widely accepted by clinicians as CT-based VC.  Until acceptance for this modality increases 
and more radiologists are adequately trained to read MRC studies, CT-based VC remains a 
practical alternative to OC. 
It theoretically may be possible to utilize the in-vivo dose measurements obtained in 
this study along with histograms of the CT images containing the median TLD location 
within the rectum to predict patient rectal dose.  Based on a literature review, it is believed 
that such a dose prediction technique has not been attempted previously.  Since the HU 
numbers upon which CT images are based is actually a measure of incident x-ray 
attenuation compared with that of water, and since CT irradiates patients from all angles, a 
histogram with a defined DFOV would provide data regarding the number and size of pixels 
providing the various amounts of x-ray beam attenuation during the CT scan.  Since 
primary beam characteristics can be established with ionization chamber measurements at 
isocenter, fundamentally all of the information required to estimate patient rectal dose may 
be present.  This technique would likely fail to accurately predict doses close to a patient’s 
surface as these doses are known to vary with x-ray tube position.   
 
5.6 Conclusions 
A study was performed to acquire internal in-vivo measurements on patients 
undergoing virtual colonoscopy (VC) at MD Anderson Cancer Center.  Such a study 
incorporating internal in-vivo measurements is not believed to have been performed 
previously for virtual colonoscopy or for multi-detector computed tomography (MDCT) 
scans in general.  Such in-vivo measurements are important in order to benchmark the 
current indirect methods that are standard for determining patient dose from computed 
tomography (CT), including:  measurements within a phantom, Monte Carlo simulation, and 
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cadaveric measurements.  Our desire is that this study will pave the way for future internal 
in-vivo dose measurements in multiple organs to develop a better understanding of how 
current indirect dose estimates compare to actual measurements. 
TLD response was characterized for the Radiologic Physics Center (RPC)’s B09 
batch of thermoluminescent dosimeter (TLD) TLD-100 powder at the doses and energies 
encountered in VC at MD Anderson Cancer Center.  Based on TLD measurements 
obtained within a computed tomography dose index (CTDI) body phantom, TLD dose 
linearity values were determined at 120 kVp (KL,120) with a percent coefficient of variation 
(%CoV) less than 3.56% at all doses.  A third-order polynomial regression with a goodness 
of fit factor of R2=0.992 was constructed from this data, and this KL,120 regression model 
was used to measure rectal doses administered to an anthropomorphic phantom and to 
patients during VC at MD Anderson Cancer Center. 
Mean rectal dose measurements of 8.8 mGy, 5.7 mGy, and 3.5 mGy were acquired, 
respectively, during simulated VC (using the MD Anderson Cancer Center technique) within 
an anthropomorphic phantom that was configured to represent the 15th, 87th, and 99th 
percentile of US adult patients aged 18-64.  The measured rectal doses decreased in an 
exponential manner with increasing phantom effective diameter.  As observed in the 
measurements that were obtained to quantify the TLD response at diagnostic doses and 
energies, the %CoV increased with decreasing dose.  The %CoV for the 99th percentile 
phantom configuration was calculated to be <5%, which implied that the TLDs were able to 
provide rectal dose measurements with reasonable precision for nearly all patients that are 
likely to undergo VC. 
In-vivo rectal dose measurements were also acquired during VC using the MD 
Anderson Cancer Center protocol within 6 patients.  The average rectal doses measured in 
the population of patients (of four TLD dose measurements per patient) ranged from 9.0 to 
13.1 mGy.  The measured rectal doses within a young adult male patient was favorably 
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predicted by the exponential regression model developed from the anthropomorphic 
phantom rectal dose measurements, while the typical VC patient population (older, mostly 
female adults) was favorably predicted by the size specific dose estimate (SSDE) dose 
model (as long as measurements were obtained sufficiently superior within the rectum).  In 
contrast to what was observed in the previous TLD measurements, the TLD response at 
diagnostic doses and energies did not increase in %CoV with decreasing dose.  The largest 
TLD measurement %CoV from the in-vivo data was 10.0%, which implied that the TLDs 
provided rectal dose measurements with reasonable precision for all patients in this study.   
The between-patient percent coefficient of variation of the average TLD rectal dose 
measurements for each patient was calculated to be 14.2%.  We therefore failed to prove 
our hypothesis that the between-patient percent coefficient of variation would exceed 50%.  
Further, we have failed to prove our hypothesis that the anthropomorphic phantom and 
uniform phantom-based rectal dose measurements would not provide dose estimates within 
the 95% confidence interval of the mean patient dose measurements as the SSDE dose 
model met this criteria for three patients and the anthropomorphic phantom met this criteria 
for the young adult patient who does not represent the typical VC population.  Our results 
suggest that we may be able to accept our hypothesis for the CTDI volume (CTDIvol) dose 
estimate, the CTDIvol dose estimate that disregarded the peripheral CTDI phantom 
exposure measurements (CTDIvol,center) and the Farmer chamber dose estimates as each of 
these techniques yielded doses that were outside the 95% confidence interval of the mean 
for our initial patient population (n=6). 
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